Genomic organization and functional characterization of a novel cancer associated gene - U0-44 by LEONG TUCK CHOY, CAINE
CAINE LEONG TUCK CHOY
NATIONAL UNIVERSITY OF SINGAPORE 
2006 
GENOMIC ORGANIZATION AND FUNCTIONAL 
CHARACTERIZATION OF A NOVEL CANCER 
ASSOCIATED GENE – UO-44 
 GENOMIC ORGANIZATION AND FUNCTIONAL 
CHARACTERIZATION OF A NOVEL CANCER 
ASSOCIATED GENE – UO-44 
CAINE LEONG TUCK CHOY
BSc (Hons)
A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY  
DEPARTMENT OF PHARMACOLOGY 




Memories of happiness, sadness and not to forget frustration throughout these 
few years have made this time one of the most enriching and fulfilling days of my 
life.  
First of all, I would like to thank Professor Philip Keith Moore, the Head of 
Department of Pharmacology, for giving me this opportunity to participate in this 
post-graduate program. Next, I would also like to thank Professor Hui Kam Man, 
the Director of the Division of Cellular and Molecular Research at the National 
Cancer Centre of Singapore (NCCS), for giving me a chance to work in NCCS where 
all my research was conducted. Most of all, I would love to thank my supervisor 
Associate Professor Huynh The Hung, Department of Pharmacology, National 
University of Singapore, for his valuable guidance and immense support throughout 
this project.  
In particular, I would like to extend my greatest gratitude to Choon Kiat, who 
has been such an inspiration to me and for being my best buddy in the lab. In addition, 
I would also like to express my deepest appreciation to Cedric for guiding me when I 
first started this project and for meticulously proofreading this thesis. Most 
importantly, I would like to thank to all members of the Molecular Endocrinology 
Laboratory at the National Cancer Centre of Singapore, both past and present. 
Especially, Chye Sun, Chee Pang, Hung, Esther and Yihui for all their precious 
support and encouragement throughout these years. Additionally, I would also like to 
thank all the researchers in the Division of Cellular and Molecular Research and 
Division of Medical Sciences at the National Cancer Centre of Singapore for always 
being so ever ready to offer the use of their equipment and reagents. 
 ii
Above all, I would like to express my heartfelt gratefulness to my wife 
Angeline and my son Rex for being the main driving-force in my life.  Additionally, I 
would also like to thank my sister, Celian, for always being there for me. Last but not 
least, I want to dedicate this thesis to my dad and mum, Tony and Lisa, without 
which none of this will be possible. 
 iii
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS i 
TABLE OF CONTENTS iii 
SUMMARY vi 
LIST OF TABLES viii 
LIST OF FIGURES ix 
LIST OF ABBREVIATIONS xii 
AWARDS AND PUBLICATIONS  xv 
 
Chapter 1 LITERATURE REVIEW 1 
1.1 Zona Pellucida and CUB Domain Proteins 1 
 1.1.1 The Zona Pellucida – Conserved Module For Polymerization of 
Extracellular Proteins 
1 
  1.1.1.1 Zona Pellucida 1 – 3 2 
  1.1.1.2 Transforming Growth Factor-β Receptor Type III and 
Endoglin 
2 
  1.1.1.3 Deleted in Malignant Brain Tumors 1 (DMBT1) 4 
 1.1.2 The CUB Domain – In Developmentally Regulated Proteins 5 
  1.1.2.1 Membrane-Type Serine Protease 1 (MT-SP1) 7 
  1.1.2.2 CUB Domain Containing Protein 1 (CDCP-1) 8 
  1.1.2.3 Platelet-Derived Growth Factor D (PDGF-D) 8 
1.2 Estrogens 9 
 1.2.1 Exposure of Estrogen and the Risk of Ovarian Cancer 10 
 1.2.2 Tamoxifen and Antiestrogens 12 
 1.2.3 Estrogen Regulated Genes in Ovarian Cancer 13 
  1.2.3.1 Progesterone Receptor 14 
  1.2.3.2 Cathepsin D 14 
  1.2.3.3 C-myc Early Growth Response Gene 15 
  1.2.3.4 pNR-2/pS2 15 
  1.2.3.5 Fibulin-1 16 
  1.2.3.6 HER-2/neu 16 
  1.2.3.7 Breast and Ovarian Cancer Susceptibility Gene 1 17 
  1.2.3.8 Kallikreins 18 
1.3 Treatment of Ovarian Cancers 18 
 1.3.1 Surgery and Chemotherapy for Ovarian Cancer 19 
 1.3.2 Cisplatin Therapy 20 
 1.3.3 Cisplatin Mode of Action and Molecular Basis of Resistance 21 
1.4 RNA interference (RNAi) 25 
 1.4.1 Discovery and Development of RNAi and siRNAs 25 
 1.4.2 RNAi Technology in Gynecologic Cancers in-vitro 26 
 1.4.3 Challenges in siRNA Technology 30 
     
Chapter 2 INTRODUCTION 33 
2.1 Isolation of UO-44 (UTCZP) 33 
2.2 Estrogen and Tamoxifen Induced UO-44 Expression (ERG-1) 34 
2.3 UO-44 Role in Susceptibility in Pancreatitis (ITMAP-1) 34 
2.4 Objective of this Study 35 
 
 iv
Chapter 3 MATERIALS AND METHODS 36 
3.1 Reagents 36 
3.2 Cell Lines and Cell Culture 36 
3.3 Animals 38 
3.4 Probe Labeling 38 
3.5 Human Ovarian cDNA Library for Human Ortholog of UO-44 38 
3.6 Rapid Amplification of cDNA Ends (RACE) 40 
3.7 Cloning of UO-44 cDNAs 41 
 3.7.1 Cloning of HuUO-44 – A, B, C, D and E transcripts 41 
 3.7.2 Cloning of RatUO-44 – A, B, C, D and E 42 
3.8 Multiple Tissue Expression Array, Multiple Tissue Northern, Cancer 
Profiling Array and Cancer Cell Line Profiling Array 
43 
3.9 Semi-quantitative RT-PCR of Human and Rat UO-44 44 
3.10 Quantitative (Real-time) PCR of UO-44 45 
3.11 Generation and Transfection HuUO-44-eGFP fusion Constructs 46 
3.12 UO-44 Antibodies and Immunohistochemistry 47 
3.13 Cisplatin Treatment 49 
3.14 Cellular Proliferation Assay 49 
3.15 Cytotoxicity Assay 50 
3.16 Knockdown of HuUO-44 in NIH-OVCAR3 Through RNA Interference 
(RNAi) 
50 
3.17 Generation of HuUO-44 Stable Transfectants 51 
3.18 Flow Cytometry  52 
3.19 Computational and Statistical Analysis 53 
 
Chapter 4 RESULTS 55 
4.1 Cloning, Sequencing and Characterization of the Human UO-44 55 
 4.1.1 Screening and Sequencing of HuUO-44 cDNA 55 
 4.1.2 5’ Rapid Amplification of cDNA Ends (RACE) 57 
 4.1.3 Cloning of Human UO-44 Variants 59 
 4.1.4 Genomic Structure of Human UO-44 gene 66 
 4.1.5 Tissue Distribution Profile of Human UO-44 66 
4.2 Establishing a Rat Model for Characterization of UO-44 70 
 4.2.1 Genomic Structure of Rat UO-44 70 
 4.2.2 Isolation and Cloning of Rat UO-44 Variants 72 
 4.2.3 Comparative Genomics of Human, Rat and Mouse UO-44 76 
 4.2.3 Hormonal Regulation of UO-44 Variants 85 
 4.2.6 Pregnancy Induced Expression of UO-44 Variants 85 
4.3 UO-44 and Cancer 88 
 4.3.1 Overexpression of Human UO-44 in Ovarian Cancers 88 
 4.3.2 Expression of Human UO-44 in Ovarian Tissues and Cancer 
Cell lines 
91 
 4.3.3 Inhibition of Ovarian Cancer Cell Attachment and Proliferation 97 
 4.3.4 Cancer Cell Line Profiling Array 97 
 4.3.5 Involvement of HuUO-44 in Cisplatin Sensitivity 101 
 4.3.6 Knockdown of HuUO-44 Sensitizes Ovarian Cancer Cells to 
Cisplatin 
105 
 4.3.7 Expression of HuUO-44 Conferred Resistance to Cisplatin 114 
 
 v
Chapter 5     DISCUSSION 117 
5.1 Human UO-44 gene 117 
 5.1.1 Features in HuUO-44 Gene 117 
 5.1.2 The Origin of Human HuUO-44 Isoforms 120 
 5.1.3 UO-44, a Multifunctional Protein 122 
5.2 Rat Model for Further Characterization of UO-44 123 
 5.2.1 UO-44 is Highly Conserved in Human, Mouse and Rat 124 
 5.2.2 Genomic Organization of Rat UO-44 Gene 127 
 5.2.3 Rat UO-44 Isoforms 128 
 5.2.4 Tamoxifen, β-estradiol (E2) and Pure Anti-estrogens (ICI 
182780) Role in Regulation of Rat UO-44 Isoforms 
129 
 5.2.5 Rat UO-44 a Pregnancy Induced Gene in the Mammary Glands 130 
5.3 Human UO-44 and Ovarian Cancers 130 
 5.3.1 Estrogen-regulated Proteins as Potential New Markers for 
Ovarian Cancers 
131 
 5.3.2 HuUO-44 – A Protein Involved in Ovarian Cancer Cell 
Adhesion and Cell Motility 
132 
 5.3.3 Involvement of Human UO-44 in Cisplatin Chemoresistance 133 
   














Ovarian cancer is currently the second leading cause of gynecological 
malignancy and cisplatin or cisplatin-based regimens have been the standard of care 
for the treatment of advance epithelial ovarian cancers. However, the efficacy of 
cisplatin treatment is often limited by the development of drug resistance either 
through the inhibition of apoptotic genes or activation of anti-apoptotic genes. This 
thesis encompasses the molecular cloning and characterization of a putative 
oncogene, UO-44. UO-44 (GenBank accession no. AF022147) is an estrogen 
regulated uterine-ovarian specific complementary DNA that was previously isolated 
through differential display of a tamoxifen-induced rat uterine cDNA library. The 
objective of this study is to further examine the role of this gene in the initiation and 
progression of ovarian cancers.  
Human UO-44 (HuUO-44) cDNA was obtained through a combination of 
screening a human ovarian cDNA library, 5’ RACE and RT-PCR.  The gene HuUO-
44 is mapped to chromosome 10q26.13 and contains 9 exons. Putative functional 
motifs identified in HuUO-44 are two CUB domains and a zona pellucida domain. 
Through reverse-transcription PCR (RT-PCR), four novel spliced variants of HuUO-
44 were isolated; these variants were obtained through a complex series of alternative 
splicing events between exons 2 to 6. These HuUO-44 mRNA variant isoforms is 
suggested to play a role in regulating gene expression.  
Gene expression analysis via the Multiple Tissue Northern blot detected two 
HuUO-44 transcripts of approximately 2 and 3 kb in the pancreas. Using the Cancer 
Profiling Array, HuUO-44 transcript was found overexpressed in a majority of 
ovarian tumors (12 of 14 or 86 %) compared to corresponding normal tissues. 
Transfection studies demonstrated the membrane-associated nature of HuUO-44 and 
 vii
through immunohistochemistry, HuUO-44 was located to the normal ovarian and 
ovarian tumor epithelial cells. In ovarian cancer cells (NIH-OVCAR3), HuUO-44 was 
detected only at the leading edge of the dividing cells. Importantly, a marked loss in 
cell attachment and proliferation was observed in NIH-OVCAR3 cells when cultured 
in the presence of a polyclonal HuUO-44 antiserum. These findings suggest the 
potential role of HuUO-44 in cell motility, cell-cell interactions and/ or interactions 
with the extracellular matrices.  
Interestingly, the Cancer Cell Line Profiling Array revealed that the 
expression of HuUO-44 was suppressed in the ovarian cancer cell line (SKOV-3) 
after treatment with several chemotherapeutic drugs. Similarly, this suppression in 
HuUO-44 expression was also correlated to the cisplatin sensitivity in two other 
ovarian cancer cell lines NIH-OVCAR3 and OV-90 in a dose dependent manner. To 
elucidate the function of HuUO-44 in cisplatin sensitivity in ovarian cancer cell, small 
interfering RNAs (siRNAs) were employed to mediate HuUO-44 silencing in ovarian 
cancer cell line, NIH-OVCAR3 and SKOV3. HuUO-44 RNA interference (RNAi) 
resulted in the inhibition of cell growth and proliferation. Importantly, HuUO-44 
RNAi significantly increased sensitivity of NIH-OVCAR3 to cytotoxic stress induced 
by cisplatin (P < 0.01). Strikingly, we have also demonstrated that overexpression of 
HuUO-44 significantly conferred cisplatin resistance in NIH-OVCAR3 cells (P < 
0.05). Taken together, UO-44 is involved in conferring cisplatin resistance; the 
described HuUO-44-specific siRNA oligonucleotides that can potently silence HuUO-
44 gene expression may prove to be a valuable pre-treatment target for intra-tumor 
therapy of ovarian epithelial cancers. 
 viii
LIST OF TABLES 
No. Title Page 
Table 1.1 RNAi agents in drug development. 32 
Table 3.1 Sequences of oligonucleotides used for RT-PCR (a), Cloning 
(b), Sequencing (c), PCR (d) and 5’ RACE Primer (e). 
37 
Table 4.1  Summary of the different HuUO-44 spliced variants. 65 
Table 4.2     Exon/Intron boundaries of human UO-44. 67 
Table 4.3 Exon/Intron boundaries of rat UO-44. 74 
Table 4.4 Summary of the different rat UO-44 spliced variants. 78 
Table 4.5 Functional modules and their relative functions in the 
human, mouse and rat UO-44 promoters. 
84 
Table 4.6 Sequence and target exons of the HuUO-44 siRNAs U1, U2 
and U3*. 
106 
   





LIST OF FIGURES 
 
No. Title Page 
Figure 1.1 Schematic representation of the overall architecture of 
mouse ZP glycoproteins, ZP1, ZP2 and ZP3. 
3 
Figure 1.2      Multiple effects of endogenous and synthetic estrogens on 
tissues that contribute to estrogen carcinogenesis. 
11 
Figure 1.3     An overview of pathways involved in mediating cisplatin-
induced cellular effects. 
22 
Figure 1.4     Factors modulating repair of cisplatin-induced DNA 
adducts and regulating replicative bypass. 
23 
Figure 1.5     Mechanisms involved in inhibiting the apoptotic signal in 
cisplatin-resistant tumor cells. 
24 
Figure 1.6     SiRNA interference mechanism: short hairpin RNAs and 
long dsRNAs all are processed by Dicer to form siRNAs. 
27 
Figure 1.7   Potential applications of RNA interference in cancer 
research and therapy 
29 
Figure 4.1 Library screened HuUO-44 cDNA (GenBank accession 
no. AF305835) nucleotide sequence (2126 bp) and 
deduced aa sequence (357 aa). 
56 
Figure 4.2 5’RACE illustration and sizes of the resulting contigs. 58 
Figure 4.3 Expression of human UO-44 splice-variants in 
normal/tumor ovarian and uterine tissues. 
60 
Figure 4.4 Illustration of HuUO-44 spliced-variants. 62 
Figure 4.5  Full-length human UO-44 (HuUO-44D) nucleotide 
sequence (2339 bp) and deduced amino acid sequence 
(607 amino acids). 
63 
Figure 4.6  Graphical representation of human UO-44 genomic 
organization in a region within human chromosome 10. 
68 
 x
Figure 4.7 Multiple Tissue Northern (MTN) of HuUO-44. 69 
Figure 4.8 Multiple Tissue Expression Array (MTE) of HuUO-44. 71 
Figure 4.9  Graphical representation of rat UO-44 genomic 
organization in a region within rat chromosome 1. 
73 
Figure 4.10 Expression of rat UO-44 spliced-variants in the ovary. 75 
Figure 4.11 Illustration of rat UO-44 spliced-variants. 77 
Figure 4.12 A schematic of UO-44s and other CUB or Zona pellucida 
proteins. 
79 
Figure 4.13  Multiple sequence alignment of rat, mouse and human 
UO-44 peptide sequences. 
80 
Figure 4.14  Comparative genomics analysis of human, mouse and rat 
UO-44. 
82 
Figure 4.15  Common elements framework analysis in the human, 
mouse and rat UO-44 promoters. 
86 
Figure 4.16 Semi-quantitative One-step RT-PCR analysis of UO-44 
spliced-variants expression in the uterus of pure anti-
estrogens (ICI 182780), tamoxifen and β-estradiol treated 
rats. 
87 
Figure 4.17  Pregnancy induced expression of UO-44 variants in the 
mammary glands.   
89 
Figure 4.18 Cancer Profiling Array (CPA, normal/ tumor ovary) of 
human UO-44. 
90 
Figure 4.19 Semi-quantitative RT-PCR of HuUO-44 using total RNA 
extracted from normal ovarian epithelium, ovarian tumors 




Figure 4.20  Transfection study of HuUO-44-eGFP in ovarian cancer 
cells (NIH-OVCAR3). 
94 
Figure 4.21  Immunohistochemical staining of HuUO-44 in an ovarian 
cancer cell line NIH-OVCAR3. 
95 
Figure 4.22  Immunohistochemical staining of HuUO-44 in paraffin-
embedded sections of a representative normal ovarian 
epithelial and ovarian epithelial cancer. 
96 
Figure 4.23 Effects of HuUO-44 antiserum on cell attachment and 
proliferation of ovarian cancer cells (NIH-OVCAR3). 
98 
Figure 4.24  Expression of human UO-44 (HuUO-44) in the ovarian 
cancer cell line (SKOV3) treated with 26 individual agents 
using the Cancer Cell Line Profiling Array. 
100 
Figure 4.25 Cytotoxic effect of cisplatin in ovarian cancer cell lines 
(NIH-OVCAR3, ES-2, SKOV-3 and OV-90). 
102 
Figure 4.26 Effect of cisplatin on HuUO-44 expression in ovarian 
cancer cell lines (NIH-OVCAR3, ES-2, SKOV-3 and OV-
90). 
103 
Figure 4.27  Effect of cisplatin on HuUO-44 expression in ovarian 
cancer cell lines (NIH-OVCAR3). 
104 
Figure 4.28  HuUO-44 sequence specific siRNA silencing of HuUO-44 
expression in NIH-OVCAR3 ovarian cancer cells. 
107 
Figure 4.29      Dose dependent silencing of HuUO-44 gene by siRNA in 
NIH-OVCAR3 ovarian cancer cells. 
110 
Figure 4.30 Dose dependent silencing of HuUO-44 by siRNAs in 
SKOV-3 ovarian cancer cells. 
111 
Figure 4.31  HuUO-44 RNAi enhanced chemosensitivity of ovarian 
cancer cells, NIH-OVCAR3. 
112 
Figure 4.32 Overexpression of HuUO-44 conferred cisplatin resistance 




LIST OF ABBREVIATIONS 
 
α-MEM   Alpha Modified Eagle medium 
AMD    Age-related Muscular Degeneration 
BRCA1  Breast and Ovarian Cancer Susceptibility Gene 1 
CCP    Complement Control Protein  
CDCPs  CUB Domains-Containing Proteins 
CFCS   Consensus Furin Cleavage Site  
CPA   Cancer Profiling Array 
CUB Complement Subcomponents – C1r/C1s, Embryonic Sea 
Urchin Protein – Uegf and Bone Morphogenetic Protein 1 – 
Bmp1   
DMBT1  Deleted in Malignant Brain Tumors 1 
dsRNAs   Double Stranded RNAs  
E2   Estradiol 
ECM   Extracellular Matrix  
EGF   Epidermal Growth Factor 
eGFP   Enhanced Green Florescence Protein  
EMBL   European Molecular Biology Laboratory 
ER   Estrogen Receptor 
ERG1    Estrogen Regulated Gene 1 
FBS   Fetal Bovine Serum  
FGF   Fibroblast Growth Factor 
GAPDH  Glyceraldehydes-3-Phosphate Dehydrogenase 
GSP   Gene Specific Primer 
HB-EGF  Heparin-Binding EGF-like growth factor 
 xiii
Hi-Glu-DMEM High glucose Dulbecco’s Modified Eagle Medium 
IGF-1   Insulin-like Growth Factor – 1  
IP    Intraperitoneal   
Itmap-1   Integral Membrane Associated Protein – 1 
KLKs    Kallikreins  
LB    Luria-Bertani  
MTE   Multiple Tissue Expression 
MTN   Multiple Tissue Northern 
MT-SP1   Membrane-Type Serine Protease 1 
MTT    [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
NCBI   National Centre for Biotechnology Information 
ORF   Open Reading Frame 
PAN   Plasminogen N-terminus  
PBS    Phosphate Buffer Saline  
PCR   Polymerase Chain Reaction 
PDGF    Platelet-Derived Growth Factor  
PI   Propidium Iodide  
PR   Progesterone Receptor 
PS   Penicillin-Streptomycin 
RACE   Rapid Amplification of cDNA Ends  
RGD    Arginine-Glycine-Aspartate  
RISC    RNA-induced silencing complex 
RNAi   RNA Interference  
RT-PCR  Reverse Transcription-Polymerase Chain Reaction 
SDS-PAGE  Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
 xiv
SIDs    SRCR interspersed domains 
siRNAs  Short Interfering RNAs 
SP   Signal Peptide 
SPDI    Secreted Protein Discovery Initiative 
SRCR   Scavenger Receptor Cysteine Rich 
SSC   Sodium chloride-Sodium Citrate solution 
TBS   Tris Buffer Saline 
TBST   Tris Buffer Saline Tween-20 
TF   Transcription Factors 
TGFR3  Transforming Growth Factor-β Receptor Type III 
TM    Transmembrane  
TMD   Transmembrane Domain 
UTCZP   Uterine Cub Zona pellucida Protein  
UTR   Untranslated Region 
VEGF   Vascular Endothelial Growth Factor 
ZP   Zona Pellucida 
 
 xv
LOCAL AND INTERNATIONAL AWARDS 
 
 Awarded 1st prize for oral presentation at the 5th Combined Annual Scientific 
Meeting 2004 (“Life Sciences in Singapore.”), National University of Singapore. 
Presentation title: Molecular Characterization of a Membrane-Associated Protein 
HuUO-44 and its Potential Role in Ovarian Cancer Cell Attachment and 
Proliferation.  
 
 Awarded 2nd prize for oral presentation at the 3rd Annual Graduate Student 
Society-Faculty of Medicine (GSS-FOM) Meeting 2003, National University 
of Singapore. Presentation title: Molecular Cloning and Characterization of a 
Putative Oncogene, HuUO-44, in Human Ovarian Carcinogenesis. 
 
 Awarded AVON international scholar-in-training award poster presented at 
the 94th American Association for Cancer Research (AACR), Annual Meeting 
2003, Washington D. C., USA. (July 11-14, 2003) Poster title: Molecular 





 Caine Tuck Choy Leong, Choon Kiat Ong, Sun Kuie Tay and Hung Huynh. 
Silencing expression of UO-44 (CUZD1) using small interfering RNA 
sensitize human ovarian cancer cells cisplatin in-vitro. Oncogene 2007 Feb 8; 
26(6):870-80. (Appendix 2) 
 
 Caine Tuck Choy Leong, Cedric Chuan Young Ng, Choon Kiat Ong, Chee 
Pang Ng and Hung Huynh. Molecular Cloning and Characterization of a 
Putative Transmembrane Protein, HuUO44, Overexpressed in Human Ovarian 




 This project was awarded a National Medical Research Council of Singapore 
grant (NMRC/0887/2004) of $199,382.50 for the period from 1st Jan 2005 to 
31th Dec 2008 to Huynh Hung. (Grant Titled: Functional Characterization of 
HuUO-44 an estrogen regulated membrane-associated protein, as a Biomarker 
for Ovarian Cancer Prognosis Diagnosis and Treatment.) 
 
INVITED TALK/ PRESENTATION 
 
 Invited Speaker, Bio-Rad Laboratories (Real-time PCR – Strategies and 
Applications), National University of Singapore (19th May 2006).  
 
 Poster presentation, Combined Scientific Meeting 2005, Singapore. Poster 
title: Tamoxifen, Estrogens and Anti-estrogens Regulation of a Uterine and 





Chapter 1  LITERATURE REVIEW 
1.1 Zona Pellucida and CUB Domain Proteins 
1.1.1 The Zona Pellucida – Conserved Module For Polymerization of 
Extracellular Proteins 
Zona pellucida (ZP) domains are found in many eukaryotic extracellular 
proteins of diverse molecular architecture and biological functions (Bork and Sander, 
1992; Wassarman et al., 2001). These include egg coat proteins, inner ear proteins, 
urinary proteins, pancreatic proteins, transforming growth factor-β receptors, immune 
defense proteins, nematode cuticle components, and fly proteins (Bork and Sander, 
1992; Litscher et al., 1999; Wassarman et al., 2001).  
ZP domains proteins often contain other types of domains, such as proline-rich 
(P) or trefoil (Bork and Sander, 1992; Carr, 1992), epidermal growth factor (Appella 
et al., 1988), CUB or BMP (Bork and Beckmann, 1993; Fukagawa et al., 1994), PAN 
(plasminogen N terminus) (Tordai et al., 1999), SRCR (scavenger receptor cysteine 
rich) (Resnick et al., 1994), von Willebrand factor (Ruggeri, 2003), or other domains 
(Bork et al., 1996; Letunic et al., 2004). Most ZP domain proteins are glycosylated 
and possess an amino-terminal (N-terminal) signal peptide and either a carboxyl 
terminal (C-terminal) putative transmembrane domain (TMD) or glycosyl 
phosphatidylinositol- (GPI-) anchor (Jovine et al., 2004).  ZP proteins have been 
characterized from a wide variety of mammalian eggs, including rodents, 
domesticated animals, marsupials, and primates (Breed et al., 2002; Spargo and Hope, 
2003). In general, ZP proteins are found in filaments and/ or matrices, which is 





2002). Although ZP proteins are found in proteins of diverse functions, this domain is 
likely to play a common role.  
 
1.1.1.1 Zona Pellucida 1 – 3 
ZP is a thick extracellular coat that surrounds all mammalian eggs and plays a 
vital role in oogenesis, fertilization and preimplantation development (Wassarman, 
1988; Wassarman et al., 2001). There are three glycosylated isoforms of ZP in the 
mouse, named ZP1 – 3, these three isoforms has a ZP domain near to the C-terminus, 
a signal peptide at the N-terminus, a consensus furin cleavage site (CFCS), a C-
terminal putative TMD, and a short cytoplasmic tail (Figure 1.1). These proteins are 
concurrently synthesized, secreted, and assembled into ZP as mouse oocytes grow. 
The secreted from of ZP1 – 3 lack signal peptides and is cleaved at the CFCS. It is 
apparent that ZP1 – 3 have regions of similarity, suggesting that these regions may be 
derived from a common ancestral gene.  
 
1.1.1.2 Transforming Growth Factor-β Receptor Type III and Endoglin 
Transforming growth factor-β receptor type III (TGFR3), or betaglycan, is the 
most abundant TGF-β binding protein at the cell surface. Among its essential 
functions, TGFR3 plays an important role in the restructuring of blood vessels during 
angiogenesis in mammals (Bandyopadhyay et al., 1999; Bandyopadhyay et al., 2002). 
It contains a signal peptide at the N-terminus, a ZP domain, a C-terminal putative 
TMD, and a cytoplasmic tail (Lopez-Casillas et al., 1991; Wang et al., 1991; Moren 
et al., 1992; Lin et al., 1992). TGFR3 binds all 3 TGF-β isoforms with high affinity 
and has been suggested to facilitate binding of TGF-β to TGF-β type II receptor 





Figure 1.1 Schematic representation of the overall architecture of mouse ZP 
glycoproteins, ZP1, ZP2 and ZP3. The polypeptide of each ZP glycoprotein is 
drawn to scale, with the N and C termini indicated. Key features of the polypeptide, 
including the N-terminal signal peptide (green), P or trefoil domain (yellow), ZP 
domain (red), CFCS (X), TMD (black), and C-terminal propeptide region (blue bar) 
are depicted. Only putative N-linked glycosylation sites, conforming to the strict 
pattern Asn-X-Ser/Thr-X, where X can be any amino acid other than Pro, as shown 





  Endoglin (~180 kDa Mr; disulfide-linked homodimer) is a membrane 
glycoprotein, which is structurally related to TGFR3. This protein binds TGF-β 
isoforms 1 and 3 with high affinity through the association with the type II receptor 
(Fonsatti et al., 2001; Sorensen et al., 2003) and is crucial for the cardiovascular 
development and vascular remodeling (Fonsatti et al., 2003). In addition, mice 
deficient in endoglin showed signs of defective angiogenesis. The interaction between 
endoglin and TGFR3 may therefore function to regulate the TGF-β signaling 
pathways in cancer (Li et al., 1999; Wong et al., 2000; Parker et al., 2003; Copland et 
al., 2003).   
 
1.1.1.3 Deleted in Malignant Brain Tumors 1 (DMBT1) 
DMBT1 (deleted in malignant brain tumors 1) is a scavenger receptor 
cysteine-rich (SRCR) gene at chromosome 10q25.3-26.1 and has been initially cloned 
by virtue of its frequent homozygous deletion and lack of expression (Mollenhauer et 
al., 1997; Somerville et al., 1998; Mori et al., 1999; Wu et al., 1999). Though 
DMBT1 has been regarded as a candidate tumor suppressor gene for the human brain, 
lung and digestive tract cancers; it differs substantially from conventional tumor 
suppressors and is in fact potentially multifunctional (Mollenhauer et al., 2000; 
Mollenhauer et al., 2001; Mollenhauer et al., 2002b; Mollenhauer et al., 2002c; 
Mollenhauer et al., 2004). DMBT1 is a relatively large secreted glycoprotein with up 
to 13 N-terminal SRCR domains separated by short serine-theonine-rich amino acid 
motifs known as SRCR interspersed domains (SIDs) (Mollenhauer et al., 2002a), 
which are potential sites for extensive O-glycosylation. The three major functional 





known to mediate protein-protein interactions (Wassarman, 1988; Bork and Sander, 
1992; Bork and Beckmann, 1993;J ovine et al., 2005). 
Takito et. al reported a mouse ortholog of DMBT1, Hensin, which is 
expressed in virtually all epithelia and brain (Takito et al., 1999). This protein 
contains 8 SRCR, 2 CUB and a ZP domain, in the presence of gelactin-3 it assembles 
into dimers and tetramers to form long fibres in the ECM (Hikita et al., 1999; Hikita 
et al., 2000). Similar to DMBT1, this alternatively spliced form is deleted in a large 
number of epithelia tumors and is suggested to be involved in apical secretion and 
endocytosis (Hikita et al., 1999; Al Awqati et al., 1999). 
In recent years, ZP domain has been identified in various proteins of diverse 
functions and it is a module that is frequently found in extracellular proteins that 
polymerize into higher-order structures, such as filaments and matrices. ZP proteins 
are often glycosylated and have mucin-like properties. These proteins are often found 
to contain other functional modules (eg. CUB, EGF, and PAN domains) and perform 
functions distinct from the structural role played by the ZP domain. Owing to its 
transmembrane nature, ZP proteins may also serve as receptors or 
mechanotransducers. Its is clear that ZP proteins is a large and important family of 
proteins that will continue to grow in size and its association with the onset of 
diseases will be of great interest to researchers in the many years to come.     
 
1.1.2 The CUB Domain – In Developmentally Regulated Proteins  
Communications between cells during the process of development requires a 
network of distinct interactions. Programming of these interactions in nature is most 
likely created by combining structurally and functionally independent domains 





(Doolittle and Bork, 1993). The extracellular CUB domain is an example of such a 
module that is found in functionally diverse, mostly developmentally regulated 
proteins. It was first identified in the complement subcomponents C1s and C1r 
(C1s/C1r), which are proteins found in the circulating blood (Leytus et al., 1986; Tosi 
et al., 1987). This domain was named after the first three identified proteins of this 
family, the Complement subcomponents – C1r/C1s, the embryonic sea urchin protein 
– Uegf and the bone morphogenetic protein 1 – Bmp1 (Bork, 1991).  
Though this domain is found in functionally diverse proteins, the majority of 
the CUB domains-containing proteins (CDCPs) are developmentally regulated and 
have a vital function in embryonic development (Bork and Beckmann, 1993). These 
proteins include growth factors, proteases, activators of the complement system, and 
proteins involved in cell adhesion or interaction with the extracellular matrix 
components (Stohr et al., 2002). Almost all CUB domains contain four conserved 
cysteines, which probably form two disulfide bridges (C1 – C2, C3 – C4). The 
structure of the CUB domain is very similar to that of immunoglobulins and play a 
crucial role in cell adhesion (Duke-Cohan et al., 1998).  
Amongst the first CDCPs identified was the complement subcomponents C1s 
and C1r. Both proteins contain two CUB domains, an epidermal growth factor (EGF)-
like domain, two complement control protein (CCP) domains and a trypsin family 
serine protease domains, which play a part in the mammalian complement system 
(Tosi et al., 1989a; Tosi et al., 1989b). These two CDCPs also aid in protease 
activation of trypsinogen and cleavage of collagen and fibronectin (Bork and 
Beckmann, 1993). Another CDCP, the vertebrate bone morphogenetic protein 1 
(BMP-1) is a glycosylated metalloproteinase that induces cartilage and bone 





found in BMP-1 has been shown to play a role in the secretion and stability of the 
protein (Garrigue-Antar et al., 2002).  
Embryonic development and cancer can be viewed as flip sides of the same 
coin. During embryogenesis, signal transduction pathways result in basic cell 
behaviors such as programmed cell death, proliferation, migration and differentiation. 
During oncogenesis, these same signal transduction cascades are misinterpreted, 
pathologically reactivated or ignored, resulting in aberrant cellular behaviors. 
Analogous to this assumption, several CDCPs listed below have been shown to play a 
role in carcinogenesis.  
 
1.1.2.1 Membrane-Type Serine Protease 1 (MT-SP1) 
Both the human and mouse matriptase/MT-SP1, a matrix-degrading 
transmembrane serine proteinase, contains an arginine-glycine-aspartate (RGD) 
integrin-binding motif in the first CUB domain (Netzel-Arnett et al., 2003). It has also 
been reported that the removal of the cytoplasmic and transmembrane regions in MT-
SP1 causes the protein to remain membrane bound on the surface of COS cells 
(Tsuzuki et al., 2005). This suggests the involvement of the CUB motif in integrin-
mediated cell surface binding by regulating cell-cell and/ or cell-substratum 
adhesions. Interestingly, MT-SP1 is highly expressed in prostate, breast, and 
colorectal cancers in vitro and in vivo (Oberst et al., 2001), and Takeuchi et al. have 
demonstrated that inhibition of this enzyme suppresses both primary tumor growth 
and metastasis in a rat model of prostate cancer (Takeuchi et al., 1999). Many of these 
membrane anchored serine proteases have restricted tissue distribution in normal 





tumorigenesis. Targeting these membrane anchor serine proteases, thus reveal new 
approaches for treatment of cancers and other diseases. 
 
1.1.2.2 CUB Domain Containing Protein 1 (CDCP-1) 
The CUB domain containing protein-1 (CDCP-1) is a transmembrane 
molecule that is expressed in metastatic colon, lung and breast cancers (Scherl-
Mostageer et al., 2001; Buhring et al., 2004). More recently, strong expression 
CDCP1 protein expression was found on the surface of highly metastatic hepatic cell 
line M+Hep3 (Hooper et al., 2003). In their report, normal colon tissues expression of 
CDCP1 was restricted to cell surface of the epithelial cells, while cancerous colon 
tissues expressed high levels of CDCP1 in the mucus of malignant glands (Hooper et 
al., 2003). Taken together, these findings suggest that the upregulation of CDCP1 
functions to modulate the cell substrate adhesion or interaction with the extracellular 
matrices. 
 
1.1.2.3 Platelet-Derived Growth Factor D (PDGF-D) 
The platelet-derived growth factor (PDGF) protein family is a strong 
stimulator of cell proliferation, chemotaxis and transformation. It has been known to 
play a key role in cell-cell communication for normal development and also during 
pathogenesis (Rosenkranz and Kazlauskas, 1999; Yu et al., 2003). The PDGF 
isoforms exert their biological functions through the activation of two structurally 
related cell surface receptor tyrosine kinases (α-PDGFR and β-PDGFR) (Deuel, 
1987; Rosenkranz and Kazlauskas, 1999). The recently discovered PDGF C and D 
isoforms have a unique two-domain structure with an amino-terminal CUB domain 





have demonstrated that PDGF D dimer expression causes the accelerated early onset 
of prostate tumor growth and drastically enhances prostate carcinoma cell interaction 
with the surrounding stromal cells (Ustach et al., 2004). It is suggested that the CUB 
domain may serve to interact with the cell surface proteins and such interactions may 
alter the PDGFR signaling pathways resulting in tumorigenesis. 
 
1.2 Estrogens  
Several causes of the most common cancers are often linked to inappropriate 
and/ or prolonged exposure to synthetic or endogeneous steroidal hormones (Henderson 
et al., 1988; Preston-Martin et al., 1990; Henderson et al., 1991). Steroidal estrogens are 
hormonally active molecules that are involved in sex and growth characteristics (2002). 
Steroidal hormones are lipophilic molecules that are vital for cell growth, differentiation, 
and function of many human and vertebrate tissues. Estrogens control the female 
secondary sexual characteristics, maintain the lining of the uterus, and prepare the body 
for pregnancy (Report on Carcinogens, 2002). Estradiol - 17β is the most active 
naturally occurring estrogen and its metabolite estrones are secreted by the ovaries in 
women with normal menstrual cycles and by the placenta during pregnancy.  
Conjugated estrogens, estradiol and synthetic esters of estradiol especially 
ethinylestradiol and estradiol valerate, are most commonly used in estrogen replacement 
therapy or in combination with a progesterone for hormone replacement therapy (Cunat 
et al., 2004). Since the early 1960s, estrogens have been used in oral contraceptives. 
However, prolong estrogen exposure induces cell proliferation in estrogen-dependent 
target cells, affect cellular differentiation, and alter gene expression (Yager and Liehr, 
1996). Although the molecular mechanisms of estrogen carcinogenicity are not well 





endometrial, cervical, and mammary tumors. The paradigm in Figure 1.2 illustrates the 
effects that endogenous and synthetic estrogens have on cells and tissues (Yager and 
Liehr, 1996). This emphasizes the complexity of estrogen carcinogenesis and 
demonstrates that each effect and response occurs is possibly tissue specific.  
 
1.2.1 Exposure of Estrogen and the Risk of Ovarian Cancer 
Ovarian cancer is the sixth most common cancer in female worldwide with an 
estimated 190,000 new cases and 114,000 deaths as a result of neoplasia each year 
(Parkin, 2001). In Singapore, ovarian cancer is the fourth commonest cause of death in 
female with an increasing incidence over the past 3 decades (Ang, 2005). More than 50 
% of the patients diagnosed with ovarian cancer develop malignant tumors and only a 
quarter of those diagnosed with ovarian cancer will survive for 5 or more years (Perez-
Gracia and Carrasco, 2002). This high fatality rate is mainly because most ovarian 
cancers are usually detected only at very late stages (Cunat et al., 2004). If detected 
early, chances of survival are much higher (Rosano et al., 2003). 
Steriodal estrogens are often referred to as human carcinogens based on the 
causal associations between exposure to steroidal estrogens and human cancers 
(Henderson et al., 1988; Preston-Martin et al., 1990; Henderson et al., 1991). Likewise, 
ovarian cancers are often associated with elevated levels of estrogens (Clinton and Hua, 
1997) as this hormone promotes growth, differentiation and remodeling of the uterus 
during the estrous cycle and pregnancy. These processes are regulated by the 
interactions with nuclear estrogen receptors (ERs) -α and -β, which function as 
ligand-inducible transcription factors.  
 Estrogens modulate genes that regulate cell growth and differentiation, such 






Figure 1.2     Multiple effects of endogenous and synthetic estrogens on tissues 
that contribute to estrogens carcinogenesis (adapted with modifications from 






receptors (White et al., 1995; Marcantonio et al., 2001). In general, estrogens increase 
the rate of cell proliferation by recruiting non-cycling cells into the cell cycle, and by 
shortening the overall cell cycle time by reducing the length of the G1 phase (Huynh 
et al., 2001). Ovarian carcinoma cells proliferation in response to estrogen has also 
been previously shown in several ER positive ovarian carcinoma cells (Nash et al., 
1989; Geisinger et al., 1990; Langdon et al., 1990). Consistent to this finding, the 
prevalent effect of exogenous estrogen may be the due to the increased risk as a result 
of stimulation of cell proliferation in postmenopausal women.  
 
1.2.2 Tamoxifen and Antiestrogens 
Tamoxifen belongs to the type 1 (non-steroidal) anti-estrogens exhibiting 
mixed estrogenic and anti-estrogenic activity. It acts as an estrogen antagonist and is 
currently used in adjuvant therapy for breast cancer prevention and treatment, 
however, long-term administration leads to increased risk for endometrical cancer in 
postmenopausal women (Kazandi et al., 2002). This observation of atrophic post-
menopausal endometrium may cause hyperplasia progess into atypia and cancer seen 
in estrogen replacement therapy cases. It was previously reported that tamoxifen 
significantly increases uterine weight, whereas ICI 182780 a pure anti-estrogen 
suppresses it. Tamoxifen has been shown to inhibit IGF-1 gene expression in the 
uterus, and alters the expression of other genes that regulates proliferation (Clarke et 
al., 2001; Huynh et al., 2001). 
The presence of ER in a subset of ovarian cancers (Rao and Slotman, 1991; 
Kommoss et al., 1992); estrogen induces proliferation of ER positive ovarian 
carcinoma cells in culture (Nash et al., 1989; Geisinger et al., 1990; Langdon et al., 





Wimalasena et al., 1993; Langdon et al., 1994a; Langdon et al., 1994b); the increased 
risk of ovarian cancer due to prolong exposure to estrogen in estrogen replacement 
therapy; and the expression of growth regulatory genes induced by estrogen in breast 
and ovarian carcinoma cells in culture suggest the potential of anti-estrogen hormonal 
therapies.  
However, the overall clinical response rate for ovarian cancer patients to 
tamoxifen therapy is a mere 15 – 18 % compared to breast cancer, which is 
significantly higher. This poor response rate could be attributed to the following 
reasons: i) fewer ovarian cancers express ERs, a requirement for hormone 
responsiveness, possibly lower than in breast cancers and less than the original 
estimate of 60 % (Rao and Slotman, 1991); ii) estrogens may play a more complex 
role in ovarian cancers which is common in postmenopausal women, iii) estrogens 
and anti-estrogens may be synthesized or metabolized differently in ovarian epithelial 
cells (Wimalasena et al., 1991; Chien et al., 1994) and iv) the antagonist activity of 
tamoxifen might be weaker in ovarian epithelial cancer cells (Gottardis et al., 1988; 
Berry et al., 1990; Webb et al., 1995). It is therefore necessary to identify subgroups 
of patients that are likely to respond to anti-estrogen therapy through the profiling of 
estrogen responsive genes or elements for effective treatment of ovarian cancers. 
     
1.2.3 Estrogen Regulated Genes in Ovarian Cancer 
Estrogen receptors (ER) -α and -β are expressed in both normal and malignant 
cells. Ovarian epithelial cell proliferation like that in breast cells may therefore be 
stimulated by estrogens through the induction of growth regulatory genes (Dickson 
and Lippman, 1987). Expression profiling of such genes can be used to predict 





estrogen responsive gene products found in ovarian carcinoma cell lines and ovarian 
cancer tissues. 
 
1.2.3.1    Progesterone Receptor 
The progesterone receptor (PR) is produced under the control of estrogens in 
normal steroid target tissues and in breast carcinoma cells (Horwitz et al., 1978). 
However, PR is regulated only in some (Hamilton et al., 1984; Nash et al., 1989; 
Langdon et al., 1994b) but not all (Nash et al., 1989; Hua et al., 1995) estrogen 
responsive ovarian carcinoma cell lines. This proves that PR is not always coupled to 
estrogen responsive growth; nevertheless, its presence suggests the presence of a 
functional ER and is still a good indicator for responsive anti-estrogen therapy. 
Though PR has been detected in only about half of the clinical ovarian cancer samples 
through biochemical methods and in about 31 % was diagnosed through 
immunohistochemical analysis (Kommoss et al., 1992). The presence of PR is still a 
positive prognostic indicator in ovarian cancer as it is often associated with a higher 
degree of differentiation (Rao and Slotman, 1991). 
 
1.2.3.2    Cathepsin D 
Cathepsin D is a lysosomal protease that is secreted by breast carcinoma cells, 
and is believed to be involved in metastasis (Gottardis et al., 1988). In ovarian 
carcinoma cell lines, estrogen-induced secretion of cathepsin D correlates to the 
growth regulation in PE04 and BG1 ovarian cancer cells. On the other hand, cathepsin 
D is produced constitutively in ER+ ovarian carcinoma cell line, SKOV-3, which is 
resistant to estrogens and anti-estrogens regulation. This constitutive production of 





cells (Rochefort, 1994) suggest that this protease will not be appropriate in predicting 
hormone responsiveness of ovarian cancers. Despite initial studies, which indicates 
that the production of cathepsin D do not correlate with the presence of ER and PR, 
expression of this protease is higher in omental metastases compared to its 
corresponding primary tumors (Scambia et al., 1991; Scambia et al., 1994). 
 
1.2.3.3    C-myc Early Growth Response Gene 
Estrogens are considered one of the mitogens that induce the nuclear oncogene 
c-myc in breast carcinoma cells (Schuchard et al., 1993; Chien et al., 1994). In 
CAOV-3 and PE04 ovarian carcinoma cells, the induction of c-myc by estrogens is 
correlated to growth stimulation (Chien et al., 1994; Hua et al., 1995), while in 
SKOV-3 cells, the induction of c-myc by estrogens is not coupled to a proliferative 
response (Hua et al., 1995). Conversely, the elevated levels of c-myc expression in 
ovarian cancers are likely due to gene dose rather than estrogen responsiveness. 
 
1.2.3.4     pNR-2/pS2 
pS2 is an estrogen induced secreted protein that is positively correlated with 
ER in tumors (Masiakowski et al., 1982;Nunez et al., 1987). The overexpression of 
pS2 protein in breast cancer, thus advocated the potential of this protein as a 
prognosis and estrogen responsive marker in endocrine therapy (Foekens et al., 
1990a). However, estrogens in ovarian cancer cell lines do not regulate pS2 protein 
even in the ones that have induced progesterone receptors (PR) or growth regulated 
(Langdon et al., 1994b). In addition, pS2 protein has only been found in a subset of 
ovarian tumors (Foekens et al., 1990b; Wysocki et al., 1990; Henry et al., 1991; 





presence of ER and the response to estrogen in breast cancers can be extrapolative  to 
ovarian cancers. 
 
1.2.3.5     Fibulin-1 
In ovarian cancer cell lines, estrogens induce the extracellular matrix (ECM) 
protein, fibulin 1 (Clinton et al., 1996). Its association with other ECM components 
like fibronectin, laminin and nidogen suggests that fibulin 1 is involved in cell 
morphology, adhesion and motility (Balbona et al., 1992; Pan et al., 1993). 
Nonetheless, the distribution of this protein is ubiquitous in the connective tissue and 
in blood but generally not found in epithelial cells and several types of cancer cells 
(Roark et al., 1995).  The discovery that estrogens induces fibulin 1 in ovarian cancer 
cells, thus reveal its role in locoregional invasion and metastasis. These findings 
revealed the potential of developing fibulin 1 based treatment strategies on controlling 
the spread of ovarian cancer in the peritoneal cavity.    
 
1.2.3.6     HER-2/neu 
HER-2 /neu is a receptor – like tyrosine kinase that is overexpressed in 20 % 
of ovarian cancers (Slamon et al., 1989; Zhang et al., 1989; Berchuck et al., 1990; 
Haldane et al., 1990; Kury et al., 1990; Press et al., 1990; Mandai et al., 1994). This 
gene is often associated with cancer progression and poor prognosis in breast and 
ovarian cancers. Though estrogens induce many growth regulatory genes, HER-2/neu 
proto-oncogene is downregulated by estrogen in breast cancer cell lines. Despite the 
fact that estrogens regulate many growth regulatory genes in breast and ovarian 
cancer, estrogens do not cause down-regulation of HER-2/neu in ovarian cancer cell 





demonstrated that silencing of HER-2/neu resulted in slower cell proliferation, 
increased apoptosis, increased G0/G1 arrest, and decreased tumor growth (Yang et 
al., 2004).  
In addition, the “humanized” monoclonal antibody of HER-2, trastuzumab 
(Herceptin) is reported to improve therapeutic efficacy when used in combination 
with chemotherapy in breast and ovarian cancers in-vitro (Schaller et al., 1999; Shak, 
1999; Scholl et al., 2001). The relationship between HER-2/neu expression and 
response to antiestrogen therapy in breast cancers and the inhibition of ovarian cancer 
cell growth through silencing of this gene or protein, thus stimulate the prospective 
value of HER-2/neu as a prognostic, diagnostic and/ or treatment target in ovarian 
cancers.   
 
1.2.3.7     Breast and Ovarian Cancer Susceptibility Gene 1 
Breast and Ovarian Cancer Susceptibility Gene 1 (BRCA1) is a gene that is 
involved in breast and ovarian cancers, which appears to function as a tumor 
suppressor gene (Miki et al., 1994). Though mutations in BRCA1 has been found in 
sporadic ovarian cancers, these similar mutations have not yet been identified in 
sporadic breast cancers (Futreal et al., 1994; Hosking et al., 1995; Merajver et al., 
1995). Identification of cancer susceptible carrier mutant alleles of BRCA1 in 
hormone responsive tissues has advocated the possible hormone regulated expression 
of this gene. In vivo studies, suggest that BRCA1 expression in the mammary glands 
of ovariectomized female mice is regulated by estrogen and progesterone (Marquis et 
al., 1995).  
Conversely, the gene expression in the ovary is restricted to the follicle cells 





determine whether BRCA1 expression in ovarian surface epithelial cells is regulated 
by estrogen and progesterone as shown in the breast or whether the gene expression 
may be modulated during different times of the estrous cycle particularly when the 
surface epithelium is being repaired after ovulation. 
 
1.2.3.8     Kallikreins 
Kallikreins (KLKs) are a subgroup of serine proteases with diverse 
physiological functions that is an emerging family of prognostic factor in ovarian 
cancers. The most prominent kallikrein is human isoform-3 (KLK3), which is the 
best-known biomarker in clinical medicine for early detection and management of 
prostate cancers (Diamandis, 1998). Nonetheless, discovery of kallikrein isoform-1 
(KLK1) upregulation in human endometrium during the middle of the menstrual cycle 
suggests the involvement of estrogens in the upregulation of this protein (Clements et 
al., 1994). About 15 KLKs have since been isolated and these have been shown to be 
potential biomarkers for ovarian cancers both at the mRNA and protein levels (Obiezu 
and Diamandis, 2005). It is therefore interesting to evaluate whether the established 
kallikreins serum markers when used in combination with one of the most common 
ovarian cancer biomarker, CA-125 (Woolas et al., 1993; McIntosh et al., 2004; 
Schorge et al., 2004), can improved the prognosis, diagnosis and screening of early 
stage ovarian cancers.  
 
1.3 Treatment of Ovarian Cancers 
Despite advances in ovarian cancer treatment in the past 40 years, it remains 
as the second most common gynecological malignancy (McGuire, III and Markman, 





as the common symptoms of persistent abdominal swelling pain and pressure of the 
pelvis can be attributed to a number of causes (Lister-Sharp et al., 2000). Ovarian 
cancers are often discovered during routine pelvic examination after an abdominal 
mass is formed or when the tumor has metastasized (Memarzadeh and Berek, 2001). 
In concurrence, treatment of ovarian cancer is based on the staging of the disease, 
which reflects the extent and spread of the cancer to other parts of the body.  
 
1.3.1 Surgery and Chemotherapy for Ovarian Cancer 
Surgery is the current intervention of choice for ovarian cancers (Lister-Sharp 
et al., 2000). Hysterectomy with bilateral salpingo-oophorectomy (removal of the 
fallopian tubes and ovaries) is usually performed in young patients with low-grade 
unilateral epithelial lesions or non-epithelial malignancy. Reproductive capability can 
only be preserved by excision of the affected ovary (after surgical staging 
procedures). On the other hand, tumor debulking is often performed to improve the 
efficacy of adjunctive therapies in advanced cases (Beers and Berkow, 1999). In most 
patients, optimal debulking is achieved and prognosis is directly correlated to the 
success of such cytoreductive surgery (Memarzadeh and Berek, 2001). 
For several decades, chemotherapy is regarded as the standard therapy for the 
majority of women with advanced epithelial ovarian cancer following tumor 
debulking.  More than two decades ago, women with advanced ovarian cancers are 
commonly treated with monotherapies using alkylating agents like melphalan, 
cyclophosphamide, chlorambucil and thiotepa (McGuire, III and Markman, 2003). 
The overall response rate of these drugs range from 33 % to 65 %, with complete 





Dunton, 1997). Among the responders the survival median is only around 17 – 20 
months (Dunton, 1997). 
 
1.3.2  Cisplatin Therapy  
From the mid 1970s onwards, cisplatin [cis-diamminedichloroplatinum (II)] 
has been established as one of the potent antitumor agents, which is known to display 
clinical activity against a wide variety of solid tumors and treatments with these 
platinum based compounds have been a standard of care for women diagnosed with 
advanced epithelial ovarian cancer for more than two decades (Muggia et al., 2000). 
Treatment of patients refractory to alkylating agents with cisplatin reported overall 
response rates of 26.5 % and 29 % (Wiltshaw and Kroner, 1976; Young et al., 1979). 
Likewise in 1985, a randomized comparison of first line single-agent cisplatin with an 
alkylating agent  (cyclophosphamide) in 86 women with advanced ovarian cancer 
demonstrated significantly longer survival and response duration in patients receiving 
the cisplatin treatment (Lambert and Berry, 1985). These findings are followed by 
several other reports that demonstrated superior response and survival rates with 
combination over single agent therapies (Neijt et al., 1984; Williams et al., 1985; 
Omura et al., 1986), resulting in the combination of cisplatin with alkylating agent 
being established as standard treatment for advanced ovarian cancers. 
The overall clinical response rate with cisplatin in ovarian cancer patients is 
about 67 % and its failure is often associated with significant neurotoxicity, 
ototoxicity, nephrotoxicity and gastrointestinal as well as myelosuppression (Muggia 
et al., 2000; McGuire, III and Markman, 2003). Other new drugs including paclitaxel, 
docetaxel, vinorelbine, irinotecan, and gemcitabine are currently being used together 





limited efficacy of cytotoxic chemotherapy remains a key obstacle for the treatment of 
patients with advance ovarian cancer.      
 
1.3.3 Cisplatin Mode of Action and Molecular Basis of Resistance 
Cisplatin belongs to the chemotherapy group of alkylating agents that binds to 
DNA creating adduct, crosslinks, and strand breaks that inhibit DNA replication 
leading to the activation of several signal transduction pathways that involves ATR, 
p53, p73 and MAPK resulting in the activation of apoptosis (Judson et al., 1999; 
Siddik, 2003). The overall pathways involved in mediating cisplatin-induced cellular 
effects are summarized in Figure 1.3 (Siddik, 2003).  
However, this DNA damage-mediated apoptosis signals can be attenuated and 
this may be a result of resistance, which is a major limitation of cisplatin-based 
chemotherapy. There are several mechanisms that contribute to cisplatin resistance, 
these include reduced drug uptake, increase drug inactivation, and increased DNA 
adduct repair (Richon et al., 1987; Teicher et al., 1987; Eastman and Schulte, 1988). 
Formation of DNA adducts of cisplatin is vital in inducing apoptosis and by 
enhancing the rate of adducts repair the apoptotic process is attenuated; the factors 
that contribute to the enhanced repair are indicated in Figure 1.4 (Siddik, 2003).  
Nonetheless, the origin of these pharmacological based mechanisms is at the 
molecular level. These mechanisms that inhibit propagation of DNA damage signal to 
apoptosis comprises the loss of damage recognition, overexpression of HER-2/neu, 
activation of PI3-K/Akt pathway, loss of p53 function, overexpression of 
antiapoptotic bcl-2, and inhibition of caspase activation (Figure 1.5) (Siddik, 2003). 
These molecular events represent the resistant phenotype that varies between tumors 





Figure 1.3    An overview of pathways involved in mediating cisplatin-induced 
cellular effects. Cell death or cell survival will depend on the relative intensity of 
the signals generated and the crosstalk between the pathways involved (adapted 





Figure 1.4    Factors modulating repair of cisplatin-induced DNA adducts and 






Figure 1.5    Mechanisms involved in inhibiting the apoptotic signal in 
cisplatin-resistant tumor cells. More than one mechanism is usually observed in 
resistant cells, and this contributes to the multifactorial nature of cisplatin resistance 






The considerable toxicity observed in patients receiving cisplatin in 
combination with palitaxel, thus prompted the development of novel therapeutic 
options particularly ones that employed a combinational approach that targeted genes 
involved in apoptosis and tumor progression. However, unraveling the mechanisms 
responsible for cisplatin resistance have been limited by the difficulty in using 
biochemical approaches to identify genes involved in apoptosis and tumor 
progression. Fortunately, the rapid development of techniques in molecular biology to 
disrupt single gene expression in cells via RNA interference (RNAi) has provided an 
unambiguous strategy to identify genes whose products function to modulate the 
cytotoxicity of cisplatin.   
 
1.4 RNA interference (RNAi) 
1.4.1 Discovery and Development of RNAi and siRNAs 
Advances in the field of gene down-regulation using RNAi, through the 
introduction of complementary double stranded RNAs (dsRNAs) into cells can 
effectively suppress gene expression by mRNA degradation or inhibition of 
translation (Ryther et al., 2005; Tebes and Kruk, 2005). Specifically, the dicer 
processes these dsRNAs through cleavage into 19 – 21 nucleotide duplexes known as 
short interfering RNAs (siRNAs). Following cleavage by the dicer, these siRNAs are 
then incorporated into a silencing complex known as RISC (RNA-induced silencing 
complex), which identifies and silences complementary messenger RNAs (Figure 
1.6). This silencing mechanism of gene expression by RNA molecules was first 
discovered in nematode worms (Caenorhabditis elegans) (Fire et al., 1991; Guo and 





complementary to the dsRNAs. This relatively easy ablation of gene expression 
(“functional knockout”) using RNAi has provided the possibility of using a library of 
siRNAs to analyze the significance of hundreds and thousands of different genes that 
are upregulated in disease given the appropriate model (Paddison et al., 2004; Silva et 
al., 2004).  Genetic and biochemical studies have also confirmed that RNAi pathway 
underlying dsRNA-induced gene silencing is present in many, if not most, eukaryotic 
organisms (Hannon, 2002). 
The two main goals of RNAi approaches for cancer therapy involves silencing 
expression of cell cycle and/ or an antiapoptotic gene in cancer cells, thus inhibiting 
tumor growth and killing malignant cells (Izquierdo, 2005). In agreement, RNAi may 
theoretically target any gene related to cancer progression phenomena like metastasis, 
invasion and/ or angiogenesis. Significantly, this specific targeting of genes involved 
in the growth or survival of the cancer cell may selectively eliminate malignant cells 
without damaging normal cells, or the siRNA could selectively be delivered into 
cancer cells. Figure 1.7 summarized the potential of RNAi technology both as a 
powerful cancer research tool and a promising anticancer option.  
  
1.4.2 RNAi Technology in Gynecologic Cancers in-vitro 
Silencing of several targets using siRNA has already been reported to cause 
growth suppression of various cancer cell lines and is therefore a promising approach 
for gene therapy (Ryther et al., 2005; Devi, 2006). However, due to the involvement 
of numerous genes in tumor progression, simultaneous inhibition of multiple target 
genes may be necessary to effectively inhibit tumor progression. It is therefore 
necessary to combine the use of siRNA with other compounds, such as 
























Figure 1.6    SiRNA interference mechanism: short hairpin RNAs and long 
dsRNAs all are processed by Dicer to form siRNAs. Small interfering RNAs can 
also be directly delivered into cells through transfection. The double stranded 
siRNA then complexes with argonaute proteins to form the RISC complex. The 
sense strand is removed from the double stranded siRNA, leaving the antisense 
strand to anneal to the target mRNA. When the sequence has a perfect match, the 
target mRNA is degraded, but if the sequence has an inexact sequence match, the 





In fact, a few siRNAs have already been shown to enhance sensitivity to 
different chemotherapeutic drugs in vitro (Cioca et al., 2003; July et al., 2004). For 
instance, silencing various targets in ovarian cancer including Her-2/neu can result in 
in vitro decreased cell proliferation, increased apoptosis, increased G0/G1 arrest and 
decreased tumor growth (Yang et al., 2004). Likewise, H-ras RNAi resulted in 
decreased ovarian tumor growth and ovarian cancer cell lines transformation 
efficiencies (Yang et al., 2003; Choudhury et al., 2004; Yang et al., 2004). Similarly, 
targeting heparin-binding EGF-like growth factor (HB-EGF) with siRNA also 
resulted in decreased tumor growth in ovarian cancer cell lines (Menendez et al., 
2004). In addition, siRNA targeting proteins that confer multidrug resistance, p-gp 
and GST has also been previously shown to restore cisplatin sensitivity in-vitro (Duan 





Figure 1.7  Potential applications of RNA interference (RNAi) in cancer research 
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 also been shown to sensitize ovarian cancer cells to paclitaxel (Miyamoto et al., 
2004). 
1.4.3 Challenges in siRNA Technology 
Following the great success of siRNAs in cell culture and with Science 
magazine hailing RNAi as the “Breakthrough of the Year” in 2002, the past few years 
have seen enormous interest in RNAi applications for clinical therapies.  However, 
generating a siRNA for efficient gene silencing in animals is going to be more 
challenging and many issues must be addressed before use in-vivo routinely. Despite 
the specificity of siRNAs and efficacy issues, the therapeutic potential of siRNA for 
treatment of various diseases is still a promising avenue. This is especially true for 
diseases, which involves expression of mutant genes including dominant negative 
proteins, of aberrant splicing isoforms or overexpressed genes leading gain and loss of 
function.   
However, the mode of delivery may turn out to be the rate-limiting step in the 
development of RNAi based therapies in vivo. Conversely, viral vectors are not often 
required for successful RNAi as these can be directly injected into the animals or 
tumors. Nonetheless, the advantages of RNAi in vivo are that the duplex siRNAs are 
more stable than single stranded antisense molecules and these achieves a stronger 
inhibition of gene expression than previous antisense technologies (Braasch et al., 
2003; Hough et al., 2003; Carstea et al., 2005).    
To date, several successful in vivo studies have realized the therapeutic 
potential of RNAi. McCaffrey et al. have demonstrated that the injection of a plasmid 
containing siRNA into the tail vein of mice was able to suppress up to 90 % of the 
target gene, Hepatitis C (McCaffrey et al., 2002). Likewise, the RNAi of the Fas gene 





pancreas of the mice (Song et al., 2003). Targeting the hepatitis B virus genome in 
infected mice with siRNA has also been shown to successfully inhibit viral replication 
and protein production (Klein et al., 2003; McCaffrey et al., 2003). In addition, using 
adenoviral-mediated delivery of siRNA targeting polyglutamine aggregation, Xia et 
al. demonstrated the therapeutic RNAi benefit in neurodegenerative disorders (Xia et 
al., 2002). Correspondingly, the cationic lipid complexed siRNA targeting VEGF 
(vascular endothelial growth factor) has shown to inhibit ocular neovascularization in 
the mouse model (Reich et al., 2003). Finally, intraperitoneal, intravenous and 
subcutaneous injections of free siRNA targeting VEGF in fibrosarcoma-bearing mice 
have been shown to reduce VEGF expression by 70 % as well as a 66 % decrease in 
tumor volume over 16 days (Filleur et al., 2003). Taken together, these studies 
demonstrated the great potential of siRNA delivery in vivo. 
RNAi represents an exciting new era of functional genomics by selectively 
targeting specific genes. Recent years have seen RNAi rapidly being employed in 
mainstream research. Realizing the therapeutic potential of RNAi, Acuity 
Pharmaceuticals filed the first Investigational New Drug application with the FDA for 
therapeutic RNAi to treat age-related muscular degeneration (AMD) and is currently 
in Phase I trials. Shortly after, Sirna Therapeutics also filed an application with the 
FDA for its siRNA to treat AMD. Table 1.1 summarized several RNAi agents 
developed by biotechnology companies as potent inhibitors in various diseases. Given 
the success of RNAi in several in vivo studies as well as the promising data from 
gynecologic malignancies in tissue culture and animal studies, it is only a matter of 
time before RNAi enters the realm of clinical therapeutics either as a therapeutic 
agent or a chemosensitizing agent for treatment of gynecological and/ or other types 













































Chapter 2 INTRODUCTION 
2.1  Isolation of UO-44 (UTCZP) 
Estrogens promote the growth, differentiation, and remodelling of the uterus 
during the estrous cycle and pregnancy. This hormone has been shown to play a vital 
role in the cellular proliferation and epithelial differentiation of the uterus and ovaries 
during early stages of pregnancy through the modulation of genes that regulate cell 
growth and differentiation. Tamoxifen is a type 1 (non-steroidal) anti-estrogen that 
exhibits mixed estrogenic and anti-estrogenic activity. This drug has previously been 
reported to significantly increase uterine weight, while pure anti-estrogens (ICI 
182780) administration suppresses it (Huynh and Pollak, 1993). It has also been 
shown that tamoxifen not only inhibited expression of IGF-I (Insulin Growth Factor I) 
in the uterus but also alter expression of genes that regulated proliferation (Huynh and 
Pollak, 1994).    
With the objective to identify novel tamoxifen inducible genes in the uterus, 
differential display was employed to examine the transcript-expression profiles of 
overiectomized uterus, after treatment with tamoxifen. Out of the 14 clones isolated, 
the longest clone contained a 2.2 kb insert that is found overexpressed in the uterus 
and ovary (Huynh et al., 2001). This tamoxifen induced complementary DNA 
(cDNA) is named UO-44 (uterine-ovarian specific gene – 44, GenBank accession no. 
AF022147). The mouse ortholog of this cDNA (UTCZP – uterine cub zona pellucida 
protein, GenBank accession no. U69699) has also been isolated in the mouse uterus 6 
days prior to birth but not expressed in the non-pregnant uterus or in a variety of adult 
and fetal tissues (Kasik, 1998). Conceptual translation of UTCZP encoded for a 





signal peptide followed by two contiguous CUB domains, a ZP domain, a putative 
TMD, and a short cytoplasmic C-terminal tail. This report suggested that UTCZP 
played an important role in the events that occur during late pregnancy.  
 
2.2  Estrogen Regulation of UO-44 Expression (ERG-1) 
Unlike the mouse ortholog, the rat UO-44 is expressed in both pregnant and 
non-pregnant uteri (Chen et al., 1999; Huynh et al., 2001). Chen et al., reported a 
cDNA known as ERG1 (estrogen regulated gene 1, GenBank accession no. 
AF167170) that is regulated by estrogens, and its expression is restricted to the uterus 
and oviduct (Chen et al., 1999). This cDNA shared a 99 % homology to rat UO-44 
cDNA, which is also expressed in the granulosa cells of the ovary (Huynh et al., 
2001). In this report, Huynh et al. have demonstrated that the expression of UO-44 
gene expression in the uterus correlated well with the positive or negative uterotrophic 
effects of ER antagonists and partial agonist. 
 
2.3  UO-44 Role in Susceptibility in Pancreatitis (ITMAP-1) 
The mouse ortholog of UO-44 also known as Itmap-1 (integral membrane 
associated protein – 1) contains functional motifs identical to that found in UTCZP. 
This protein is prominently expressed in the pancreatic acinar cells and is localized to 
the zymogen granule membranes (Imamura et al., 2002). Strikingly, the homozygous 
nulls mice of Itmap-1 is reported to have increased severity of pancreatitis, which 
might be attributed by the impaired activation of trypsinogen but these nulls have no 





2.4  Objective of this Study 
In reproductive organs, endogenous estrogens promote cell proliferation 
through the modulation of genes that regulate cell growth and differentiation. UO-44 
is an estrogen-regulated gene that has been implicated in pregnancy development, 
epithelial proliferation and differentiation, and increased severity of pancreatitis. In 
addition, a more recent bioinformatics assessment under the Secreted Protein 
Discovery Initiative (SPDI) has also identified UO-44 as one of the novel secreted 
and transmembrane human proteins (Clark et al., 2003).  
This study will test the hypothesis that UO-44 is involved in the initiation and 
progression of ovarian cancers. To establish this the following objectives have to be 
achieved: (i) screening, cloning, sequencing and establishing the full-length human 
UO-44 gene (HuUO-44); (ii) establishing a rat model to characterize the functions and 
regulations of UO-44 through the cloning of the rat orthologs of this gene; (iii) using 
the rat model to study the regulatory effect of pregnancy development on UO-44 in 
the mammary gland;  (iv) determining the expression profile of HuUO-44 in ovarian 
cancers, discovering the potential use of UO-44 as a biomarker for ovarian cancers, 
and/ or estrogens responsiveness ; and (v) examining the consequence of HuUO-44 
overexpression or silencing in ovarian cancer cells. 




Chapter 3  MATERIALS AND METHODS 
3.1 Reagents 
Horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit 
secondary antibodies were purchased from Pierce, Rockford, Illinois. Unless 
otherwise indicated, chemicals used were purchased from Sigma Chemical Co, St 
Louis, MO. Primers used for polymerase chain reaction (PCR), reverse transcription - 
PCR (RT-PCR) and real-time PCR were supplied by Proligo Primers & Probes, 
Singapore. Sequences and uses of all primer were summarized in Table 3.1. 
 
3.2  Cell Lines and Cell Culture 
Ovarian cancer cell lines (ES-2, NIH-OVCAR3, Pa-1, OV-90 and SKOV-3) 
and cervical cancer cell lines (Caski, HeLa, HT3 and Siha) were purchased from the 
American Tissue Culture Collection, Manassas, VA. All cell culture media used were 
supplied by Sigma Chemical Co, St Louis, MO. ES-2 and SKOV-3 were maintained 
in McCoy’s 5A medium, while NIH-OVCAR3, PA-1, OV-90 were maintained in 
RPMI 1640 medium, Alpha Modified Eagle medium (α-MEM) and High-Glucose 
Dulbecco’s modified Eagle’s medium (Hi-Glu DMEM), respectively. Cervical cancer 
cell lines, HeLa and Siha were maintained in Alpha Modified Eagle medium (α-
MEM), while Caski and HT-3 were maintained in RPMI 1640 medium and McCoy’s 
5A medium, respectively. All cell culture media contained 1 % 
penicillin/streptomycin (Gibco, Gland Island, NY) and was supplemented with 10 % 
fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). All tissue culture dishes were 
purchased from NUNC Inc, Naperville, IL. 





Table 3.1 Sequences of oligonucleotides used for RT-PCR (a), Cloning (b), 
Sequencing (c), PCR (d) and 5’ RACE Primer (e). 
Oligonucleotide Sequence 
c T7  (5’- TAATACGACTCACTATAGGG -3’) 
c SP6  (5’- CTATTTAGGTGACACTATAG -3’) 
c Nested-HuUO-44/F  (5’- ATGCCAATTCTTACCGGGG -3’) 
c Nested-HuUO-44/R  (5’- GAGTTAAAAGCCTCTAGGTAG -3’) 
e 5’RACE-HuUO-44/R  (5’- AGCTCCAGCAGAGGTGAGTCCTCTTCCC 
-3’) 
c RACE-Nested-HuUO-44/F  (5’- CTCCAATCACCTGACAGTCT -3’) 
c RACE-Nested-HuUO-44/R  (5’- CCACAAAGCCATGATCCTGC -3’) 
a, b, c, d HuUO-44-E1/F  (5’- CACCATGCCAATTCTTACCGGGG -3’) 
a, b, c, d HuUO-44-E9/R  (5’- GTTAATAGTTCTGCAGCTTCT -3’) 
c, d HuUO-44-E7/R  (5’- CACAATAATCTGGAGTTGTTTC -3’) 
c HuUO-44-E2/R  (5’- TCTTTCTATTGTCCAGGTGC -3’) 
c HuUO-44-E5/F  (5’- ATGCCAATTCTTACCGGGG -3’) 
c HuUO-44-E6/R  (5’- GAGTTAAAAGCCTCTAGGTAG -3’) 
c, d HuUO-44-E7/F  (5’- CACCATGGCTCTTTTTGAATCCAATTC -
3’) 
a, b, c RatUO-44-E1/F  (5’- ATGGAGGTCACTGGAAGGC - 3’) 
a, b, c RatUO-44-E9/R  (5’- TCTTCGACGTCCAGATGGATC - 3’) 
a, b, c RatUO-44-E6/R  (5’- TGACTGTAGGTATGACTTGCT - 3’) 
a, b, c RatUO-44-E7/F  (5’- TTGCATCTCCAACCTATGACT - 3’) 
c RatUO-44-E8/R  (5’- TTGGTCCTATAACAGAATCAGT -3’) 
a TubulinF  (5’- AACGTCAAGACGGCCGTGT -3’) 
a TubulinR  (5’- GACAGAGGCAAACTGAGCAC -3’) 
c, d Gate-FL-HuUO-44/F  (5’- CACCATGCCATTGACCCTCTTAATT -3’) 
c, d HuUO-44-eGFP/R  (5’- CTCGCCCTTGCTCACCATATAGTTCTGCA 
GCTTCTGGT -3’) 
c, d eGFP/F  (5’- ATGGTGAGCAAGGGCGAG -3’) 









Animal were maintained and treated according to the protocol approved by the 
institutional animal care committee at the National Cancer Centre of Singapore. 
Twenty-four female Sprague-Dawley rats (fifty days old and weighing approximately 
250g) were divided into 4 equal groups. Each group (n = 6) received daily 
intraperitoneal (IP) injection of either phosphate buffer saline (PBS) or 3 different 
doses of β-estradiol, tamoxifen and ICI 182780 for 21 days. After the last injection, 
the rats were allowed to rest for an additional 2 days before they were sacrificed. The 
ovary, uterus and mammary gland were harvested, snap frozen in liquid nitrogen and 
stored at -80 oC. 
 
3.4 Probe Labeling 
All probes used in cDNA library screening, Southern and Northern blot 
analyses were radioactively labeled with  [α-32P]deoxy-CTP (Perkin-Elmer, Boston, 
MA) using the Rediprime II DNA Labeling System (Amersham, Pharmacia Biotech, 
Arlington Heights, IL) as described by the manufacturer. Unincorporated [α-
32P]deoxy-CTP was removed using the QIAquick Nucleotide Removal Kit (Qiagen, 
GmbH, Hilden). 
 
3.5 Human Ovarian cDNA Library for Human Ortholog of 
UO-44 
Cloning of the human ortholog of UO-44 (HuUO-44) was performed through 
screening of a Human Adult Ovarian Premade cDNA Library (Invitrogen, Carlsbad, 
CA). The frozen bacteria stock was diluted to 1/100 with Luria-Bertani (LB) medium 




and plated onto LB-carbenicillin (Invitrogen, Carlsbad, CA) plates to generate about 1 
x 106 colonies. The colonies were immobilized onto Zeta-Probe Genomic Tested 
Blotting Membrane (nylon) (Bio-Rad, Laboratories, Inc., CA) and the immobilized 
colonies were lysed in a denaturation solution (1.5 M NaCl and 0.5 M NaOH) for 5 
min. Following denaturation, neutralization of the denatured membranes was then 
carried out for 5 min in a neutralization solution (1.5 M NaCl, 0.5 M Tris-Cl pH 8.0); 
followed by 2 washes with 2 x SSC for 5 min. Fixation of the DNA onto the 
membrane was performed with UV in a UV Stratalinker 2400 (Stratagene, La Jolla, 
CA).  
Prior to hybridization with the radioactive labeled probe, the colony-
immobilized membranes were pre-hybridized for 3 h at 42 oC in a solution containing 
50 % formamide, 4 x SSPE, 1 % SDS, 0.5 % skim milk and 0.1 mg/ml sonicated 
salmon sperm DNA. A 500 bp fragment of the rat UO-44 cDNA (nucleotides 1780-
2280, GenBank accession no. AF022147) was used as hybridization probe for this 
cDNA library screening. This radioactive labeled probe was denatured at 99 oC for 5 
min before hybridization overnight at 42 oC in a solution containing 50 % formamide, 
4 x SSPE, 1 % SDS, 0.5 % skim milk and 10 % dextran sulphate. Subsequently, the 
hybridized membranes were washed 3 times for 15 min each at room temperature 
with 2 x SSC and 0.1 % SDS. High stringency wash was carried out with 0.1 x SSC 
and 0.1 % SDS at 42 oC till a low background count was achieved. Secondary 
screening was performed and Southern blot analysis was used to confirm clone 
identity.  
Positive clones were fully sequenced using T7 (5’- TAATACGACTCACTAT 
AGGG -3’), SP6 (5’- CTATTTAGGTGACACTATAG -3’), Nested-HuUO-44/F (5’- 
ATGCCAATTCTTACCGGGG -3’) and Nested-HuUO-44/R (5’- GAGTTAAAAGC 




CTCTAGGTAG -3’) sequencing primers. The authenticity of the clones was verified 
using automated sequencing (ABI 377) via dideoxy chain termination using the 
BigDye version 3.0 (Applied Biosystems, CA, USA). Sequence analysis was carried 
out using Laser gene sequence analysis software (Dnastar Inc, Madison, WI). 
 
3.6 Rapid Amplification of cDNA Ends (RACE) 
To establish the full-length cDNA of HuUO-44, 5’ RACE was performed 
using the SMART™ RACE cDNA amplification kit (Clontech, Palo Alto, CA) 
according to the manufacturer’s direction with the following modification: The 
secondary PCR amplifications of the primary RACE products were performed using 
Advantage® Genomic polymerase (Clontech, Palo Alto, CA), instead of the 
polymerase recommended, i.e. Advantage® 2 Polymerase (Clontech, Palo Alto, CA). 
Gene-specific primer, 5’RACE-HuUO-44/R (5’- AGCTCCAGCAGAGGTGAGTCC 
TCTTCCC -3’) was designed based on the 5’ end sequence of the cDNA library 
isolated HuUO-44 cDNA (GenBank accession no. AF305835).  
The RACE products were identified using Southern blot analysis and were 
subsequently cloned into pCR®-Blunt-II-TOPO vector (Invitrogen, Carlsbad, CA) 
according to the manufacturers instructions. These HuUO-44 RACE fragments were 
sequenced using T7, SP6, RACE-Nested-HuUO-44/F (5’- CTCCAATCACCTGACA 
GTCT -3’) and RACE-Nested-HuUO-44/R (5’- CCACAAAGCCATGATCCTGC -3’) 
primers. Sequence analysis was carried out as described above. 




3.7 Cloning of UO-44 cDNAs 
3.7.1 Cloning of HuUO-44 – A, B, C, D and E transcripts 
Cloning of HuUO-44 cDNA variants was achieved through reverse-
transcription followed by polymerase chain reaction (RT-PCR). To generate the 
cDNA template for PCR cloning, total RNA was extracted using Trizol Reagent 
(Invitrogen, Carlsbad, CA) and 1 ug of total RNA was reversed transcribed using One 
Step RT-PCR Kit (Qiagen, GmbH, Hilden) with the following PCR primers: forward 
primer HuUO-44-E1/F (5’- CACCATGCCAATTCTTACCGGGG -3’) designed in 
exon 1 at the 5’ and the reverse primer HuUO-44-E9/R (5’ – GTTAATAGTTCTGCA 
GCTTCT -3’) in exon 9 at the 3’ end according to the manufacturer’s instructions. 
The following cycles was used in One Step RT-PCR reaction: reverse transcription at 
45 oC for 30 min; activating Taq Polymerase at 95 oC for 15 min; followed by 30 
cycles of 94 oC for 10 sec, 55 oC for 1 min, 68 oC for 1 min 30 sec, and final extension 
at 68 oC for 10 min. The amplified products were separated on a 1 % agarose gel and 
Southern blot was performed to confirm the variants identity.  
To obtain a better resolution of the different HuUO-44 variants, One-step RT-
PCR was repeated with forward primer HuUO-44-E1/F and reverse primer HuUO-44-
E7/R (5’- CACAATAATCTGGAGTTGTTTC -3’), which resides in exon 1 and 6, 
respectively. The PCR products were separated on a 1 % agarose gel (Invitrogen, 
Carlsbad, CA); the different sized bands were excised and gel extracted using the 
QIAquick Gel Extraction Kit (Qiagen, GmbH, Hilden). The gel extracted PCR 
products were subsequently cloned into pCR®-Blunt-II-TOPO vector (Invitrogen, 
Carlsbad, CA), according to the manufacturers instructions. Sequencing of the HuUO-
44 variants was carried out using T7, SP6, HuUO-44-E2/R (5’- TCTTTCTATTGTCC 
AGGTGC -3’), HuUO-44-E5/F (5’- ATGCCAATTCTTACCGGGG -3’), HuUO-44-




E6/R (5’- GAGTTAAAAGCCTCTAGGTAG -3’), HuUO-44-E7/F (5’- CACCATGG 
CTCTTTTTGAATCCAATTC -3’) and HuUO-44-E7/R primers.  
 
3.7.2 Cloning of RatUO-44 – A, B, C, D and E 
Similarly, the cloning of the splice variants of rat UO-44 was also performed 
using One Step RT-PCR with PCR primers residing in exon 1, RatUO-44-E1/F (5’ -
ATGGAGGTCACTGGAAGGC - 3’), and exon 9, RatUO-44-E9/R (5’ - TCTTCGA 
CGTCCAGATGGATC - 3’). To obtain a better resolution of the different rat UO-44 
variants, One-step RT-PCR was repeated with primer, RatUO-44-E1/F and RatUO-
44-E6/R (5’ - TGACTGTAGGTATGACTTGCT - 3’), which resides in exon 1 and 6, 
respectively. Total Rat UO-44 expression was determined through RT-PCR 
amplification using primers, RatUO-44-E7/F (5’ - TTGCATCTCCAACCTATGACT 
- 3’) and RatUO-44-E9/R.  
Amplification of the rat UO-44 variants was performed using One Step RT-
PCR with the following cycles: reverse transcription at 45 oC for 30 min; activating 
Taq Polymerase at 95 oC for 15 min; followed by 35 cycles of 94 oC for 10 sec, 60 oC 
for 1 min, 68 oC for 1 min, and final extension at 68 oC for 10 min. The RT-PCR 
products of the rat UO-44 variants were separated on a 1 % agarose gel (Invitrogen, 
Carlsbad, CA); the different sized bands were excised and gel extracted using the 
QIAquick Gel Extraction Kit (Qiagen, GmbH, Hilden). The gel extracted PCR 
products were subsequently cloned into pCR®-Blunt-II-TOPO vector (Invitrogen, 
Carlsbad, CA), according to the manufacturers instructions. The identities of the Rat 
UO-44 variant clones were verified through sequencing with the following primers: 
T7, SP6, RatUO-44-E1/F, RatUO-44-E6/R, RatUO-44-E7/F, RatUO-44-E8/R (5’- TT 
GGTCCTATAACAGAATCAGT -3’) and RatUO-44-E9/R. 




3.8 Multiple Tissue Expression Array, Multiple Tissue 
Northern, Cancer Profiling Array and Cancer Cell Line 
Profiling Array 
The Multiple Tissue Expression (MTE), Cancer Profiling Array (CPA) and 
Cancer Cell Line Profiling Array blots were purchased from (Clontech, Palo Alto, 
CA), while the Multiple Tissue Northern (MTN) blot was acquired from (Invitrogen, 
Carlsbad, CA). All blots were hybridized with a 625 bp fragment of the HuUO-44 
cDNA (1520-2144 bp, GenBank accession no. AY260047). This probe was 
radioactively labeled [α-32P] and hybridized following the manufacturer’s 
instructions. Glyceraldehydes-3-phosphate dehydrogenase (GAPDH: American Type 
Culture Collection, Manassas, VA) cDNA probe was used for normalization of the 
MTN blot, while the MTE, CPA and Cancer Cell Line Profiling Array was 
normalized with a ubiquitin probe provided by the manufacturer.  
Pre-hybridization of the arrays and blots were performed at 50 oC for 1 h in 
ExpressHyb™ (Clontech, Palo Alto, CA) with sheared salmon testis DNA added to a 
final concentration of 0.1 mg/ml. The radiolabeled probe was denatured at 99 oC for 5 
min and subsequently mixed directly into the pre-hybridization solution, hybridization 
was carried out overnight at 50 oC. After hybridization, the arrays or blots were 
washed 3 times at 55 oC in wash solution 1 (2 x SSC, 0.5 % SDS) for 30 min each 
time, repeated with wash solution 2 (0.2 x SSC, 0.5 % SDS) and a final rinse in 2 x 
SSC at room temperature. Blots were exposed to a phosphor-imager (Bio-Rad, 
Laboratories, Inc, CA).  As for the Northern blot analysis, washing was performed at 
45 oC with wash solution 1 and 2. Densitometric scanning and analysis of 




autoradiographs or the phospho-images were performed using the Quantity One 
software (Bio-Rad, Laboratories, Inc., CA).    
 
3.9 Semi-quantitative RT-PCR of Human and Rat UO-44  
The normal ovarian epithelium and ovarian tumor samples were obtained from 
patients and the study received Ethics Board approval at the National Cancer Centre 
of Singapore and Singapore General Hospital, tissue samples obtained were snap 
frozen in liquid nitrogen. Total RNA was extracted using Trizol Reagent (Invitrogen, 
Carlsbad, CA) following the manufacturer’s instructions. Total expression of HuUO-
44 was analyzed using the semi-quantitative One-step RT-PCR Kit (Qiagen, GmbH, 
Hilden). RT-PCR was performed using 1 μg of total RNA and primers used resided in 
exon 7 (HuUO-44E7/F) and exon 9 (HuUO-44/R). One Step RT-PCR of HuUO-44 
was carried out with the following cycles: reverse transcription at 45 oC for 30 min; 
activating Taq Polymerase at 95 oC for 15 min; followed by 30 cycles of 94 oC for 10 
sec, 55 oC for 1 min, 68 oC for 1 min, and final extension at 68 oC for 10 min.  
Semi-quantitative RT-PCR analysis of the total rat-UO-44 expression was 
carried out using primers residing in exon 7 (RatUO-44-E7/F) and 9 (RatUO-44-
E9/R). The amplification cycles used were: reverse transcription at 50 oC for 30 min; 
activating Taq Polymerase at 95 oC for 15 min; followed by 35 cycles of 94 oC for 1 
min, 55 oC for 1 min, 72 oC for 1 min, and final extension at 72 oC for 10 min.  α-
tubulin was used for normalization of the HuUO-44 and Rat UO-44 RT-PCRs. 
Amplification of a 400 bp fragment of α-tubulin cDNA was performed a pair of α-
tubulin primers, TubulinF (5’- AACGTCAAGACGGCCGTGT -3’) and TubulinR 
(5’- GACAGAGGCAAACTGAGCAC -3’). RT-PCR cycles used for amplification of 
α-tubulin were: reverse transcription at 50 oC for 30 min; activating Taq Polymerase 




at 95 oC for 15 min; followed by 27 cycles of 94 oC for 1 min, 60 oC for 1 min, 72 oC 
for 1 min, and final extension at 72 oC for 5 min. All RT-PCR products were 
separated on a 1.5 % agarose gel (Invitrogen, Carlsbad, CA) and the identities of the 
bands were verified through sequencing. 
 
3.10 Quantitative (Real-time) PCR of UO-44  
For quantitative real-time PCR analysis, the first strand cDNA was obtained 
through the reverse transcription of 1 μg of total RNA using SuperScript II Reverse 
Transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
1 μl of the resulting cDNA was used in the subsequent PCR reaction in iQTM SYBR® 
Green Supermix (Bio-Rad, Laboratories, Inc, CA), with following cycles 95 oC for 3 
min; followed by 40 cycles of 95 oC for 10 sec, 60 oC for 30 sec, 72 oC for 30 sec. 
MyiQ Real-Time PCR Detection System (Bio-Rad, Laboratories, Inc, CA) was used 
to real-time monitor the PCR amplification and the DNA concentration of each 
reaction was determined quantitatively using a standard curve. Primers used for 
analysis of HuUO-44 and Rat UO-44 expression were the ones mentioned in Section 
3.9.  
Normalization of the quantitative gene expression analysis was also performed 
using α-tubulin as a reference gene, to determine the differences in the amount of 
total RNA and to compensate for different RT efficiencies. The α-tubulin primers 
used for normalization was the same ones mentioned in Section 3.9. Agarose gel 
electrophoresis and melt curve analysis was used to confirm the absence of non-
specific amplification products.  
 




3.11 Generation and Transfection HuUO-44-eGFP fusion 
Constructs 
Amplification of HuUO-44D transcript containing an open reading frame of 
607 aa fused to an eGFP protein was achieved using the following primers: Gate-FL-
HuUO-44/F (5’- CACCATGCCATTGACCCTCTTAATT -3’), HuUO-44-eGFP/R 
(5’- CTCGCCCTTGCTCACCATATAGTTCTGCAGCTTCTGGT -3’), eGFP/F (5’- 
ATGGTGAGCAAGGGCGAG -3’) and eGFP/R (5’- TTACTTGTACAGCTCGTCC 
A -3’). Two separate PCR were performed with the ORF of HuUO44 amplified using 
GateHuUO-44/F and HuUO-44-eGFP/R primers, while the ORF of eGFP was 
amplified using eGFP/F and eGFP/R primers. PCRs were set up with 50 ng of the 
pTOPO-HuUO-44D plasmid DNA (cloned in Section 3.7.1) in a total volume of 50 μl 
containing 10 pmol of each primer, 100 nmol of each dNTP, 1 IU of Native Pfu 
Polymerase (Stratagene, La Jolla, CA), 1.5 mM MgCl2 and 1 x Native Pfu Buffer 
(Stratagene, La Jolla, CA). Next an overlapping PCR was performed with the two 
previous PCR products as templates using Gate-FL-HuUO-44/F and eGFP/R primers.  
All PCR were performed using the following cycles: 95 oC for 5 mins; 
followed by 25 cycles of 95 oC for 30 min, 55 oC for 30 min, 72 oC for 1 min 30 sec, 
and a final extension of 72 oC for 5 min. The resulting HuUO-44-eGFP fusion PCR 
product was subsequently cloned into pCR®-Blunt-II-TOPO vector (Invitrogen, 
Carlsbad, CA) and sub-cloned directionally in to a pcDNA3 (Invitrogen, Carlsbad, 
CA) mammalian expression vector via HindIII and NotI restriction enzyme sites 
found on both vectors. An eGFP positive control was constructed with the same 
strategy using only eGFP/F and eGFP/R primers for PCR. The ORF of HuUO-44 in 
the resultant clones were verified through sequencing using primers mentioned in 
Section 3.6.1 with the addition of eGFP/F and eGFP/R.  




After sequence verification, HuUO-44-eGFP-pcDNA3.0 and eGFP-pcDNA3.0 
constructs, plasmid maxi-preps of the constructs were prepared using the Endofree® 
Plasmid Maxi Kit (Qiagen, GmbH, Hilden). Prior to the day of transfection, 5 x 106 
NIH-OVCAR3 cells were seeded onto ethanol washed 12 mm coverslips that were 
placed in a 100 mm tissue culture dish. The plate was about 70 % confluent during 
transfection, 10 μg of either HuUO-44-eGFP-pcDNA3.0 or eGFP-pcDNA3.0 plasmid 
was transfected into the NIH-OVCAR3 cells after 20 min preincubation with 10 μl of 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in serum free OPTI-MEM 
(Invitrogen, Carlsbad, CA). After 6 h of transfection, the transfection mix was 
replaced with RPMI-1640 culture medium. Coverslips was removed at 24 and 48 h 
post-transfection, and fixed in 10 % formalin for 10 min. The fixed coverslips were 
washed twice with Phosphate Buffered Saline (PBS) and mounted onto a slide. 
Observation was carried out using an Olympus BX60 Optical Microscope (Olympus, 
Melville, NY) equipped with epifluorescence optics and appropriate filters for FITC. 
 
3.12 UO-44 Antibodies and Immunohistochemistry 
After rare codon analysis, a 636 bp 3’ region of HuUO-44 cDNA (nucleotides 
1521 – 2156, GenBank accession no. AY260047) was selected for recombinant 
protein generation. This region was amplified using HuUO-44-E7/F and HuUO-44-
E9/R. The following PCR cycles were used: 95 oC for 5 min; followed by 25 cycles of 
95 oC for 30 sec, 55 oC for 30 sec, 72 oC for 1 min 30 sec, and a final extension of 72 
oC for 5 min. The PCR product was subsequently cloned using the Gateway 
Expression System TM (Invitrogen, Carlsbad, CA) into a pDEST-17 vector that 
contained histidine tags. The pDEST17-HuUO-44 vector was then transformed into 
salt inducible BL-21-SI cells. Positive clones were induced in a 500 ml culture with 




300 mM NaCl for 5 h and the induced cells were lysed and purified using Nickel-
NTA-agarose (Qiagen, GmbH, Hilden) according to the QIAexpressionist manual 
provided by the manufacturer. The recombinant protein was dialyzed extensively 
against PBS and concentrated using a Centricon® Centrifugal Filter Unit, YM-10 
(Milipore, Billerica, MA) prior being used as an antigen for antibody generation. 
Polyclonal antibodies were raised in rabbits according to standard protocols. Anti-sera 
following the seventh boost were used in these studies. The specificity of the 
antibodies was verified by western blot analysis against the recombinant HuUO-44 
protein and excess antigen binding. 
NIH-OVCAR3 ovarian cancer cells (4 x 104 per chamber) were seeded into 8-
chamber slides 24 h prior to staining. Fixing was performed in 4 % formaldehyde for 
15 min, followed by two washes with Tris Buffer Saline (20 mM Tris, 200 mM NaCl, 
pH 7.6) (TBS) for 5 min. For the ovarian tissue samples, prior written informed 
consent was obtained from patients and the study received Ethics Board approval at 
the National Cancer Centre of Singapore and Singapore General Hospital, tissue 
samples obtained were snap frozen in liquid nitrogen.  
Prior to analysis, the samples from tumors and adjacent were fixed in 10 % 
formalin for 24 h and embedded in paraffin. Five μM paraffin sections were cut, 
dewaxed with xylene, and rehydrated as described (Nielsen and Krogh, 1998). 
Antigen retrieval was performed by boiling the slides in 10 mM citrate buffer pH 6.0 
for 20 min. The following steps were then carried out on both the cell line slides and 
tissue sections; endogenous peroxidase activity was block by 3 % hydrogen peroxide 
in methanol for 30 min. After two washes of Tris Buffer Saline (20 mM Tris, 200 mM 
NaCl, pH 7.6) (TBS), the sections were pre-incubated with 5 % skim milk in TBS 
containing 0.1 % Tween-20 (TBST) for 5 min and incubated overnight at 4 oC, with 




purified primary anti-sera generate against the recombinant HuUO-44. 
Immunohistochemistry was performed using the strepavidin-biotin peroxidase 
complex method according to the manufacturer’s instructions (Lab Vision, Fremont, 
CA) using AEC as the chromogen and counterstained with 5 % hematoxylin.  
 
3.13 Cisplatin Treatment 
Cisplatin [cis-diamminedichloroplatinum (II)] was purchased from Mayne 
Pharma Plc, Warwickshire, UK. This stock solution at 1 mg/ml concentration was 
stored at 4 oC and was diluted in warmed growth medium to the required 
concentrations (μM) before each in vitro experiment. 
 
3.14 Cellular Proliferation Assay 
Pre-adsorption of HuUO-44 antibodies from the rabbit HuUO-44 anti-serum 
was performed by passing the HuUO-44 anti-serum through a column containing 
CNBr-activated SepharoseTM 4B (Amersham, Pharmacia Biotech, Arlington Heights, 
IL) coupled with HuUO-44 recombinant protein described in section 3.12.  Wells of a 
twelve-well tissue culture plate were seeded with 5 x 104 cells containing 2 ml of 
RPMI-1640 media containing 1 % penicillin/streptomycin (Gibco, Gland Island, NY) 
and supplemented with either 10 % HuUO-44 antiserum or the pre-absorbed HuUO-
44 antiserum. After 1, 3, 5 and 7 days of incubation (37 oC, 5 % CO2), cells were 
harvested with trypsin - EDTA solution (Life Technologies, Gaithersburg, MD) and 
counted using a hemocytometer and trypan blue dye exclusion. Each time point was 
performed in triplicates and the mean values were used for comparison. 




3.15 Cytotoxicity Assay 
The effects of HuUO-44 siRNAs and the control medium GC siRNA 
transfections on cisplatin sensitivity in NIH-OVCAR3 cells in vitro cytotoxicity 
assays were performed using the using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay. Cells were seeded into 48-well plates at 4 x 104 
cells/ well and were treated with different doses of cisplatin ranging from 0 – 53.3 
μM. After 48 h of treatment, 40 μl of 10 mg/ml MTT reagent in serum free media was 
added to each well and incubated in the dark for 4 h at 37 oC. Formazan crystals were 
dissolved in the SDS-DMF solution, which was made up using 0.7 M SDS (Bio-Rad, 
Laboratories, Inc, CA) containing 50 % N,N-Dimethylformamide (Sigma Chemical 
Co, St Louis, MO) and the solution pH was adjusted to 4.3. After dissolving the 
resulting formazan product, the absorbance was determined with a Benchmark Plus 
Microplate Spectrophotometer (Bio-Rad, Laboratories, Inc, CA) at 570 nm. 
Normalization was performed with the values obtained from the untreated cells to 
determine the percentage of survival. Each treatment was performed in triplicates.  
 
3.16 Knockdown of UO-44 in NIH-OVCAR3 Through RNA 
Interference (RNAi) 
All the HuUO-44 specific siRNAs were supplied by Invitrogen, Carlsbad, CA. 
The sequence of the siRNAs listed on Table 4.6 corresponded to the human UO-44 
(GenBank Accession Number AY260047) and CUZD1 (GenBank Accession Number 
NM_022034) cDNA sequences. The StealthTM RNAi Negative Control Med GC that 
has no homology to the vertebrate transcriptome was used as a negative control. 
Transfection of HuUO-44 siRNA U1, U2, U3 and the negative control was 
performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cells were seeded 




the day before siRNA transfection in 6 well plates and were 50 - 60 % confluent 
during transfection. The RNA duplex was diluted in sterile water and 100 nM of the 
siRNA duplex was used in each transfection mixture. NIH-OVCAR3 cells were 
treated with the siRNA after 20 min preincubation with 5 μl of Lipofectamine 2000 in 
serum free OPTI-MEM (Invitrogen, Carlsbad, CA). When cells were transfected with 
all three HuUO-44 siRNAs, one third of each siRNA duplex was used.  Six hours 
after transfection, the transfection mix was replaced with RPMI – 1640 culture 
medium described above. Transfection of siRNA was performed daily for two 
consecutive days then harvested 24 h following the final transfection. 
 
3.17 Generation of HuUO-44 Stable Transfectants 
Amplification of HuUO-44 full-length (FL) open reading frame of 1824 bp 
was achieved using the following primers: Gate-FL-HuUO-44/F (5’- 
CACCATGCCATTGACCCTCTTAATT -3’) and HuUO-44-E9/R (5’- GTTAATAG 
TTCTGCAGCTTCT -3’). PCR was performed using a plasmid containing the 
transcript HuUO-44D (GenBank accession no. AY260047) as template, in a total 
volume of 50 μl containing 10 pmol of each primer, 100 nmol of each dNTP, 1 IU of 
Native Pfu Polymerase (Stratagene, La Jolla, CA), 1.5 mM MgCl2 and 1 x Native Pfu 
Buffer (Stratagene, La Jolla, CA). The following cycles was used for PCR: 95 oC for 
5 mins; followed by 25 cycles of 95 oC for 30 min, 55 oC for 30 min, 72 oC for 1 min 
30 sec, and a final extension of 72 oC for 5 min. The resulting PCR product was 
subsequently cloned into pCR®-Blunt-II-TOPO vector (Invitrogen, Carlsbad, CA) 
and sub-cloned directionally in to a pcDNA3 (Invitrogen, Carlsbad, CA) mammalian 
expression vector via HindIII and NotI restriction enzyme sites found on both vectors.  




After sequence verification of the HuUO-44FL-ORF-pcDNA3.0 constructs, a 
maxi-prep of the construct was prepared using the Endofree® Plasmid Maxi Kit 
(Qiagen, GmbH, Hilden). Prior to the day of transfection, 5 x 106 NIH-OVCAR3 cells 
were seeded onto a 100 mm tissue culture dish. The plate was about 70 % confluent 
during transfection, 10 μg of HuUO-44FL-pcDNA3.0 or pcDNA3.0 plasmids were 
transfected into the NIH-OVCAR3 cells after 20 min preincubation with 10 μl of 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in serum free OPTI-MEM 
(Invitrogen, Carlsbad, CA). The transfection mix was replaced with growth medium, 
6 h after transfection.  After a further 12 h of incubation, the transfected cells were 
trypsinized and selection was initiated in growth medium containing Geneticin – 
G418 (Invitrogen, Carlsbad, CA) at a concentration of 500 μg/ml. Single colonies of 
stable transfectants were then isolated and assayed for HuUO-44 expression using 
real-time PCR analysis. 
 
3.18 Flow Cytometry 
Externalization of phosphatidylserine (PS) was examined with a two-color 
analysis of FITC – labeled Annexin V binding and propidium iodide (PI) uptake flow 
cytometry (Vermes et al., 1995). For this analysis, 1 x 106 cells were stained using the 
commercially available kit, Annexin V – FITC Apoptosis Detection Kit I (BD 
Biosciences Pharmingen, San Diego, CA) according to the manufacturer’s 
instructions.  
Cell debris was characterized by a low FSC/SSC and was excluded from the 
analysis. Single cells stained with either FITC – Annexin V or PI was used to adjust 
compensation. Fluorescence was quantified using FL1 and FL2 channels of the 
FACSCalibur flow cytometer (BD Biosciences Pharmingen, San Diego, CA); data 




acquisition and analysis were carried out using the CellQuest® software (BD 
Biosciences Pharmingen, San Diego, CA). Positioning of quadrants on Annexin V/ PI 
dot plots was performed based on a previous report (van Engeland et al., 1996). The 
lower left quadrant represented living cells (Annexin V-/ PI-); the upper left quadrant 
represented necrotic cells (Annexin V-/ PI+); the lower right quadrant represented 
early apoptotic/primary apoptotic cells (Annexin V+/ PI-); and the upper right 
quadrant represented late apoptotic/ secondary necrotic cells (Annexin V+/ PI+). 
 
3.19 Computational and Statistical Analysis  
Sequence identity and prediction of open reading frames (ORF) were 
performed using analysis software from the National Centre for Biotechnology 
Information (NCBI). The CLUSTAL W v1.82 program (EMBL) was used to perform 
the multiple sequence alignment and homology studies between rat, mouse and 
human UO-44 cDNAs. The predicted amino acid sequences were analyzed using 
Pfam CDS-Conserved Domain Search (NCBI) to detect conserved domains, SignalP 
(Nielsen and Krogh, 1998) for analyzing the presence of signal peptides and TMpred 
(Hofmann and Stoffel, 1993) program for detection of possible transmembrane 
regions.  
All the programs used for promoter analysis were provided by Genomatix 
Software GmbH, München, Munich [http://www.genomatix.de/]. Prediction of the 
human, mouse and rat UO-44 putative promoters through comparative genomics 
analysis was performed using the program Eldorado, while the program MatInspector 
(Quandt et al., 1995; Cartharius et al., 2005) was employed to determine the 
transcription factor binding sites within three putative promoters. Functional modules 
within the putative UO-44 promoters were identified using the ModelInspector 




program (Frech et al., 1997) and identify common transcription factors organization 
within the putative UO-44 promoters was carried out using the program 
Frameworker. 
All experiments were repeated at least three times and the data were subjected 






Chapter 4  RESULTS 
4.1  Cloning, Sequencing and Characterization of the Human 
UO-44  
Establishing the full-length sequence of the human UO-44 (HuUO-44) would 
help to determine the genomic structure of the gene, which will enable the elucidation 
of the association between the intron-exon arrangement and protein structural 
domains. In addition, information on the gene structure would also form a basis for 
identification and characterization of the UO-44 promoter, which would enable the 
unraveling of the mechanisms of activation, control and regulation of UO-44 in the 
initiation and progression of ovarian cancers.    
 
4.1.1  Screening and Sequencing of HuUO-44 cDNA 
The initial attempt to characterize UO-44 was to isolate the human ortholog of 
the rat UO-44 previously described (Chen et al., 1999; Huynh et al., 2001). The 
HuUO44 cDNA sequence was obtained through a combination of screening a human 
ovarian cDNA library and 5’- Rapid Amplification of cDNA Ends (RACE). A 450 bp 
DNA fragment from the rat UO-44 (GenBank accession no. AF022147) that was 
previously reported to be present in the uteri of tamoxifen-treated rats but lost in the 
ovariectomized rat uteri was radioactively labeled as a probe for screening a human 
ovarian cDNA library (Huynh et al., 2001). Screening of this library gave rise to the 
isolation of four positive clones, of which one harboring the longest insert of about 
2.1 kb was sequenced and further analyzed (GenBank accession no. AF305835) 
(Figure 4.1A). The rat UO-44 and the resulting HuUO-44 cDNA were 79 % and 73 % 





Figure 4.1 Library screened HuUO-44 cDNA (GenBank accession no. 
AF305835) nucleotide sequence (2126 bp) and deduced aa sequence (357 aa). A)
The sequence of the library screened HuUO-44 cDNA is listed above; nucleotides are 
numbered on the left and the predicted translational region is indicted in pink. B)
Pfam CDS-Conserved Domain Search identified a region at amino acids (aa) 26-329 
as a zona pellucida (ZP) domain. 
uterus-ovary specific putative 







with the peptide sequence of this library screened HuUO-44 clone using the Pfam 
Conserved Domain Search – CDS (NCBI) identified a region at amino acids (aa) 26-
329 as a zona pellucida (ZP) domain (Figure 4.1B); this domain bears similarity to 
that found in TGF betaglycan, uromodulin and members of the ZP protein family 
(Einspanier et al., 1991; Bork and Sander, 1992; Jovine et al., 2002).  
 
4.1.2  5’ Rapid Amplification of cDNA Ends (RACE) 
Establishing the presence of variants transcripts was another aspect of 
deciphering the genomic organization of HuUO-44. Identification of variant 
transcripts would enable further characterization of the function and regulation of 
HuUO-44. To identify the presence of other HuUO-44 transcipts, 5’ RACE was 
performed using poly (A)+ mRNA derived from human ovarian tissues. Amplification 
of the cDNA ends was carried out using a gene specific primer (GSP) designed to 
target the 5’ region located at the 150 bp position of the HuUO-44 cDNA cloned from 
screening of the human ovarian cDNA library.  
The 5’ RACE amplification obtained three DNA fragments of 0.2 kb, 0.4 kb 
and 1.4 kb (Figure 4.2A) that were subsequently cloned and sequenced. Sequence 
analysis revealed that the three 5’ RACE products aligned completely at the 3’-end 
but varied in length at the 5’-end. Sequence alignment of the cDNAs fragments from 
the 5’ RACE and cDNA library screened HuUO-44 clone predicted three putative 
transcripts of 2.2, 2.4 and 3.3 kb in size (Figure 4.2B). The library screened HuUO-44 
cDNA described in previous section 4.1.1 contained exons 4 to 9, while the 5’ RACE 





Figure 4.2 5’RACE illustration and sizes of the resulting contigs. A) 5’ RACE 
performed with a uterine cDNA library, giving rise to three fragments of 0.2, 0.4 and 
1.4 kb in size. All three 5’RACE products were sequenced and contig to the cDNA 
library clone sequence. B) Schematic diagram of the contig alignment of the RACE 
products and the cDNA library screened HuUO-44 clone resulting in contigs of 2.2, 2.4 







4.1.3  Cloning of Human UO-44 Variants 
The results from the 5’ RACE provide the first clue to the existence of HuUO-
44 variant isoforms. To ascertain the presence of other HuUO-44 variants, a pair of 
primers residing in exon 1 and exon 9 of the predicted HuUO-44 cDNA contigs, 
illustrated in section 4.1.3 was designed for RT-PCR amplification. RT-PCR was 
performed in one paired normal ovarian and ovarian tumor tissues; four cervical 
cancer cell lines (Caski, HeLa, HT-3 and Siha); and two ovarian cancer cell lines (Pa-
1 and NIH-OVCAR3). Cloning and sequencing of the RT-PCR products revealed the 
presence of four novel HuUO-44 splice variants. Sequence analysis established that 
alternative splicing occurred between exon 2 to 6. To obtain a better resolution of the 
bands, RT-PCR was repeated using primers that were located in exons flanking the 
spliced exons; the primers used in this nested amplification resided in exon 1 and 7 
(Figure 4.3A).  
The smallest band of 150 bp represented the smallest HuUO-44 splice variant, 
HuUO-44A, this was 1.4 kb in size and contains an ATG in exon 7 (Figure 4.3B). 
HuUO-44A is produced by splicing exon 2 to exon 6 (GenBank accession no. 
AY260050) (Figure 4.4). Conceptual translation of this mRNA isoform from this 
ATG yields a protein of 241 amino acids (aa) with a predicted molecular mass (MW) 
of approximately 28 kDa. Isoform HuUO-44B is 2 kb in size and is represented by the 
750 bp bands, this transcript is obtained through the splicing of exon 2, exon 4 
internally and exon 5 internally (GenBank accession no. AY260049) (Figure 4.4). The 
900 bp bands represented HuUO-44C that is 2.2 kb in size, this variant is produced by 
splicing exon 2 and 4 internally (GenBank accession no. AY260048) (Figure 4.4). 
The cDNA library screened HuUO-44 clone (HuUO-44L; GenBank accession no. 





Figure 4.3 Expression of human UO-44 splice-variants in normal/tumor 
ovarian tissues and ovarian cancer cell lines. A) Schematic diagram of RT-PCR 
of HuUO-44 variants, each exon is represented by an open box and numbered 
below. Primers HuUO-44/F and HuUO-44-E7/R were used in the One-Step RT-
PCR. B) HuUO-44 variants in a paired normal (N) /tumor (T) ovaries, cervical 
cancer cell lines (1 - Hela, 3 - HT3, 4 - Caski and 5 - Siha) and ovarian cancer cell 
lines (2 - Pa1OV and 6 - NIH). Sequence analysis of the four RT-PCR products 
reviewed four novel splice variants, HuUO-44A is represented by the 150 bp 
band, HuUO-44B by a 750 bp band, HuUO-44C by a 900 bp band and HuUO-







44B and HuUO-44C contained an ATG at exon 6 encoding for a protein of 326 aa 
with a predicted MW of approximately 36 kDa. HuUO-44D is the largest splice 
variant of 2.3 kb in size and is represented by a 1000 bp band, this transcript is 
produced through splicing of exon 4 internally (GenBank accession no. AY260047) 
(Figure 4.4). This transcript contained an ATG at exon 1 and encoded for a protein of 
607 aa with a predicted MW of 68 kDa.  
The predicted protein encoded by HuUO-44D isoform was evaluated against 
the non-redundant protein database GenBank. Conserved domain search using Pfam 
identified functional motifs found in HuUO-44D as CUB domains (aa 53-145 and aa 
154-264) and ZP domain (aa 277-519) (Figure 4.5). Signal peptide search using 
SignalP program predicted a putative signal peptide (at aa 1-21) at the N-terminal and 
TMpred program identified a 19 aa transmembrane region at the C-terminal. The N-
terminal containing the signal peptide, two CUB domains and one ZP domain were 
predicted to be present in the extracellular region and the remaining 18 aa at the C-
terminal downstream of the transmembrane region were presumably the cytoplasmic 
part of HuUO-44. HuUO-44D encoded for two CUB domains and a ZP domain while 
HuUO-44-A, -B, -C and the cDNA library screened HuUO-44 clone all encoded for 
only the ZP domain (Table 4.1). HuUO-44L cDNA was not detected in this RT-PCR 
amplification with primers residing in exon 1 and 9. The exon 4 in all the HuUO-44 
variants isolated here contained only a 151 bp internally spliced fragment of the 
HuUO-44L cDNA exon 4 that was found to be 1188 bp in size.  
Through sequencing of the HuUO-44 variant RT-PCR products, another novel 
HuUO-44 variant was identified, HuUO-44E. This transcript was 2.2 kb in size, 
which was similar in nucleotide length to variant HuUO-44C. HuUO-44E was 





Figure 4.4 Illustration of HuUO-44 spliced-variants. HuUO-44 – library 
screened clone contains exons 4 – 9 (GenBank accession no. AF305835). HuUO-
44A contains exons 1 and 7 – 9 (AY260050). HuUO-44B contains exons 1 – 4, 5 
internally spliced and 6 – 9 (AY260049). HuUO-44C contains exons 1, 3 – 9 
(AY260048). HuUO-44D is the predicted full-length clone; it contains exons 1 –
9 (AY260047). HuUO-44E is a newly isolated clone, which contains exons 1 – 9 
with exon 5 internally spliced. All the clones that were isolated using RT-PCR 
contains an internally spliced exon 4 of 151 bp, while the library screened clone 





  1                                                            GA 
  3  GGCCACCTGTTTGTGATGTGCAGGCACAGAAGAAAGGCACAGCTCCCCATCAGTTTCATGGAAAAT 
 69  AACTCAGTGCCTGCTGGGAACCAGCTGCTGGAGATCCCTACAGAGAGCTTCCACTGGGGGCAACCC 
135  TTCCAGGAAGGAGTTGGGGAGAGAGAACCCTCACTGTGGGGAATGCTGATAAACCAGTCACACAGC 
201  TGCTCTATTCTCACACAAATCTACCCCTTGCGTGGCTGGAACTGACGTTTCCCTGGAGGTGTCCAG 
267  AAAGCTGATGTAACACAGAGCCTATAAAAGCTGTCGGTCCTTAAGGCTGCCCAGCGCCTTGCCAAA  
333  atggagcttgtaagaaggctcatgccattgaccctcttaattctctcctgtttggcggagctgaca  
      M  E  L  V  R  R  L  M  P  L  T  L  L  I  L  S  C  L  A  E  L  T  22 
 
399  atggcggaggctgaaggcaatgcaagctgcacagtcagtctagggggtgccaatatggcagagacc 
      M  A  E  A  E  G  N  A  S  C  T  V  S  L  G  G  A  N  M  A  E  T  44 
465  cacaaagccatgatcctgcaactcaatcccagtgagaactgcacctggacaatagaaagaccagaa 
      H  K  A  M  I  L  Q  L  N  P  S  E  N  C  T  W  T  I  E  R  P  E  66  
 
531  aacaaaagcatcagaattatcttttcctatgtccagcttgatccagatggaagctgtgaaagtgaa 
      N  K  S  I  R  I  I  F  S  Y  V  Q  L  D  P  D  G  S  C  E  S  E  88  
 
597  aacattaaagtctttgacggaacctccagcaatgggcctctgctagggcaagtctgcagtaaaaac 
      N  I  K  V  F  D  G  T  S  S  N  G  P  L  L  G  Q  V  C  S  K  N  110  
 
663  gactatgttcctgtatttgaatcatcatccagtacattgacgtttcaaatagttactgactcagca 
      D  Y  V  P  V  F  E  S  S  S  S  T  L  T  F  Q  I  V  T  D  S  A  132 
 
729  agaattcaaagaactgtctttgtcttctactacttcttctctcctaacatctctattccaaactgt 
      R  I  Q  R  T  V  F  V  F  Y  Y  F  F  S  P  N  I  S  I  P  N  C  154  
 
795  ggcggttacctggataccttggaaggatccttcaccagccccaattacccaaagccgcatcctgag 
      G  G  Y  L  D  T  L  E  G  S  F  T  S  P  N  Y  P  K  P  H  P  E  176  
 
861  ctggcttattgtgtgtggcacatacaagtggagaaagattacaagataaaactaaacttcaaagag 
      L  A  Y  C  V  W  H  I  Q  V  E  K  D  Y  K  I  K  L  N  F  K  E  198 
 
927  attttcctagaaatagacaaacagtgcaaatttgattttcttgccatctatgatggcccctccacc 
      I  F  L  E  I  D  K  Q  C  K  F  D  F  L  A  I  Y  D  G  P  S  T  220 
 
993  aactctggcctgattggacaagtctgtggccgtgtgactcccaccttcgaatcgtcatcaaactct 
      N  S  G  L  I  G  Q  V  C  G  R  V  T  P  T  F  E  S  S  S  N  S  242 
 
1059 ctgactgtcgtgttgtctacagattatgccaattcttaccggggattttctgcttcctacacctca 
      L  T  V  V  L  S  T  D  Y  A  N  S  Y  R  G  F  S  A  S  Y  T  S  264 
 
1125 atttatgcagaaaacatcaacactacatctttaacttgctcttctgacaggatgagagttattata 
      I  Y  A  E  N  I  N  T  T  S  L  T  C  S  S  D  R  M  R  V  I  I  286  
 
1191 agcaaatcctacctagaggcttttaactctaatgggaataacttgcaactaaaagacccaacttgc 
      S  K  S  Y  L  E  A  F  N  S  N  G  N  N  L  Q  L  K  D  P  T  C  308 
 
1257 agaccaaaattatcaaatgttgtggaattttctgtccctcttaatggatgtggtacaatcagaaag 
      R  P  K  L  S  N  V  V  E  F  S  V  P  L  N  G  C  G  T  I  R  K  330  
 
1323 gtagaagatcagtcaattacttacaccaatataatcaccttttctgcatcctcaacttctgaagtg 
      V  E  D  Q  S  I  T  Y  T  N  I  I  T  F  S  A  S  S  T  S  E  V  352 
  
1389 atcacccgtcagaaacaactccagattattgtgaagtgtgaaatgggacataattctacagtggag 
      I  T  R  Q  K  Q  L  Q  I  I  V  K  C  E  M  G  H  N  S  T  V  E  374 
 
1455 ataatatacataacagaagatgatgtaatacaaagtcaaaatgcactgggcaaatataacaccagc 
      I  I  Y  I  T  E  D  D  V  I  Q  S  Q  N  A  L  G  K  Y  N  T  S  396 
 
1521 atggctctttttgaatccaattcatttgaaaagactatacttgaatcaccatattatgtggatttg 
      M  A  L  F  E  S  N  S  F  E  K  T  I  L  E  S  P  Y  Y  V  D  L  418 
 
1587 aaccaaactctttttgttcaagttagtctgcacacctcagatccaaatttggtggtgtttcttgat 
      N  Q  T  L  F  V  Q  V  S  L  H  T  S  D  P  N  L  V  V  F  L  D  440 
 
1653 acctgtagagcctctcccacctctgactttgcatctccaacctacgacctaatcaagagtggatgt 
      T  C  R  A  S  P  T  S  D  F  A  S  P  T  Y  D  L  I  K  S  G  C  462 
 
1719 agtcgagatgaaacttgtaaggtgtatcccttatttggacactatgggagattccagtttaatgcc 
      S  R  D  E  T  C  K  V  Y  P  L  F  G  H  Y  G  R  F  Q  F  N  A  484  
 
1785 tttaaattcttgagaagtatgagctctgtgtatctgcagtgtaaagttttgatatgtgatagcagt 
      F  K  F  L  R  S  M  S  S  V  Y  L  Q  C  K  V  L  I  C  D  S  S  506 
 






      D  H  Q  S  R  C  N  Q  G  C  V  S  R  S  K  R  D  I  S  S  Y  K  528 
 
1917 tggaaaacagattccatcataggacccattcgtctgaaaagggatcgaagtgcaagtggcaattca 
      W  K  T  D  S  I  I  G  P  I  R  L  K  R  D  R  S  A  S  G  N  S  550 
1983 ggatttcagcatgaaacacatgcggaagaaactccaaaccagcctttcaacagtgtgcatctgttt 
      G  F  Q  H  E  T  H  A  E  E  T  P  N  Q  P  F  N  S  V  H  L  F  572 
 
2049 tccttcatggttctagctctgaatgtggtgactgtagcgacaatcacagtgaggcattttgtaaat 
      S  F  M  V  L  A  L  N  V  V  T  V  A  T  I  T  V  R  H  F  V  N  594 
 
2115 caacgggcagactacaaataccagaagctgcagaactattaaCTAACAGGTCCAACCCTAAGTGAG  
      Q  R  A  D  Y  K  Y  Q  K  L  Q  N  Y stop  607 
2181 ACATGTTTCTCCAGGATGCCAAAGGAAATGCTACCTCGTGGCTACACATATTATGAATAAATGAGG  
2247 AAGGGCCTGAAAGTGACACACAGGCCTGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
2313 AAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
Figure 4.5 Full-length human UO-44 (HuUO-44D) nucleotide sequence 
(2339 bp) and deduced amino acid sequence (607 amino acids). The sequence of 
HuUO-44D isoform is listed above, nucleotides are numbered on the left, and the 
amino acids are numbered on the right. The translational start site is at the 5’ end 
and the polyadenylation signal at the 3’ untranslated region are in bold and 
underlined. The two CUB domains (CUB-1 and CUB-2) is indicated by        and the 
zona-pellucida (ZP) domain by       . The signal peptide (SP) is indicated by       at 
the amino terminal and a putative transmembrane region (TM) is indicated by       at 








































contained two ATGs, one at exon 1 and the other at exon 6. HuUO-44E was found to 
encode for two polypeptides of 229 aa and 326 aa, which encoded for a 26 kDa and 
36 kDa protein, respectively. Interestingly, the 26 kDa protein encoded the 2 CUB 
domains, while the ZP domain was encoded by the 36 kDa protein. This transcript 
encoded for all the functional domains found in the full-length HuUO-44 (HuUO-
44D) but as two separate proteins (Table 4.1) 
 
4.1.4 Genomic Structure of Human UO-44 gene 
The putative gene structure of HuUO-44 was determined through BLAST 
search of the human genome resources from the NCBI database 
[www.ncbi.nlm.nih.gov] with the sequences of the three 5’ RACE and RT-PCR 
contigs. All exon-intron junctions conformed to the splice consensus (5’GT/AG3’) 
rule (Table 4.2). Mapped to chromosome 10q26.13, the HuUO-44 gene spans 14 kb 
and contains 9 exons ranging from 151 bp to 1188 bp and introns ranging from 338 bp 
to 4433 bp (Figure 4.6). 
 
4.1.5 Tissue Distribution Profile of Human UO-44 
Rat UO-44 was previously shown to be highly expressed in the uterus and 
ovary, which contributed to its designation of being a uterine-ovarian specific gene, 
UO-44 (Huynh et al., 2001). To determine expression of HuUO-44 in various tissues, 
the Multiple Tissue Northern (MTN) and Multiple Tissue Expression (MTE) blots 
were probed with a 625 bp fragment of the HuUO-44 cDNA (1520-2144 bp, 
GenBank accession no. AY260047) that contained exons 7, 8 and 9. This HuUO-44 
probe was designed to detect all HuUO-44 variants. On the MTN, two transcripts of 





























































































































































































































































































Figure 4.7 Multiple Tissue Northern (MTN) of HuUO-44. Blot was probed 
with a radioactive labeled 625 bp 3’ HuUO44 cDNA probe as described in the 
Materials and Methods. Two transcripts of approximately 2 kb and 3 kb in size 
were observed in the pancreas (Pan). HuUO-44 mRNA was below detectable 
levels in the cervix (Cr), ovary (Ov), testis (Tes), prostate (Pro), muscle (Mus), 
uterus (Ut), bladder (Bla), kidney (Kid), spleen (Spl), heart (Ht), brain (Br), liver 





these transcripts correlated to the sizes of the three 5’ RACE contigs (Figure 4.2B). 
The intensities of the bands observed on the MTN suggest that the expression of the 3 
kb transcripts was extremely low compared to the prominent 2 kb transcripts. The 
Multiple Tissue Expression (MTE) array revealed that the highest level of HuUO-44 
transcript was observed also in the pancreas, while the duodenum and appendix only 
expressed a relatively higher level of HuUO-44 mRNA compared to the rest of the 
tissues (Figure 4.8). The tissue expression profile of HuUO-44 suggested that it 
maybe a protein related to the endocrine system. 
 
4.2 Establishing a Rat Model for Characterization of UO-44 
With the increased use of transgenic and knockout models in biomedical 
research, mice and rats are becoming the animal models of choice in many 
physiological and pharmacological experiments. They also serve as a platform for in 
vivo characterization of novel genes. To develop a rat model for further 
characterization of UO-44 role in the initiation and progression of ovarian and uterine 
cancers, we have cloned and isolated 4 novel spliced variants of the rat UO-44. 
 
4.2.1 Genomic Structure of Rat UO-44 
The cloning of the rat UO-44 was previously isolated from a cDNA library 
generated from tamoxifen treated ovariectomized rat uterus (Huynh et al., 2001), the 
resulting cDNA (GenBank accession no. AF022147) was 99 % identical to the 
Estrogen Regulated Gene 1 (ERG1) that was subsequently cloned (Chen et al., 1999). 
The putative gene structure of rat UO-44 gene was determined by BLAST search of 
the rat genomic sequence from the NCBI database [www.ncbi.nlm.nih.gov]. Rat UO-





Figure 4.8 Multiple Tissue Expression Array (MTE) of HuUO-44. A) The 
MTE blot was probed with a radioactive labelled 625 bp 3’ HuUO44 cDNA as 
described in the Materials and Methods. The cDNA expression dots are 
represented in the tissue type index grid (B).  High levels of HuUO-44 transcripts 







information, the genomic structure of the rat UO-44 gene was deduced (Figure 4.9), 
and the exon/intron boundaries were established. Each of the 5’-donor and 3’-acceptor 
splice sites conformed to the consensus sequences with high conservation, invariable 
GT/AG dinucleotides present at the immediate exon/intron boundaries (Table 4.3). 
The rat UO-44 gene spanned a genomic region of approximately 15 kb and comprised 
also of 9 exons with sizes ranging from 151 bp to 392 bp. All the exons of the rat UO-
44 were almost identical in size to its human ortholog, HuUO-44, with the exception 
of exon 4.  
 
4.2.2 Isolation and Cloning of Rat UO-44 Variants 
To facilitate the development of the rat model, it was necessary to identify and 
clone the various rat UO-44 variants. The cloning of the splice variants of rat UO-44 
was performed using One-Step RT-PCR with total RNA isolated from rat ovaries. 
Primers used in the One-step RT-PCR amplification resided in exon 1 (Rat UOE1/F) 
and exon 9 (RatUOE9/R) (Figure 4.9). Sequencing of the various rat UO-44 variant 
clones identified 4 novel variants of the rat UO-44 with alternative splicing observed 
between exon 1 to 6. To obtain a better resolution of the different rat UO-44 variants, 
One-step RT-PCR amplification was repeated with primers residing in exon 1 (Rat 
UOE1/F) and exon 6 (Rat UOE6/R) (Figure 4.9). Analysis of total rat UO-44 (T) 
expression using primers residing in exon 7 (RatUOE7/F) and exon 9 (RatUOE9/R) 
obtained only one RT-PCR product confirming that splicing occurs only between 
exon 1 and 6 (Figure 4.9). Variant specific amplification (V) yielded five RT-PCR 
products of 200, 400, 500, 700 and 900 bp, which represented the rat UO-44D, -C, -B, 





































































































































































































































































Figure 4.10 Expression of rat UO-44 spliced-variants in the ovary. One-step 
RT-PCR of Rat UO-44 spliced variants (V) using primers residing in exon 1 and 6, 
and total rat UO-44 RTPCR (T) using primers residing in exon 7 and 9. Variant 
specific amplification (V) yielded five RT-PCR products of 200, 400, 500, 700 and 






Rat UO-44D is 1.6 kb in size and is represented by the 200 bp band in the 
variant specific RT-PCR. This variant is obtained through the splicing of exon 3, 4 
and 5 (Figure 4.11). Conceptual translation of this variant yields a protein of 389 aa 
with a predicted MW of 44 kDa (Table 4.4). Represented by a 400 bp band, variant 
UO-44C is 1.9 kb in size and is obtained through the splicing of exon 2 and 3 (Figure 
4.11). This mRNA variant isoform encoded a protein of 486 aa and the predicted MW 
is 55 kDa (Table 4.4). Represented by the 500 bp band, variant UO-44B is 2.0 kb in 
size and is produced via the splicing of exon 2 and exon 5 internally (Figure 4.11). 
UO-44B is found to encode for a protein of 327 aa with a predicted MW of 37 kDa 
(Table 4.4). The largest UO-44 splice variant is UO-44A that is 2.1 kb in size, this 
variant is represented by the 700 bp band and is produced through the splicing of exon 
2 (Figure 4.11). UO-44A is found to encode for a protein of 406 aa with a predicted 
MW of 46 kDa (Table 4.4). The full length UO-44 is represented by the 900 bp 
fragment and this cDNA is 2.3 kb in size. Conceptual translation of the full-length rat 
UO-44 cDNA gave rise to a protein of 607 aa with a predicted MW of 69 kDa.  
Similar to HuUO-44D described in section 4.1.3, conserved domains found in 
rat UO-44 are a signal peptide, two CUB domains, a zona-pellucida domain and a 
transmembrane domain. (Figure 4.12). Figure 4.12 also illustrated some other CUB 
and ZP domain proteins, which have been implicated in cancers. DMBT1 and Hensin 
(mouse ortholog of DMBT1) shared the same functional motifs as UO-44. 
 
4.2.3 Comparative Genomics of Human, Rat and Mouse UO-44  
The comparisons of the human, rat and mouse UO-44 cDNA and peptide 
sequences were illustrated in Figure 4.13. Multiple sequence alignment showed that 





Figure 4.11 Illustration of rat UO-44 splice-variants. Full-length rat UO-44 
(GenBank accession no. AF022147) contains 9 exons. UO-44A contains exons 1 
and 3 – 9. HuUO-44B contained exons 1, 3, 4, 5 internally spliced and 6 – 9. UO-
44C contains exons 1, 4 – 9. UO-44D contains exons 1, 2 and 6 – 9. HuUO-44E is 




































































































































































































































































RatUO-44        MEVTGRLFIWAILAVSCRAQLNSTAAEGRPRCTASLGGANLGETHKALILNLNADENCTW 60 
MouseUO-44      MEVTGRLFIWAILAVSCGAQLNSTEAEGKSRCTASLGGANLGETHKALVLQLSANENCTW 60 
HumanUO-44      MELVRRLMPLTLLILSCLAELTMAEAEGNASCTVSLGGANMAETHKAMILQLNPSENCTW 60 
                **:. **:  ::* :** *:*. : ***.. **.******:.*****::*:*...***** 
 
RatUO-44        TIERPENRSIRIIFSHIQLDPDSRCENESIKVFDGRSTSGPLLGEACSKNDFVPVFESSA 120 
MouseUO-44      TIERPENRSIRIIFSYIKLDPGSRCETENIKVFDGSSTSGPLLGKACSRNDFVPVFESSS 120 
HumanUO-44      TIERPENKSIRIIFSYVQLDPDGSCESENIKVFDGTSSNGPLLGQVCSKNDYVPVFESSS 120 
                *******:*******:::***.. **.*.****** *:.*****:.**:**:*******: 
 
RatUO-44        NSLTFQIVTDWTRVQRSVFIFYYFFSSGTTIPNCGGYLQTLEGSFSSPNYPRPHPELAYC 180 
MouseUO-44      NSMTFQIVTGLTKFPRSVFIFYYFFSAATVIPNCGGDLRALEGSFSSPNYPKPHPELAYC 180 
HumanUO-44      STLTFQIVTDSARIQRTVFVFYYFFSPNISIPNCGGYLDTLEGSFTSPNYPKPHPELAYC 180 
                .::******. ::. *:**:******.   ****** * :*****:*****:******** 
 
RatUO-44        VWHIQVEKGYKINLNFTELFLEMDEYCRFDFIAVYDGPSTTSGLLKQVCGRGTPTFESSS 240 
MouseUO-44      VWHIQVGKGYKIQLKFTDLLLEMDENCKFDFIAVYDGPSTTAGLLKQLCG-VEPTLESSS 239 
HumanUO-44      VWHIQVEKDYKIKLNFKEIFLEIDKQCKFDFLAIYDGPSTNSGLIGQVCGRVTPTFESSS 240 
                ****** *.***:*:*.:::**:*: *:***:*:******.:**: *:**   **:**** 
 
RatUO-44        DAMTVVLSTDYANSYRGFFASYASTYVQEVNTHSLSCASDKMRVIISKSYLQSLNYHESN 300 
MouseUO-44      DAMTVVLSTDYANSYKGFSASYTSIYIHDVNTTSLSCVSDKMRVIISKSYLPALNYNESN 299 
HumanUO-44      NSLTVVLSTDYANSYRGFSASYTSIYAENINTTSLTCSSDRMRVIISKSYLEAFNSNGNN 300 
                :::************:** ***:* * .::** **:* **:********** ::* : .* 
 
RatUO-44        LQLNDPTCRPSVSNVVEFSIPLHECGTIKKIEDHTISYTNIITFTQSPESAVITRKRHLQ 360 
MouseUO-44      LQLNDPTCRPNVSNVIEFSIPLHECGTVKKIEDHAISYTNRITFIESPVSAVITRQKLLQ 359 
HumanUO-44      LQLKDPTCRPKLSNVVEFSVPLNGCGTIRKVEDQSITYTNIITFSASSTSEVITRQKQLQ 360 
                ***:******.:***:***:**: ***::*:**::*:*** ***  *. * ****:: ** 
 
RatUO-44        IVVTCEMEYNSTVEILYITEDDVIQNQSVLGKYNTSMALYESGSFENLIQESPYYVDLNQ 420 
MouseUO-44      IVVTCEMEYNSTVEIMYITEDDIIQNQSVLGKYNTSLALYESDSFENLVQESPYYVDLNQ 419 
HumanUO-44      IIVKCEMGHNSTVEIIYITEDDVIQSQNALGKYNTSMALFESNSFEKTILESPYYVDLNQ 420 
                *:*.*** :******:******:**.*..*******:**:**.***: : ********** 
 
RatUO-44        TLFVQATLHTSDPSLVVFLDTCRASPTSDFASPTYDLISSGCSRDETCEVYPLFGHYGRF 480 
MouseUO-44      TLFVQATLHTSDPSLVVFLDTCRASPTSDFASPTYDLISSGCCQDETCKVYPLFGHYGRF 479 
HumanUO-44      TLFVQVSLHTSDPNLVVFLDTCRASPTSDFASPTYDLIKSGCSRDETCKVYPLFGHYGRF 480 
                *****.:******.************************.***.:****:*********** 
 
RatUO-44        QFNAFKFLRHLSSVYLKCKILICDTSDHTSRCNQGCVSRRKRDIPSYKWKTDSVIGPIRL 540 
MouseUO-44      QFNAFKFLKHLNSVYLKCKILICDNNDQTSRCNQGCVPRRKRDIPSYKWKTDSVIGPIRL 539 
HumanUO-44      QFNAFKFLRSMSSVYLQCKVLICDSSDHQSRCNQGCVSRSKRDISSYKWKTDSIIGPIRL 540 
                ********: :.****:**:****..*: ********.* ****.********:****** 
 
RatUO-44        KRDRLVNGDSGLLPQTHEAEISKQPLSHLHLFSFMVLALNVVIVVTATVRHFLNRWKDHG 600 
MouseUO-44      KRDRSASRDSGLLPQIHEAEISNQPLSRLYLFSFMVLALNVVIVAITTVKHFLNRWMDHR 599 
HumanUO-44      KRDRSASGNSGFQHETHAEETPNQPFNSVHLFSFMVLALNVVTVATITVRHFVNQRADYK 600 
                **** .. :**:  : *  * .:**:. ::************ *.  **:**:*:  *:  
 
RatUO-44        YQKLQVY 607 
MouseUO-44      YQKLQVY 606 
HumanUO-44      YQKLQNY 607 
                ***** * 
A) 
B) 
Figure 4.13 Multiple sequence alignment of rat, mouse and human UO-44 
peptide sequences. A) Peptide sequence alignment analysis reveal that the mouse 
and rat UO-44 peptide shared a high homology of 87 % and 84 % at the nucleotide 
and amino acid levels respectively. While the human and rat UO-44 peptides were
only 78 % and 73 % identical at the nucleotide and peptide levels, respectively. B) 
Phylogentic analysis validated that the mouse and rat UO-44 peptides were more 





nucleotide and amino acid levels respectively. Conversely, the comparison of the rat 
and human UO-44 was only 78 % and 73 % identical at the nucleotide and peptide 
levels, respectively (Figure 4.13A). 
Sequence analysis of the human and rat mouse UO-44 revealed that both 
cDNAs encoded an ORF of 1824 nucleotides, while the mouse UO-44 (GenBank 
accession no. NM_008411) harbored an ORF of 1821 nucleotides. Translation of 
these transcripts revealed that the human and rat UO-44 encoded for a 607 aa protein 
with a molecular mass of 69 kDa; the mouse UO-44 encoded for a 606 aa protein with 
a molecular mass of 68 kDa (Figure 4.13A). Phylogenetic analysis of the putative 
UO-44 peptide sequence for the three organisms indicated that the mouse and rat UO-
44s were more closely related compared to the human (Figure 4.13B).  
The human genome project possesses more than 100 gigabytes of condensed 
filtered, quality checked and ranked information on several genomes available on the 
public domain. In silico data mining has since been widely used to harness the vast 
amount of information for gene functional studies. The program ElDorado from 
Genomatix® Software GmbH was used to identify the putative promoters for the UO-
44 gene. Three putative promoters were identified via the Comparative Genomics 
analysis (Figure 4.14). Annotation CUDZ1 (GenBank accession no. NM_022034) 
was GenBank’s collective annotation for HuUO-44, ERG1 and Itmap. The relative 
sizes of putative human, rat and mouse UO-44 promoters were 601 bp, 616 bp and 
612 bp, respectively. 
Analysis of the transcription factor binding site using the program 
MatInspector (Quandt et al., 1995;Cartharius et al., 2005) revealed that the putative 
human UO-44 promoter contained a Fork head related activator-3 (FOXC1) at 17 – 






































































































































































84 – 96 bp, 213 – 225 bp and 274 – 286 bp; FOXL1 (Fork head related activator-7) at 
85 – 101 bp; and a HMG box-containing protein 1 (SOx/sRY-sex/testis determining 
and related HMG box factors) at 524 – 536 bp. Similarly, examining the putative 
mouse promoter also identified a HMG box-containing protein 1 (SOx/sRY-sex/testis 
determining and related HMG box factors) at 477 – 459 bp, together with a estrogen 
related receptor (estrogen response elements) at 565 – 563 bp.  
Regulatory units like promoters, enhancers or silencers contain functional 
modules. Many of these modules consist of at least two transcription factors binding 
sites in conserved order, separated by a spacer. Using the program ModelInspector 
(Frech et al., 1997), functional modules were identified in the putative human, mouse 
and rat UO-44 promoters. In the human UO-44 promoter, several potential modules 
were identified; these include the NF1F-EBOX (Pan et al., 2001), SP1F-AP1F (Noti 
et al., 1996), GATA-AP1F (Kawana et al., 1995), FKHD-CEBP (Christian et al., 
2002), CEBP-NFAT (Yang and Chow, 2003), CEBP-NFKB-NFAT (Li-Weber et al., 
2004), STAT-MITF (Joo et al., 2004) and CREB-EBOX (Pan et al., 2001). 
Functional modules identified in the mouse UO-44 promoter were SORY-PAX6 
(Kondoh et al., 2004), SORY-SF1F (De Santa et al., 1998) and ETSF-IRFF 
(Musikacharoen et al., 2005). For the rat UO-44 promoter, functional modules 
identified were NFKB-IRFF (Johnson and Pober, 1994) and ETSF-AP1F (Nerlov et 
al., 1992). Table 4.5 summarized all these functional modules and their relative 
functions in the human, mouse and rat UO-44 promoters. 
Promoters with common framework elements usually transcription factor 
binding sites are usually co-regulated. Detection of common organizational 
framework of transcription factors found in the three UO-44 promoters using the 


























































44 promoter (Figure 4.15). The two common transcription factors identified within 
the framework were the family of Sox/ SRY (sex determining region Y gene product)/ 
HMG factors (high mobility group proteins) and a vertebrate steriodogenic factor 1 
(SF1).   
 
4.2.4 Hormonal Regulation of UO-44 Variants 
The levels of estrogen during the lifetime in the female vary from high levels 
during pregnancy and decline following birth to the low levels that of prepuberty. It 
was previously shown that estrogens and anti-estrogens play a role in regulation of 
UO-44 (Huynh et al., 2001). To investigate the effects of hormonal regulation on UO-
44 variant expression, semi-quantitative One-step RT-PCR analysis was performed 
with uterine RNA of ovarietomized (OVX) rats that was implanted with a 17β-
estradiol SILASTIC implant with a release rate of 2.4 mg/cm.day. For ICI 182780 and 
Tamoxifen, OVX rats received daily subcutaneous injections of 1 and 2 mg/kg body 
weight for three weeks. RT-PCR analysis revealed that pure anti-estrogens totally 
suppressed expression all UO-44 variants, while tamoxifen and β-estradiol induced 
the expression of full length UO-44 and variant UO-44A (Figure 4.16). 
 
4.2.5 Pregnancy Induced Expression of UO-44 Variants   
During pregnancy, estrogens induce the growth of the uterus and stimulate the 
development of the breast ducts. Semi-quantitative One-step RT-PCR and 
Quantitative real-time PCR analysis of UO-44 expression in the breast during 
pregnancy development revealed that the gene was highly expressed during lactation 


















































































































































































































































































Figure 4.16 Semi-quantitative One-step RT-PCR analysis of UO-44 
spliced-variants expression in the uterus of pure anti-estrogens (ICI 182780), 
tamoxifen and β-estradiol treated rats. A) RT-PCR analysis revealed that pure 
anti-estrogens totally suppressed expression all UO-44 variants, while tamoxifen 
and β-estradiol induced the expression of full length UO-44 and variant UO-44A. 
B) Densitometric analysis illustrates the magnitude of induction and suppression 








(Figure 4.17A). Quantitative real-time PCR revealed that UO-44 induction in the 
mammary glands during lactation was an excess of 80 folds compared to the non-
pregnant control. This high induction of UO-44 expression in the breast suggests that 
the gene may be involved in mammary gland development during lactation and 
hormones that play a role in lactation (eg. prolactin) may also role in the induction of 
UO-44 expression.  
 
4.3 UO-44 and Cancer 
Genes that are involved in embryonic development often fulfill analogous 
roles in cancer (Bhatia-Gaur et al., 1999). The expression profiles of these genes are 
closely related to their functions (i.e. oncogenes or tumor-suppressor genes) and may 
serve as useful targets for prognosis, diagnosis and/or treatment of cancers. These 
cancer-related genes often play important roles in cell cycle, apoptosis, 
differentiation, angiogenesis, attachment, and proliferation. UO-44 gene expression 
was found to be induced by estrogens, tamoxifen and growth hormones, whereas pure 
anti-estrogen ICI 182780 was inhibitory (Huynh et al., 2001). These observations 
indicated that UO-44 might serve as a mediator of these compounds in inducing 
epithelial proliferation and differentiation in the uterus and ovaries. To further 
characterize the role of UO-44 in the initiation and progression of cancer, it is thus 
important to profile UO-44 expression in various human normal/ tumor tissues and 
cancerous cell lines. 
 
4.3.1 Overexpression of Human UO-44 in Ovarian Cancers 
Cancer Profiling Array (CPA) was used to determine the expression of HuUO-







Figure 4.17 Pregnancy induced expression of UO-44 variants in the 
mammary glands.  A) Semi-quantitative One-step RT-PCR analysis of UO-44 
expression in the mammary glands during pregnancy development revealed that 
the gene was highly expressed during lactation and subsequently reduced to pre-
pregnancy levels upon the onset of involution. B) Real-time PCR analysis 
determined that UO-44 expression in the mammary glands during lactation more 







Figure 4.18 Cancer Profiling Array (CPA, normal/ tumor ovary) of human 
UO-44. A) The CPA blot was probed with a radioactive-labeled 625 bp fragment 
of the human UO-44 cDNA (GenBank accession no. AF022147). Higher 
expression of the HuUO-44 transcript was observed in the ovary tumor samples. 
B) Relative density of the HuUO-44 transcript expression in the tumor and 
adjacent normal ovary samples were expressed as a percentage of the total sample 
examined. The outlined groups of spots represented the normal, metastatic (below 
the normal spot) and tumor cDNA from the same patient. The blot was 
normalized against the ubiquitin control. 














hybridized with the same probe used in the MTN and MTE. Densitometric analysis of 
the CPA demonstrated that HuUO-44 was overexpressed in a majority of ovarian 
tumors (12 of 14 or 86 %) compared to corresponding normal tissues. Expression of 
HuUO-44 was also higher in the two metastatic ovarian tumors found on the CPA 
(Figure 4.18), which suggest that HuUO-44 may be involved in locoregional invasion 
of ovarian cancer cells.  
 
4.3.2 Expression of Human UO-44 in Ovarian Tissues and Cancer Cell 
lines 
To determine the expression of HuUO-44 in the normal ovarian epithelium 
and ovarian tumor tissues, a semi-quantitative One-Step RT-PCR was performed 
using primers specific for all HuUO-44 variants, residing in exon 7 and 9 (Figure 
4.19). Similar levels of HuUO-44 expression were observed in one of the normal 
ovarian epithelium, both the ovarian tumors and the ovarian epithelial cancer cell line 
(NIH-OVCAR3). However, a lower HuUO-44 expression was observed in the second 
normal epithelium sample. Ovarian epithelium sample 1 was sampled by peeling only 
the epithelial layer of the ovary, whereas epithelium sample 2 was a random sample 
of the whole ovary. Therefore, the lower expression of HuUO-44 in the ovarian 
epithelium sample 2 was most likely due to the presence of other contaminating cell 
types, which may not express HuUO-44. These observations suggest that HuUO-44 
expression was epithelial-specific and the overexpression of HuUO-44 in the majority 
of the tumor samples observed in the CPA might be the consequence of a larger 
population of epithelial cells in the ovarian tumor samples.        
To further demonstrate the cellular localization of HuUO-44 protein, the 





Figure 4.19 Semi-quantitative RT-PCR of HuUO-44 using total RNA 
extracted from normal ovarian epithelium, ovarian tumors and ovarian 
epithelial cancer cell line (NIH-OVCAR3). Levels of HuUO-44 expression 
were very similar in normal ovarian epithelium (1), ovarian tumors and ovarian 
cancer cell line with the exception of normal ovarian epithelium (2). Lower 
expression of UO-44 in normal epithelial (2) was most likely due to the presence 
of contaminating cell types in the normal ovarian epithelium sample, which may 





vector containing the ORF of HuUO-44D fused to the ORF of an enhanced green 
fluorescent protein (eGFP). Observation of the HuUO-44 transfected cells revealed 
that the HuUO-44-GFP fusion protein was restricted to the cytosol 24 h after 
transfection and localized to the cell membrane 48 h after transfection, but excluded 
from the nucleus (Figure 4.20). This illustrated the membrane-associated nature of 
HuUO-44 in the cells. For the pcDNA-GFP control transfected cells, fluorescence 
was observed in both the nucleus and cytosol. 
  For immunohistochemistry, a histidine tagged recombinant protein designed 
at the ZP domain of HuUO-44 was generated in (BL21-SI) bacteria and purified using 
a nickel coupled agarose column. Polyclonal antibodies against the purified 
recombinant protein were raised in rabbits. Immunohistochemistry was performed on 
8 chamber slides containing ovarian cancer cells, NIH-OVCAR3, and paraffin-
embedded sections from a paired human normal / tumor ovarian samples. Strong 
HuUO-44 immunostaining (in brown) was observed at the cell membrane of the cells 
(Figure 4.21A) and under higher magnification, HuUO-44 was also observed to 
exclusively localize to the leading edge of the cells (Figure 4.21B). For the normal 
ovarian and ovarian tumor sections, HuUO-44 immunostaining was only restricted to 
the epithelial cells surrounding the stroma cells (Figure 4.22). The excess antigen 
(HuUO-44 recombinant protein) bound polyclonal antisera was used as a negative 
control for this immunostaining; little or no observable signal was detected in the 
negative control slides. In agreement to the RT-PCR results described in the previous 
section 4.3.2, the overexpression of HuUO-44 in ovarian cancers could be due to the 
larger population of epithelial cells in the ovarian tumors compared to the normal 





Figure 4.20 Transfection study of HuUO-44-eGFP in ovarian cancer cells 
(NIH-OVCAR3). NIH-OVCAR3 cells were transfected with 10 µg of eGFP-
pcDNA3.0 and HuUO-44-eGFP-pcDNA3.0 fusion construct. The transfected 
cells were harvested at 24 hrs and 48 hrs after transfection. Expression of HuUO-
44 was observed to be restricted to the cytosol 24 hrs after transfection and 







Figure 4.21 Immunohistochemical staining of HuUO-44 in an ovarian 
cancer cell line NIH-OVCAR3. A) A polyclonal antibody was used in the 
immunostaining of an 8-chamber slide containing an ovarian cancer cell line 
showing HuUO-44 staining (in brown) is localized to the cell membrane (200x
magnification). B) High magnification of the ovarian cancer cells showing 
HuUO-44 staining is exclusively localized to the leading edge of the cells (400x
































Figure 4.22 Immunohistochemical staining of HuUO-44 in paraffin-
embedded sections of a representative normal ovarian epithelial and ovarian 
epithelial cancer. A) Strong staining in brown of the normal epithelial cells was 
observed but not detected in the stroma cells. B) An ovarian epithelial cancer 
section showing the presence of HuUO-44 in the cancer epithelial cells. 





4.3.3 Inhibition of Ovarian Cancer Cell Attachment and Proliferation 
Cell attachment of NIH-OVCAR3 cells were greatly inhibited when cultured 
in the presence of 10 % rabbit HuUO-44 antiserum compared to the 10 % pre-
absorbed antiserum (Figure 4.23A). Very few attached cells were observed even at 24 
h post seeding of the cells in media containing HuUO-44 antiserum. In contrast, 
attachments of cells were observed as early as 6 h after seeding of the cells in media 
containing the pre-absorbed rabbit HuUO-44 antiserum, cell proliferation was 
observed at 18 h and 24 h post seeding. A marked increased in cell numbers was also 
observed after 1, 3, 5 and 7 days of culture in media containing pre-absorbed 
antiserum compared to the control antiserum plates (Figure 4.23B).   
 
4.3.4 Cancer Cell Line Profiling Array  
Effect of chemotherapeutic treatment on HuUO-44 expression in cancer cell 
lines was investigated using the Cancer Cell Line Profiling Array. There were no 
significant differences in HuUO-44 expression in the treated lung, colon, breast, 
prostate, skin, brain, kidney, liver, bone and epidermis cancer cell lines (data not 
shown). Only the ovarian cancer cell line (SKOV3) showed a reduction in HuUO-44 
expression after treatment with Geldanamycin, Aphidicoline, Carmustine, Cisplatin, 
L-Mimosine and Demecolcine by a magnitude of more than one fold of the control 
(Figure 4.24). Treatment with Hydroxyurea, Cytochalasine D, Doxorubicin, 
Desferrioxamine, Camptothecin, Mitomycine, Taxol, Thiotepa, Hydrogen Peroxide 
and Gamma Irradiation observed only a half fold reduction in HuUO-44 expression. 
Serum starvation, UV irradiation, heat shock, Cycloheximide, Actinomycin D, 
Etoposide and 5-Fluorouracil treatments did not show any significant effect on 















Figure 4.23 A) Effects of HuUO-44 antiserum on cell attachment and 
proliferation of ovarian cancer cells (NIH-OVCAR3). Each 35 mm plates were 
seeded with 2 x 105 NIH-OVCAR3 cells in media containing 10 % rabbit HuUO-
44 antiserum or pre-absorbed antiserum; observation was performed using phase-
contrast microscopy at 100x magnification. Cell attachment was observed as early 
as 6 hrs post seeding in the media containing the pre-absorbed HuUO-44 
antiserum with cell proliferation observed at 18 and 24 hrs post seeding. Very few 
attached cells were observed in the plate containing the HuUO-44 antiserum even 





Figure 4.23 B) Effects of HuUO-44 antiserum on cell proliferation of 
ovarian cancer cells (NIH-OVCAR3). Proliferation assay of NIH-OVCAR3 
cells seeded in 12 wells plates with media containing HuUO-44 antiserum and 
pre-absorbed antiserum. Exponential increase in cell numbers was observed from 
Day 1 to 7, in wells containing media supplemented with the pre-absorbed anti-
serum (represented by the red line), however cell proliferation was inhibited in 
the wells containing HuUO-44 anti-serum (represented by the blue line). This 
assay was performed in triplicates and the mean values were used for comparison. 
The points represent the means of three independent experiments and the error 



































































































































































































































4.3.5 Involvement of HuUO-44 in Cisplatin Sensitivity 
To further investigate the cytotoxic effect of chemotherapeutic drugs on 
ovarian cancer cell lines, four different ovarian cancer cell lines were treated with 
cisplatin using doses ranging from 0 to 26.7 μM for 48 h and the MTT assay was used 
to determine cell viability (Figure 4.25). NIH-OVCAR3 was found to be most 
sensitive to cisplatin, followed by SKOV-3, OV-90 and ES-2 cells. Rounding of NIH-
OVCAR3 cells was observed 48 h post-treatment with above 3.3 μM of cisplatin 
while same phenomenon was only observed in OV-90 and SKOV-3 when treated with 
above 6.7 μM of cisplatin. The cytotoxic effect of cisplatin was less pronounced in 
ES-2 as only very few rounded up cells was observed after treatment with cisplatin 
concentrations as high as 26.7 μM. 
Semi-quantitative One-step RT-PCR demonstrated that the dose dependent 
inhibition of cell viability by cisplatin was correlated to the suppression of HuUO-44 
expression in NIH-OVCAR3, SKOV3 and OV-90 (Figure 4.26). For the cisplatin 
resistant ES-2 cell line, the levels of HuUO-44 expression were the same as that in the 
untreated cells. Quantitative real-time PCR was employed to determine the magnitude 
of this cisplatin regulated suppression in HuUO-44 expression in NIH-OVCAR3 cells 
and we observed a transcript reduction of more than 90 % with 26.7 μM cisplatin 
treatment (Figure 4.27A). Figure 4.27B presented the phase contrast micrograph of 





















Figure 4.25 Cytotoxic effect of cisplatin in ovarian cancer cell lines (NIH-
OVCAR3, ES-2, SKOV-3 and OV-90). The four different ovarian cancer cell 
lines were exposed to 0 – 53.3 μM of cisplatin. After 48 h of treatment, cell 
viability was determined using the MTT assay. Data were expressed as the 
percentage of cell survival. The points represent the means of three independent 





Figure 4.26 Effect of cisplatin on HuUO-44 expression in ovarian cancer 
cell lines (NIH-OVCAR3, ES-2, SKOV-3 and OV-90). Ovarian cancer cell 
lines were exposed to 0 – 26.7 μM of cisplatin. After 48 h the cells were 
harvested and total RNA was extracted for One-step RT-PCR analysis. 
Expression of HuUO-44 was reduced in a dose-dependent manner in NIH-
OVCAR3, SKOV-3 and OV-90 after cisplatin treatment. No reduction in 
HuUO-44 expression was observed in ES-2 cells after cisplatin treatment. 












Figure 4.27 Effect of cisplatin on HuUO-44 expression in ovarian cancer cell 
lines (NIH-OVCAR3). A) Quantitative Realtime PCR analysis, confirmed that the 
increase in cisplatin dose correlated with the suppression of HuUO-44 expression. 
More than 90 % suppression in HuUO-44 expression was observed with the 26.7 
μM cisplatin treatment in NIH-OVCAR3 cells. B) Phase contrast micrography 
(magnification 200x) showing the morphological changes of NIH-OVCAR3 cells 
after treatment with 0 – 26.7 μM of cisplatin. Rounding and shrinkage of cells were 







4.3.6 Knockdown of UO-44 Sensitizes Ovarian Cancer Cells to Cisplatin 
To further demonstrate the involvement of HuUO-44 in cancer cell attachment 
and proliferation, we proceed to silence the gene in NIH-OVCAR3 cell. Three 
siRNAs of different target sequences (Table 4.6) were transfected into the cells daily 
for 2 days. siRNA U1 was designed to silence only the full length HuUO-44D 
(GenBank accession number AY260047); siRNA U2 targeted the silencing of variants 
HuUO-44B (GenBank accession number AY260049), HuUO-44C (GenBank 
accession number AY260048) and HuUO-44D; and siRNA U3 targeted the silencing 
of all HuUO-44 transcripts.  
Using semi-quantitative One-step RT-PCR for expression profiling of HuUO-
44 in the siRNAs transfected cells, it was found that siRNA U3 was most efficient in 
silencing the HuUO-44 gene expression. Combined transfection of all the siRNAs 
(U1-3) containing one-third of each siRNA also gave a similar level of silencing 
(Figure 4.28A). These findings were confirmed with real-time PCR analysis, which 
demonstrated that the HuUO-44 siRNAs contributed to different levels of HuUO-44 
transcript silencing between 17 - 74 % in NIH-OVCAR3 cells when transfected with 
U1, U2, U3 and a combination of all three HuUO-44 siRNAs, respectively (Figure 
4.28B). Transfection with siRNA U1 did not exert any significant effect on HuUO-44 
expression and no morphological changes was observed in the NIH-OVCAR3 cells. 
However, shrinkage and rounding of NIH-OVCAR3 cells was observed when the 
cells were transfected with siRNA U2, U3 and a combination of all the HuUO-44 
siRNAs (U1-3) (Figure 4.28C). Transfection of siRNA U3 or a combination of all 
HuUO-44 siRNAs severely reduced HuUO-44 mRNA levels (Figure 4.28A and 
4.28B). This cell shrinkage and rounding phenomenon was also observed in SKOV-3 


















































































































































C U1 U2 U3 U1-3
Figure 4.28 HuUO-44 sequence specific siRNA silencing of HuUO-44
expression in NIH-OVCAR3 ovarian cancer cells. A) Cells were transfected 
with 2 daily dose of 100 nM of three different HuUO-44 siRNAs (U1, U2 and 
U3) or a combination of all three siRNAs (U1-3) as described in materials and 
methods. Transfection with the medium GC control siRNAs was used as a 
negative control. HuUO-44 and α-tubulin mRNA levels were assayed using semi-
quantitative One-Step RT-PCR analysis.  B) Quantitative realtime PCR analysis 
of the HuUO-44 mRNA expression shown in (A) after normalization to α-tubulin 
mRNA levels. The bars represent the mean of the triplicate analysis; error bars 






























































































































































































































































































































































































































































































































































































































































































































































































Semi-quantitative One-Step RT-PCR analysis on the transfection of different 
doses of HuUO-44 siRNAs ranging from 10 – 200 nM in NIH-OVCAR3 cells 
revealed a dose dependent silencing of HuUO-44 transcript  (Figure 4.30A). HuUO-
44 expression in NIH-OVCAR3 cells was not affected by the tranfection with 200 nM 
of Medium GC control siRNA. Observation of the cells after 2 daily transfections of 
the different siRNA doses verified that treatment with 50 nM of HuUO-44 siRNAs 
contributed to inhibition of cell adherence and treatment with up to 200 nM of HuUO-
44 siRNAs can contribute to inhibition of cell growth (Figure 4.30B). Cell adherence 
and growth was not affected by the treatment with 200 nM of Medium GC siRNA 
controls.   
To determine whether silencing of HuUO-44 can enhance the cytotoxic effect 
of cisplatin, NIH-OVCAR3 cells were transfected with 100 nM of HuUO-44 siRNAs 
and the medium GC control siRNA twice; once for 6 h followed by recovery for 18 h 
in growth media and once 3 h before cisplatin (3.3 μM) treatment for 12 h. 
Percentages of apoptotic cells were determined using flow cytometry after fluorescent 
staining with Annexin V – FITC and PI (Figure 4.31A). The percentages of early and 
late apoptotic cells after 12 h cisplatin treatment were plotted against the untreated 
cells (Figure 4.31B). Knockdown of HuUO-44 by siRNA significantly enhanced 
cisplatin sensitivity in NIH-OVCAR3 cells (P < 0.01), increasing the percentage of 
apoptotic cells by more than 50 % compared to the Med GC control siRNA 
transfected cells. Figure 4.31C presents the phase contrast micrographs of the above 
siRNAs transfected and cisplatin treated NIH-OVCAR3 cells. HuUO-44 RNAi also 































































































































































































































































































































































































Annexin - V 
A) 
Figure 4.31 HuUO-44 RNAi enhanced chemosensitivity of ovarian cancer 
cells, NIH-OVCAR3. NIH-OVCAR3 cells were transfected with 100 nM of the 
Medium GC control and HuUO-44 siRNAs (U1, U2 and U3), followed by 
treatment with 3.3 μM of cisplatin. A) The flow cytometry analysis of a 
representative experiment following staining with Annexin V – FITC and PI. 












Figure 4.31 HuUO-44 RNAi enhanced chemosensitivity of ovarian cancer 
cells, NIH-OVCAR3. B) Graphical interpretation of the percentages of early and 
late apoptotic cells determined in (A). The increases in the percentage of apoptotic 
cells after cisplatin treatment were 6 – 10 % for the non-transfected and Med GC 
control siRNA transfected cells, while the HuUO-44 siRNAs transfected cells 
yielded 19 – 20 % apoptotic cells after cisplatin treatment. C) Phase contrast 
micrography (magnification 100x) of the above treatments illustrated the 
characteristic morphology of the apoptotic cells in the HuUO-44 knockdown cells 
after cisplatin treatment. The bars represent the means of three independent 







cisplatin to cause cell rounding compared to 48 h treatment shown in the cisplatin 
cytotoxicity assay (Figure 4.25). 
 
4.3.7  Expression of HuUO-44 Conferred Resistance to Cisplatin 
To determine whether overexpression of HuUO-44 can confer resistance to 
cisplatin, the cisplatin-sensitive NIH-OVCAR3 cells were transfected with a 
mammalian expression vector containing the ORF of HuUO-44. Two stable 
transfectant clones expressing low and high levels of HuUO-44 was selected (Figure 
4.32A) and treated with 3.3 μM cisplatin for 18 h. Rounding of the pcDNA3 stable 
transfectants was observed after 18 h of cisplatin treatment, this phenomenon was also 
observed in the HuUO-44 stable transfectant, HuUO-44(1), which overexpressed 
about 4-fold more HuUO-44 transcript compared to the control (Figure 4.32B).  
Percentages of apoptotic cells were quantitated using flow cytometry after 
fluorescent staining with Annexin V – FITC and PI (Figure 4.32C). The percentages 
of cell death after 18 h cisplatin treatment were plotted against the untreated cells 
(Figure 4.32D). Expression of high levels of HuUO-44 significantly enhanced 
cisplatin resistance in NIH-OVCAR3 cells with a 5-fold increase in the percentage of 
cell death compared to the control stable clone containing the pcDNA3 vector (P < 
0.05). Strikingly, treatment with cisplatin only resulted in a few rounded cells in the 
other HuUO-44 stable transfectant, HuUO-44(2), which overexpressed more than 40-





















































Figure 4.32 Overexpression of HuUO-44 conferred cisplatin resistance in 
cisplatin-sensitive ovarian cancer cells, NIH-OVCAR3. A) Quantitative realtime 
PCR analysis of the HuUO-44 mRNA expression of the stable transfectants after 
normalization to α-tubulin mRNA levels. Stable transfectant clones, HuUO-44(1) and 
HuUO-44(2) were found to express about than 4 and 40 folds more HuUO-44 
transcripts compared to the pcDNA3 vector stable transfectant, respectively. B) Phase 
contrast micrography (magnification 100x) illustrated the characteristic morphology 



































Annexin - V 
CisplatiNon-
Cisplatin (3.3 uM) Non-TreatedC) 
D) 
Figure 4.32 Overexpression of HuUO-44 conferred cisplatin resistance in 
cisplatin-sensitive ovarian cancer cells, NIH-OVCAR3. C) The flow cytometry 
analysis of a representative experiment following staining with Annexin V – FITC and 
PI. The percentage of cell death after cisplatin treatment was about 4 – 5 folds lesser 
in HuUO-44(2) compared to the pcDNA and HuUO-44(1).  D) Graphical 
interpretation of the percentages of cell death determined in (C). The bars represent 
the means of three independent experiments and the error bars indicate SD. 




Chapter 5  DISCUSSION 
5.1 Human UO-44 gene 
The rat UO-44 gene was previously reported to be involved in inducing 
epithelial proliferation and differentiation in the ovary and uterus (Huynh et al., 
2001). Isolation of the human ortholog of UO-44 (HuUO-44) will enable the further 
characterization of this gene in the initiation and progression of human ovarian and 
uterine cancers.  
 
5.1.1 Features in HuUO-44 Gene 
HuUO-44 cDNA was isolated through a combination of screening an ovarian 
cDNA library (GenBank accession no. AF305835) (Figure 4.1) and 5’ RACE (Figure 
4.2). RT-PCR of HuUO-44 from ovarian tissues and cancer cell lines resulted in the 
establishment of the full-length HuUO-44 cDNA, HuUO-44D (GenBank accession 
no. AY260047) (Figure 4.3). Conceptual translation of this transcript revealed that 
HuUO-44D encoded for the largest protein of 68 kDa. The conceptual translation of 
HuUO-44D revealed an almost identical gene architecture compared to the mouse (68 
kDa) and rat UO-44s (69 kDa); and HuUO-44D also encoded for the same functional 
motifs found in the other two orthologs, two CUB domains and a zona pellucida (ZP) 
domain (Figure 4.13). These two functional motifs are found in diverse proteins and 
are evolutionarily highly conserved (Bork and Beckmann, 1993;Bork and Sander, 
1992), suggesting their involvement in fundamental cellular processes. Several CUB 
and ZP domain proteins illustrated in Figure 4.13 have been implicated in cancers. 
These proteins contained similar functional domains and structure to UO-44, which 
suggested a conserved biological function. 




CUB domains are found in developmentally regulated proteins that participate 
in embryogenesis and organogenesis (Bork and Beckmann, 1993). One of the 
vertebrate CUB domain containing proteins, bone morphogenetic protein (BMP-1), 
has previously been shown to be involved in interaction with the extracellular 
matrices (Hartigan et al., 2003)(Figure 4.13). The CUB domain containing protein, 
CDCP1, have been reported to be upregulated in colorectal cancers and proposed that 
CUB domains are involved in modulating the cell substrate adhesion or the interaction 
with the extracellular matrices (Scherl-Mostageer et al., 2001)(Figure 4.13). In vitro 
studies suggested that one of the CUB containing proteins, bovine acidic seminal fluid 
protein, might serve as a mitogen, growth factor and stimulate progesterone secretion 
in cultured ovarian cells (Einspanier et al., 1991). In this study, we have demonstrated 
that HuUO-44 is involved in cell attachment and proliferation; the two CUB domains 
found at the amino terminal of UO-44 could therefore function in interactions and 
signaling of extracellular components and ligands, which contributed to cell adhesion 
and cell motility.   
ZP domain is the other functional motif found at the carboxyl end of UO-44, 
ZP domain proteins are found to be involved in sperm-egg recognition found in sperm 
receptor ZP2 and ZP3 (Bork and Sander, 1992). This domain is also found in TGF-β 
receptor type III, uromodulin and the major zymogen granule membrane protein (GP-
2) that are related to proteins involved in binding (Jovine et al., 2002;Bork and 
Sander, 1992;Einspanier et al., 1991). Each of these ZP domain proteins is usually 
found next to a putative transmembrane region suggesting a conserved biological 
function of the domain. Consistent to this observation, the ZP domain found in 
HuUO-44 is located next to a transmembrane region at the carboxyl-terminal. Other 
common biological properties of ZP domain containing proteins are: (i) they are 




generally detected in soluble form, (ii) contain a long hydrophobic sequence segment 
at or near the C-terminal, and (iii) are heavily glycosylated (Bork and Sander, 1992). 
Proteins possessing both CUB and the ZP motifs have a common feature in that they 
are secreted or located on the cell surface (Bork and Beckmann, 1993;Bork and 
Sander, 1992). 
Consistent to the properties of ZP proteins, we have also localized the HuUO-
44 protein to the cell surface of ovarian cancer cells (Figure 4.20 and 4.21); and 
computational analysis detected a signal peptide and a transmembrane region within 
the UO-44 protein (Figure 4.12) suggesting that HuUO-44 may be located on the cell 
surface and the signal peptide could regulate the secretion of the protein. Similarly, 
Imamura et al. have also demonstrated that the UO-44 mouse ortholog was a highly 
glycosylated protein (Imamura et al., 2002).  
   The UO-44 gene is mapped to chromosome 10q; a region that is frequently 
lost in many malignant tumor types, particularly in glioblastoma multiform. (Rasheed 
et al., 1995;Peiffer et al., 1995;Gray et al., 1995;Kim et al., 1998;Somerville et al., 
1998). The genomic structure of HuUO-44 shared high similarity to that of the tumor 
suppressor DMBT1 located at 10q25.3-26.1 (Mollenhauer et al., 2000;Wu et al., 
1999;Mollenhauer et al., 1997;Lualdi et al., 2000) a locus located upstream of HuUO-
44, which is located at 10q26.13. DMBT1 is considered a tumor suppressor gene 
because of its frequent deletions and/or lack of expression in malignant tumors of the 
brain (Mollenhauer et al., 1997;Somerville et al., 1998;Mollenhauer et al., 2000), the 
gastrointestinal tract (Mori et al., 1999;Mollenhauer et al., 2001), and the lung (Wu et 
al., 1999;Takeshita et al., 1999). The close proximity between DMBT1 and HuUO-44, 
suggest that HuUO-44 could be a product of gene duplication or vice versa.  




The DMBT1 is a large secreted glycoprotein that has been linked to initiation 
of cell proliferation, differentiation and repair (Cheng et al., 1996;Bisgaard et al., 
2002). Intriguingly, a conserved domain search revealed that the DMBT1 protein 
contained two CUB domains at the carboxyl terminal followed by one ZP domain; 
these domains were also present in HuUO-44 protein with the same arrangement 
(Figure 4.13). This close similarity of the two proteins thus suggested that UO-44 and 
DMBT1 might share common functions.  
 
5.1.2 The Origin of Human UO-44 Isoforms 
5’ RACE amplification and cDNA library screening established three 
contiguous transcripts of 2.2, 2.4 and 3.3 kb (Figure 4.2). Sizes of these transcripts 
coincided approximately with the 2 and 3 kb transcripts observed on the MTN (Figure 
4.7). The sequences of the 2.2 and 2.4 kb transcripts were mapped to exon 4, 
suggesting the presence of two possible transcription start sites in exon 4. For the 3.3 
kb connoting, the transcriptional start site is predicted to be in exon 1.  
Expression profiling of HuUO-44 though RT-PCR in a paired normal ovarian 
tissue and ovarian tumor, ovarian and cervical cancer cell lines resulted in the 
isolation of five novel spliced-variants, HuUO-44A, -B, -C, -D and -E that differ in 
their 5’ region (Figure 4.4). These variants were obtained through a complex series of 
alternative splicing events between exons 2 to 6 (Figure 4.6) and encoded different 
functional motifs (Table 4.1). HuUO-44D is the largest transcript isolated; the 
conceptual translated size of the HuUO-44D protein is almost identical to that of the 
mouse and rat UO-44 orthologs. The close amino acid sequence alignment of the mouse 
and rat UO-44 to the HuUO-44D peptide suggested that this transcript is the full-length 
human ortholog of UO-44 (Figure 4.12).  




Comparison of the cDNAs obtained through 5’ RACE and RT-PCR revealed 
that HuUO-44B, -C, -D and -E contained only an internally spliced exon 4* of 151 bp 
(Figure 4.4), while all three 5’ RACE cDNAs contained longer exon 4 that varied in 
size (Figure 4.2). These larger 5’ RACE cDNAs, however, shared the same ORF as 
HuUO-44B and -C, which encoded for only the ZP domains. HuUO-44 transcripts 
that encoded only the ZP domain but not the CUB domains suggested that the frame-
shift in the ORF caused by the presence of a longer exon 4 might function to regulate 
the expression of the different functional motifs.  
Analogous to this speculation, HuUO-44E, which contained an internally 
spliced exon 5 encoded for two CUB domains and a ZP domain as two separate 
proteins, which could result in different biological functions. The presence of the 
signal peptide before the CUB domains and the presence of a transmembrane region 
after the ZP domain lend speculation that the peptide containing the CUB domains 
encoded by HuUO-44E might function as a ligand and the peptide containing the ZP 
domain might serve as a receptor. Moreover, a recent GenBank annotation predicted 
two more exons at the 5’ end before the exon 1 described here and this was annotated 
as CUZD1 (GenBank accession no. NM_022034). The addition of two more exons 
resulted in a longer 5’ UTR in the gene but the ORF of HuUO-44 remained the same. 
However, these additional exons did change the subsequent outcome of the human 
UO-44 promoter analysis.   
The functional roles of these HuUO-44 mRNA isoforms are not known at the 
present time, but one could speculate that the transcriptional regulation and alternate 
splicing events might function to regulate the gene expression. The choice of 
transcriptional start sites and/ or the splicing of one or more exons might result in a 
HuUO-44 protein that lacked certain functionally important domains. However, this 




hypothesis required confirmation by gene expression analysis through silencing or 
overexpression of each splice variant in-vivo or in-vitro to examine the molecular 
events that potentially led to the activation of this gene. 
 
5.1.3  UO-44, a Multifunctional Protein 
UO-44 is an enigmatic protein that has also been implicated in diverse 
physiological functions. The first report of UO-44 suggested that the mouse ortholog 
played an important role in the uterus during pregnancy (Kasik, 1998). 
Characterization of the rat UO-44 ortholog established that estrogen induced the 
expression of the gene while pure anti-estrogen ICI 182780 was inhibitory (Chen et 
al., 1999;Huynh et al., 2001). This revealed that the expression of UO-44 is positively 
and negatively correlated with the uterotrophic effects of estrogen receptor partial 
agonist and antagonists.  
Expression profiling in the rat revealed that UO-44 is highly expressed in the 
ovaries and uterus (Chen et al., 1999;Huynh et al., 2001), however, in human the gene 
expression is found highly expressed in the pancreas (Figure 4.7). These differences 
in the expression profile of UO-44 in the rat and human are most likely attributed to 
the cell type specific expression of UO-44. This coincided to a previous report, which 
demonstrated using in-site hybridization that UO-44 is restricted exclusively to the 
luminal and glandular epithelial cells in the rat (Huynh et al., 2001). In comparison, 
the rat multiple tissue expression profile gave a better representation of the actual UO-
44 expression as the rat Northern blot was generated using total RNA extracted from 
whole organs compared to the human MTN blot, which was sampled from tissue 
sections that could be cell type bias. Given that UO-44 was an estrogen gene, one 




could also speculate that the estrous cycle at the time of sampling might also 
contribute to the high UO-44 expression observed in the rat uterus and ovary. 
Nonetheless, the high mRNA level of HuUO-44 observed in the pancreas on 
the MTE (Figure 4.8) indicated that the protein might play a role in the endocrine 
system. Relative to the expression levels of HuUO-44 in the other tissues, this high 
HuUO-44 expression in the pancreas could contribute to the masking of HuUO-44 
expression in other tissues. Interestingly, the expression analysis of HuUO-44 in a 
paired normal/ tumor pancreas on the CPA revealed that the gene is highly expressed 
in the normal pancreatic tissue compared to the tumor (data not shown). In agreement 
to this observation, a series of studies in UO-44 knock-out mice, demonstrated that 
UO-44 increased the susceptibility to severity of secretagogue and diet induced 
pancreatitis compared to the UO-44 knock-in mice, further investigation observed that 
the acinar cells has an increased susceptibility to apoptotic cell death in the UO-44 
deficient animals (Imamura et al., 2002). Although these previous in vitro and in vivo 
studies reflected UO-44 multifunctionality, its common function remains unknown. 
 
5.2 Rat Model for Further Characterization of UO-44 
Isolation of the human ortholog of UO-44 resulted in the establishment of 
novel spliced variants, which might play a role in its gene regulation. Establishment 
of the gene structure and isolation of different isoforms of rat UO-44 was performed 
to develop a rat model for further characterization of UO-44’s role in hormonal 
regulation and pregnancy development.  
 




5.2.1 UO-44 is Highly Conserved in Human, Mouse and Rat 
The combination and orientation of transcription factors has been shown to 
regulate gene expression; and common organization framework of regulatory 
elements are often found in orthologs of genes (Prakash and Tompa, 2005). In 
comparison, the human, mouse and rat UO-44s shared relatively high sequence 
similarities both at the nucleotide and peptide levels. In comparison, the mouse and 
rat UO-44s are more closely related than to their human ortholog (Figure 4.12). This 
close relationship between the mouse and rat UO-44s enabled the identification of 
similar predicted promoter sets within the two species (Figure 4.13). The differences 
in the predicted promoter sets in the comparative genomic analysis for the human 
ortholog was contributed by the use of the collective GenBank annotation of HuUO-
44, CUZD1 (GenBank accession no. NM_022034), contained 11 exons while the 
mouse and rat UO-44 contained only 9 exons. Discrepancies in the exons resulted in 
the subsequently misalignment of the exon sequences leading to the prediction of 
different promoters, which suggested that the two extra exons annotated in CUZD1 
might not be true exons in the HuUO-44 transcript as the presence of these extra 
exons have yet been verified experimentally. This accusation was in agreement with 
the further 5’ RACE upstream of exon 1 of HuUO-44, which did not yield any 
additional exons.   
Given that the putative human UO-44 promoter deduced using the CUZD1 
sequence might not be a reliable prediction, analysis of the possible mechanism of 
UO-44 regulation was performed using the putative mouse and rat UO-44 promoters. 
Three cis-regulating functional modules were identified in the mouse UO-44 promoter 
(Table 4.5); the first functional module, SORY-PAX6 was previously reported to be 
involved in eliciting cell differentiation in embryonic lens development (Kamachi et 




al., 2001;Kondoh et al., 2004). The second module identified was the SORY-SF1F 
that composed of two transcription factors (TFs), SOX 9 and SF-1. SOX9, a Sertoli 
cell factor was closely associated with its cell differentiation and Anti-Müllerian 
hormone (AMH) expression. In male embryos, AMH is produced to inhibit the 
development of Müllerian ducts that are required for development of female 
reproductive organs (De Santa et al., 1998). Though these two modules are involved 
in cellular differentiation, they have yet been implicated in cancer development. It 
will be interesting to examine their roles in the regulation of UO-44 in relation to 
cancer cell differentiation.  
The last module identified in the mouse promoter was the ETSF-IRFF, which 
was shown to activate IL12RB1 gene expression through IL15 and IFN-gamma by 
activating TFs, Pu-1 and IRF3 (Musikacharoen et al., 2005). This module has been 
known to function as repressors and activators of transcription, in relation to UO-44, 
these cis-elements might act as a molecular switch for UO-44 transcriptional 
activation and suppression. The above functional modules found within the mouse 
UO-44 promoters are associated with activation and induction of genes involved in 
embryogenesis, development and differentiation, which are consistent with the 
functions of the CUB and ZP domains found in the UO-44 protein. CUB domain 
proteins were involved in embryogenesis and organogenesis, while ZP domain 
proteins were important for protein-protein interactions (Bork and Sander, 1992;Bork 
and Beckmann, 1993). 
In the rat promoter, the two functional modules identified were: a) NFKB-
IRFF module was shown to mediate the activation of MHC class 1 transcription 
through TNF and interferons (Johnson and Pober, 1994); while the other b) ETSF-
AP1F module was reported to induce transcription from the human urokinase-type 




plasminogen activator (uPA) promoter (Nerlov et al., 1992). The two cis-regulatory 
elements found in the rat UO-44 promoter are associated with transcription activation; 
further investigation into these regulatory modules may help to unravel the 
mechanism of UO-44 associated cell proliferation. 
Strikingly, through comparative genomics analysis, common transcription 
factors (TFs) organization framework was identified in the putative mouse and rat 
UO-44 promoters (Figure 4.14).  SOX/SRY [SOX/SRY-sex/testis determining and 
related high motility group (HMG) box factors] was one of the two TFs identified; 
SOX/SRY represented a group of architectural transcription factors capable of 
directing nuclear import and DNA bending. Intriguingly, studies had suggested that 
DNA-HMG domain protein complexes protected cisplatin adducts against repair, 
resulting in the sensitization of cells to cisplatin by inhibiting repair mechanisms 
(Huang et al., 1994;Zamble et al., 1996;Trimmer et al., 1998;Arioka et al., 1999). In 
ovarian cancers, the formation of DNA adducts after cisplatin treatment might result 
in the upregulation of the HMG proteins. Increase binding of HMG proteins to the 
HMG element in the common organization framework of the UO-44 promoters could 
contribute to the repression of UO-44 transcription. This speculation was consistent to 
the downregulation of HuUO-44 expression in the ovarian cancer cell lines (NIH-
OVCAR3, SKOV3 and OV-90) after cisplatin treatment, which resulted in the 
inhibition of cell attachment and proliferation (Figure 4.25). However, several 
proteins are involved in these nucleotide excision pathways and it might also be 
possible that regulation of apoptosis signaling could also contribute to the 
downregulation of the UO-44 protein upon cisplatin treatment. 
Steroidogenic factor-1 (SF-1) was the other TF identified in the common 
organization framework of the UO-44 promoters. Studies have shown that this TF 




was essential for the development of various endocrine tissues; apparently through the 
expression of steroidogenic enzymes and signaling molecules involved in the 
steroidogenic pathway (Luo et al., 1999;Hanley et al., 2000;Parker et al., 2002). 
Significantly, the SF-1 knockout mice were found to have impaired endocrine 
development and function. Taken together, the presence SF-1 element in the UO-44 
promoter, the high expression of HuUO-44 in the pancreas and the increased severity 
of pancreatitis seen in the UO-44 knockout mice (Imamura et al., 2002), were other 
indications that the gene might play a role in endocrine development and possibly in 
the development of the pancreas.  
 
5.2.2 Genomic Organization of Rat UO-44 Gene 
Genomic organization of the human and rat UO-44 deciphered in this study 
exhibited high similarities (Figure 4.9). Both the human and rat UO-44 gene isolated 
here contained 9 exons and identical size exon were observed (Table 4.2 and 4.3). The 
predicted UO-44 spliced junction in both species contained the GT/AG dinucleotides 
consensus sequences. Both the human and rat UO-44s encoded for a protein that 
contained the same functional motifs as discussed in Section 5.1.1. The functional 
motifs found in rat UO-44 were also organized in the same as in HuUO-44 with a 
signal peptide in exon 1, 2 CUB domains in exons 2 – 5, a ZP domain in exons 5 – 7 
and a transmembrane region in exon 9.  
Though similar gene structure of the human and rat UO-44 were observed in 
this study, collective annotation of HuUO-44 (CUZD1) reported two extra exons that 
was not found in the collective annotation of the rat UO-44 (rat CUZD1, GenBank 
accession no. NM_054005). This was in agreement with the previous speculation in 
the promoter analysis that the two extra exons indicated in the collective UO-44 




annotation (GenBank accession no. NM_022034) were not part of the HuUO-44 
transcript. Regulation of UO-44 expression was possibly by the use of alternative 
promoters or through alternative splicing of exons in both species. Nonetheless, the 
process of evolution might have contributed to modify the regulation of UO-44 in 
both species as variations of alternative-splicing events were seen, but the protein and 
gene structure remained conserved.  
 
5.2.3 Rat UO-44 Isoforms  
Analysis of the rat UO-44 transcripts performed in rat ovaries revealed the 
presence of five novel spliced variants (Figure 4.11). Similar to the variant isoforms 
of HuUO-44, the rat UO-44 variants were similar at the 3’ region from exons 7 – 9 
but varied at the 5’ region from exons 1 – 6. The splicing patterns of rat UO-44A and 
-B were identical to HuUO-44B and -C, respectively. Although they all encoded for 
only the ZP domain, rat UO-44A encoded for a larger protein of 46 kDa, while 
HuUO-44-B, -C and rat UO-44B encoded for proteins of about 36 – 37 kDa (Table 
4.4). Rat UO-44C encoded for 1 CUB domain and a ZP domain, this rat UO-44 
variant was not present in the human. The two other rat UO-44 variants, UO-44D and 
-E also encoded for the ZP domains.  
Observation of the splicing patterns of HuUO-44 and rat UO-44 suggested that 
alternative splicing functions to regulate the expression of the CUB domains as all the 
UO-44 isoforms in both species encoded for the ZP domain. Consistent to this 
speculation, CUB domain proteins were found to function in the interaction with the 
extracellular matrices and the ZP domains might serve to localize the protein to the 
cell membrane or for protein secretion. However, confirmation of these postulations 




only can be determined through identification of cleavage sites within the protein or 
through localization of the different domains using tagged reporter proteins.  
5.2.4 Tamoxifen, β-estradiol (E2) and Pure Anti-estrogens (ICI 182780) 
Role in Regulation of Rat UO-44 Isoforms 
Women taking the drug tamoxifen to prevent or treat breast cancer have an 
increased risk of uterine and ovarian cancers. This is attributed to the estrogen like 
effect of the drug on the uterus and ovary, as tamoxifen is found to exhibit both anti-
estrogenic and estrogenic properties. In agreement, the expression of UO-44 full-
length transcript in the uterus was upregulated by tamoxifen and E2 (Figure 4.15). The 
level of induction of UO-44 expression was almost identical in both the tamoxifen 
and E2 treated rats demonstrating the estrogen-like effect of tamoxifen on UO-44 
expression. Conversely, the expression of UO-44A was higher in the tamoxifen 
treated rats compared to the rats treated with β-estradiol. Treatment with a pure anti-
estrogen (ICI 182780) completely inhibited the expression of all UO-44 transcripts 
(Figure 4.15). The upregulation of UO-44 by estrogens and tamoxifen but inhibition 
by pure antiestrogens (ICI 182780), suggesting that the UO-44 protein might serve as 
a mediator in estrogen and tamoxifen stimulated epithelial proliferation and 
differentiation of the uterus and ovary. 
On the other hand, no changes in UO-44 expression were observed in-vitro 
with ovarian cancer cell lines treated with tamoxifen, E2 and ICI 182780 (data not 
shown). Differences in the in-vitro and rat in-vivo findings suggested that a cascade of 
events initiated the induction of UO-44 in the rat after tamoxifen, E2 and ICI 182780 
treatments. This is most likely due to the gene not being a direct target of these 
hormones but could be stimulated by other proteins expressed in other cells present 
in-vivo. Though the functional roles of these rat UO-44 variants have yet been 




deciphered, regulation of UO-44 expression by estrogens highlighted the potential of 
UO-44 as a novel marker for hormone responsiveness after tamoxifen treatments and 
estrogen replacement therapies. 
5.2.5 Rat UO-44 a Pregnancy Induced Gene in the Mammary Glands  
UO-44 was first reported to play an important role in the uterus during 
pregnancy and estrogen was later found to be the key-inducing hormone involved in 
UO-44 gene expression (Chen et al., 1999;Huynh et al., 2001). Additionally, 
estrogens also played an active role in the development of the mammary glands, in the 
maintenance of pregnancy and bone density, in protection from cardiovascular 
diseases, and in the relief of menopausal symptoms (Yager and Liehr, 1996;Yager and 
Davidson, 2006).  Gene expression analysis of UO-44 in the mammary glands during 
pregnancy revealed exceptionally high levels of UO-44 during lactation and this was 
reduced to pre-pregnancy levels with the onset of involution (Figure 4.16).  
These high levels of UO-44 during lactation in the mammary gland suggest 
that this gene could also be important for cell proliferation in the mammary gland 
during development. In addition, the subsequent reduction in UO-44 expression 
during involution suggested that it might play a role in controlling the dynamic 
balance between cell proliferation and cell death in the lactating mammary gland. It 
will be interesting to investigate if lactation hormones like oxytocin and prolactin do 
play a role in regulating UO-44 expression. 
 
5.3 Human UO-44 and Ovarian Cancers 
The two main clinical goals of research driven by progress achieved through 
deciphering the molecular mechanisms of ovarian cancers are: i) Early ovarian cancer 
detection and ii) targeted therapies. Understanding the involvement of UO-44 in 




ovarian cancers could result in the discovery of an early diagnosis marker and a 
potential target for pre-treatment of ovarian cancers that are caused by epithelial 
invasion.  
5.3.1 Estrogen-regulated Proteins as Potential New Markers for 
Ovarian Cancers 
Ovarian neoplasms are often diagnosed at very advanced stage, almost 70 % 
of ovarian tumors are discovered at stage III (Cunat et al., 2004), as the most 
commonly presented symptoms of persistent abdominal pain and pressure in the 
pelvis, could be attributed to a number of causes (Lister-Sharp et al., 2000). Currently 
an emerging group of estrogen-regulated genes such as fibulin-1, cathepsin D and 
kallikreins are being studied to determine their prognostic value in ovarian cancers 
(Clinton and Hua, 1997;Cunat et al., 2004). In vivo studies supported UO-44 as an 
estrogen-regulated gene and through the Cancer Profiling Array, HuUO-44 was found 
overexpressed in the majority of ovarian tumors (Figure 4.17).  
Interestingly, immunohistochemical staining of ovarian sections revealed that 
HuUO-44 is expressed only to the normal ovarian and ovarian tumor epithelial cells 
but not in the stroma cells (Figure 4.21). This cell type specific expression of HuUO-
44 was confirmed using a semi quantitative RT-PCR of the normal ovarian epithelial 
layers, ovarian tumors and an ovarian epithelial cancer cell line, which also 
established that the levels of the HuUO-44 transcript in the normal ovarian epithelial 
layers were similar to that in the ovarian tumor and cell line (Figure 4.18). Even 
though the ovarian surface epithelium represented a very small fraction of the cell 
mass in the ovary, it gave rise to more than 80 % of human ovarian carcinomas 
(Auersperg et al., 1984;Tsao et al., 1995;Gregoire et al., 2001;Nitta et al., 2001). The 
higher transcript expression of HuUO-44 in the tumors observed on the CPA (Figure 




4.17) was therefore due to the presence of a greater population of epithelial cells 
compared to the normal samples, which contained predominantly stroma cells.  
In addition, the higher transcript levels of HuUO-44 in the metastatic tumor 
samples shown on the CPA (Figure 4.17) also suggested that HuUO-44 might be 
involved in promoting tumor cell extravasations. Taken together, the estrogen-
regulated expression of UO-44, its epithelial specific expression in the ovaries, further 
advocated the potential of this gene as a biomarker for early detection of ovarian 
epithelial cancers or as a general marker for estrogen-responsiveness following 
hormone replacement therapy. 
 
5.3.2 HuUO-44 – A Protein Involved in Ovarian Cancer Cell Adhesion 
and Cell Motility 
A bioinformatics assessment under the Secreted Protein Discovery Initiative 
(SPDI) had previously identified more than 1000 secreted and transmembrane human 
proteins and these predictions indicated that HuUO-44 was a secreted and 
transmembrane protein (Clark et al., 2003). This computational analysis was 
substantiated with the transfection studies employing a mammalian expression vector 
containing an enhanced green fluorescent protein (eGFP) fused to the HuUO-44D-
ORF. Localization of the HuUO-44-eGFP fusion protein to the cytosol and its 
subsequent migration to the cell membrane 48 h post transfection demonstrated the 
membrane-associated nature of this protein (Figure 4.19). HuUO-44 membrane 
association was further verified by immunohistochemical staining of HuUO-44 in 
ovarian cancer cell line, which revealed that its protein expression was only restricted 
to the leading edge of the cells (Figure 4.20). The localization of HuUO-44 to the 




membrane and to the leading edge of ovarian cancer cells suggested that the protein 
might be involved in interactions with the extracellular matrices and cellular motility. 
Numerous steps in the progression of cancer, including invasion and 
metastasis, involved a cascade of events from dysregulation of normal cell-cell 
adhesion and cell-matrix interactions. These interactions are mediated by at least five 
families of cell adhesion molecules (CAMs), namely: integrins (Hynes, 1992), 
immunoglobulins (IgCAMs) (Springer, 1990), CD44 (Goodison et al., 1999), 
selectins (Oshiba et al., 2000), and cadherins (Liotta, 1986). Besides regulating cell-
cell and cell-matrix interactions, CAMs are also found to influence cell motility, 
migration, signaling, and differentiation. Analogous to the functions of CAMs, the 
inhibition of ovarian cancer cells (NIH-OVCAR3) attachment and proliferation was 
observed when cultured in HuUO-44 antiserum (Figure 4.22), suggesting its 
involvement in cell adhesion and cell motility. In ovarian cancer, HuUO-44 might 
interact with these CAMs to promote cell growth and facilitate locoregional invasion. 
However, these interactions can only be verified through immunoprecipitation using 
HuUO-44 antibodies.  
 
5.3.3 Involvement of Human UO-44 in Cisplatin Chemoresistance 
Chemotherapy has been regarded as standard therapy for the majority of 
women with advanced epithelial ovarian cancer for several decades (McGuire, III and 
Markman, 2003). Chemoresistance could be developed through the alterations in 
apoptotic machinery, activation of anti-apoptotic pathways or expression of anti-
apoptotic genes (Siddik, 2003). Cisplatin chemotherapy has been shown to play a role 
in the induction of genes that mediate chemoresistance (Coukos and Rubin, 1998). 
Preliminary analysis of the UO-44 promoters through common TFs organization 




framework revealed the presence of a HMG domain, which was previously reported 
to cause cisplatin sensitization in cells by inhibiting DNA repair (Huang et al., 1994). 
As a follow-up to this observation, the present study investigates the involvement of 
HuUO-44 in cisplatin sensitivity in cells. 
The first clue relating HuUO-44 to chemoresistance in ovarian cancer cell 
lines was provided by the observation that HuUO-44 expression was suppressed in 
SKOV-3 cells treated with various chemotherapeutic agents with cytotoxic mode of 
action involving DNA damage (Figure 4.23).  In agreement, further investigation into 
the toxicity of cisplatin in four ovarian cancer cell lines revealed that the sensitivity to 
cisplatin is correlated to the reduction in HuUO-44 expression (Figure 4.24, 4.25 and 
4.26). The expression of HuUO-44 is seemingly strictly related to the cell exposure to 
apoptosis inducing agents and may therefore be related to the main HuUO-44 function 
under physiological conditions. 
Advances in the field of gene down-regulation using RNA interference 
(RNAi), through the introduction of short interfering double stranded RNAs (siRNAs) 
into cells can effectively suppress gene expression by mRNA degradation or 
inhibition of translation (Tebes and Kruk, 2005;Ryther et al., 2005). Silencing of 
several key oncogenes or tumor-promoting genes, including growth and angiogenic 
factors or their receptors (vascular endothelial growth factor, epidermal growth factor 
receptor), human telomerase (hTR, hTERT), viral oncogenes (papillomavirus E6 and 
E7) or translocated oncogenes (BCR-abl) using RNAi has already been reported to 
cause suppression of growth and survival of various cancer cell lines, which is 
suggested to be a promising approach for gene therapy (Ryther et al., 2005;Devi, 
2006). However, due to the involvement of numerous genes in tumor progression, 
simultaneous inhibition of multiple target genes may be necessary to effectively 




inhibit tumor progression. It is therefore necessary to combine the use of siRNAs with 
other compounds, such as chemotherapeutic agents to elicit the synergistic or additive 
antineoplastic effects in tumors.  
In fact, a few siRNAs have already been shown to enhance sensitivity to 
different chemotherapeutic drugs in vitro (Cioca et al., 2003;July et al., 2004). For 
instance, silencing of Her-2/neu in ovarian cancer can result in in vitro decreased cell 
proliferation, increased apoptosis, increased G0/G1 arrest and decreased tumor 
growth (Yang et al., 2004). Likewise, H-ras RNAi resulted in decreased ovarian 
tumor growth and ovarian cancer cell lines transformation efficiencies (Yang et al., 
2003;Yang et al., 2004;Choudhury et al., 2004). Similarly, targeting heparin-binding 
EGF-like growth factor (HB-EGF) with siRNA also resulted in decreased tumor 
growth in ovarian cancer cell lines (Menendez et al., 2004). In addition, siRNA 
targeting proteins that conferred multidrug resistance, p-gp and GST has also been 
previously shown to restore cisplatin sensitivity in-vitro (Duan et al., 2004). 
Correspondingly, inhibition of ABCB1 and ABCB4 gene by siRNA has also been 
shown to sensitize ovarian cancer cells to paclitaxel (Miyamoto et al., 2004). Though 
most RNAi studies have only been successful in-vitro, identifying delivery strategies 
remained a major challenge for clinical applications. Fortunately, the first 
breakthrough for RNAi therapeutics came when Acuity Pharma produced siRNAs 
(Sirna-027) targeting VEGF receptor-1 entered phase 2 clinical trials for the treatment 
of age-related macular degeneration (a disease that results in adult bliness)(Bumcrot 
et al., 2006). 
This present study represented the first report of the use of siRNA to silence 
the HuUO-44 gene. More specifically, the three HuUO-44 siRNAs, U1, U2 and U3 
were designed to target HuUO-44 exon 2, exon 4 and exon 6, respectively (Table 4.6). 




Silencing of these individual exons demonstrated the sequence specific silencing of 
the different variants, which contributed to the varying levels of HuUO-44 gene 
silencing (Figure 4.27). Furthermore, the dose dependent silencing of HuUO-44 
through siRNAs in ovarian cancer cell lines, NIH-OVCAR3 and SKOV3, 
demonstrated a decline in cell growth through the inhibition of cell attachment (Figure 
4.28 and 4.29). This detachment of epithelial cells from an extracellular matrix results 
in a form of apoptosis known as anoikis (Frisch and Francis, 1994).  
Strikingly, it was found that HuUO-44 RNAi significantly sensitized human 
ovarian cancer cells, NIH-OVCAR3 to cisplatin in vitro (Figure 4.30). These findings 
illustrated that HuUO-44 siRNAs significantly increased the efficacy of cisplatin 
treatment on ovarian cancer cells.  Coherent to the above RNAi studies, the 
overexpression of HuUO-44 conferred resistance to cisplatin in ovarian cancer cells 
(Figure 4.32). The reduced growth in the HuUO-44 knockdown cell line was most 
probably related to the progressive loss of ability of the cells to adhere to a substrate 
and cisplatin further activated DNA damage-mediated signal transduction pathways 
that involved ATR, p53, p73 and MAPK culminating in the activation of apoptosis.  
In general, UO-44 also known as CUZD1 encoded for a transmembrane 
associated protein that contained two CUB domains and a ZP domain, which was first 
cloned from a pregnant mouse uterus cDNA library (Kasik, 1998) and was found 
expressed in the uterus and ovaries (Huynh et al., 2001). UO-44 was upregulated in 
the uterus during cell proliferation induced by estrogens but down regulated during 
cell stress by pure anti-estrogen (ICI 182780) (Chen et al., 1999; Huynh et al., 2001).  
UO-44 was implicated in diverse physiological functions, including pregnancy 
development (Kasik, 1998; Chen et al., 1999), protection against severity of 
pancreatitis (Imamura et al., 2002) and cell adhesion (Huynh et al., 2001). 




Interestingly, novel alternatively spliced variants of UO-44 were isolated and these 
might path the way in deciphering the regulation of its gene expression. Collectively, 
these current findings revealed UO-44 may be associated with ovarian cancer cell 
invasiveness and silencing of UO-44 might enhance cell death following treatment 
with chemotherapeutic agents.  
In summary, our data demonstrated that the oligonucleotide-induced 
suppression of HuUO-44 expression intensifies apoptosis and significantly enhances 
chemosensitivity (P < 0.01). Conherent to this finding, the overexpression of HuUO-
44 in ovarian cancer cell significantly conferred resistance to cisplatin (P < 0.05).  
Based on our previous observation that HuUO-44 is epithelial specific and ovarian 
tumors contains predominantly epithelial cells, our present experimental findings 
support the development of epithelial tumor targeted strategies involving intra-tumor 
administration of HuUO-44 siRNAs to complement the conventional cytotoxic 
therapies for advance ovarian cancers. 




Chapter 6 CONCLUSION AND FUTURE STUDIES 
UO-44 is an inscrutable estrogen regulated protein that is overexpressed in the 
uterus and ovaries (Chen et al., 1999;Kasik, 1998;Huynh et al., 2001). Despite 
previous in vitro and in vivo studies that reflect its multifunctionality, its common 
function remains unclear. This present study described the cloning, sequencing and 
genomic organization of the human ortholog of UO-44, which in the process isolated 
five novel alternatively spliced-variants of this gene. These HuUO-44 variants 
encoded for different functional domains and possibly bear diverse functions, which 
revealed the crucial regulatory roles of these variants in its gene expression.  
A rat model for UO-44 was established through the cloning of five novel rat 
UO-44 spliced-variants and deciphering its genomic organization. The positive 
correlation of rat UO-44 expression to the lactation stage in the mammary glands 
implied another role of this gene in mammary development. In addition, functional 
domains found in UO-44 were also found in proteins implicated in embryonic 
development and carcinogenesis, which reinforced the notion that UO-44 may be 
associated with cellular proliferation.  
In agreement, localization of the protein to the membrane and leading edge of 
ovarian cancer cells suggested the speculative role of UO-44 in cell motility and 
locoregional invasion of ovarian cancer cells. Strikingly, the inhibition of cell 
attachment and proliferation of ovarian cancer cells by HuUO-44 anti-serum further 
supported the belief that the protein modulates the interactions with extracellular 
matrices, which constituted to its invasiveness. Additionally, it will be interesting to 
investigate if the downregulation of HuUO-44 will result in the downregulation of cell 
adhesion molecules (CAMs). On the other hand, it will also be intriguing to find out if 




these adhesion proteins or what proteins interact with UO-44 and how they control or 
activate cellular proliferation. This information will most likely be provided through 
immunoprecipitation of the UO-44 protein complex and identifying its binding 
partners. The interaction kinetics of these binding proteins to UO-44 can then be 
established through surface plasmon resonance technology. 
Further investigation on the toxicity of cisplatin in four ovarian cancer cell 
lines revealed that the sensitivity to cisplatin was correlated to the reduction in 
HuUO-44 expression. Additionally, the oligonucleotide-induced suppression of 
HuUO-44 expression was shown to intensify apoptosis and significantly enhances 
chemosensitivity (P < 0.01) in ovarian cancer cells. Consistent with the above RNAi 
studies, the overexpression of HuUO-44 in ovarian cancer cells significantly 
conferred resistance to cisplatin (P < 0.05). This indicated another potential role of 
these UO-44 siRNAs as a valuable pre-treatment target for intra-tumor application in 
ovarian cancers that involves epithelial invasion, which attributes to more than 80 % 
of ovarian cancers. 
Many growth factor families are involved in the growth and progression of 
ovarian cancer, it is therefore important to establish a model to investigate what 
regulates the expression of UO-44. It will also be interesting to examine if the 
antisense (AS) oligonucleotide targeting HuUO-44 can be developed as an intra-
tumor pretreatment for ovarian epithelial cancer prioe chemotherapy. The current 
development of this study investigates whether chemoresistance can be developed in 
stable HuUO-44 overexpressing ovarian cancer cell lines in-vivo. Hopefully in the 
near future, strategies targeting UO-44 for ovarian cancers will be ready for 
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Molecular cloning, characterization and isolation of novel spliced variants
of the human ortholog of a rat estrogen-regulated membrane-associated
protein, UO-44
Caine Tuck Choy Leong1, Chuan Young Ng1, Chee Pang Ng1, Zeng Shuan Ma1, Thanh Hung
Nguyen1, Sun Kuie Tay2 and Hung Huynh*,1
1Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre of Singapore,
Singapore 169610, Singapore; 2Department of Obstetrics & Gynaecology, Singapore General Hospital, Singapore 169608, Singapore
We have previously reported the characterization of an
estrogen-regulated rat uterine–ovarian-speciﬁc comple-
mentary DNA (UO-44). To understand the involvement of
this protein in the initiation and progression of human
ovarian and uterine cancers, we now report the cloning
and characterization of the human ortholog (HuUO-44).
HuUO-44 is mapped to chromosome 10q26.13 and
contains nine exons. Multiple tissue Northern blot
detected two HuUO-44 transcripts of approximately 2
and 3 kb in the pancreas. RT–PCR demonstrated that
HuUO-44 undergoes a complex series of alternative
splicing events between exons 2 and 6 that yielded four
novel splice variants, HuUO-44A, HuUO-44B, HuUO-
44C and HuUO-44D. Putative functional motifs identiﬁed
in HuUO-44 are two CUB domains and a zona-pellucida
domain. Transfection studies demonstrated the mem-
brane-associated nature of HuUO-44. By immunohisto-
chemistry, HuUO-44 was located to the normal ovarian
and ovarian tumor epithelial cells; in NIH-OVCAR3
ovarian cancer cells, HuUO-44 was detected only at the
leading edge of the dividing cells. Most importantly, a
marked loss in cell attachment and proliferation was
observed in NIH-OVCAR3 cells cultured in the presence
of a polyclonal HuUO-44 antiserum. These ﬁndings
suggest the potential role of HuUO-44 in cell motility,
cell–cell interactions and/or interactions with the extra-
cellular matrices.
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Introduction
Estrogens promote growth, differentiation and remodel-
ing of the female reproductive tissues, such as the
ovaries and uterus through the modulation of genes that
regulate cell growth and differentiation (Yoshinaga
et al., 1969; Katzenellenbogen and Gorski, 1975; White
et al., 1995; Katzenellenbogen and Korach, 1997).
Tamoxifen is a type 1 (nonsteroidal) antiestrogen that
exhibits mixed estrogenic and antiestrogenic activity. In
the breast, it acts as an estrogen antagonist and is
currently being used in adjuvant therapy for breast
cancer prevention and treatment; however, long-term
administration may lead to an increased risk of
developing ovarian cysts in postmenopausal women
(Kazandi et al., 2002). It has previously been reported
that tamoxifen signiﬁcantly increases uterine weight,
whereas ICI 182780 a pure antiestrogen suppresses it
(Huynh and Pollak, 1993).
We previously reported a tamoxifen-induced comple-
mentary DNA (cDNA) RatUO-44 (GenBank Accession
number AF022147) isolated from rat uterus cDNA
library (Huynh et al., 2001). RatUO-44 is strictly
regulated by estrogens, tamoxifen and growth hormone
(GH), whereas pure antiestrogen ICI 182780 is inhibi-
tory. Upregulation of RatUO-44 expression in a dose-
dependent manner has been observed in uterus of
ovariectomized and hypophysectomized rats treated
with tamoxifen and GH, respectively. Putative func-
tional motifs contained within RatUO-44 are identiﬁed
as CUB domains and a zona-pellucida (ZP) domain. An
identical cDNA sequence of a rat estrogen-regulated
gene, ERG1 (GenBank Accession number AF167170)
also reported similar ﬁndings with the indication of a
signal peptide at the amino-terminal (N-terminal) and a
transmembrane domain at the carboxyl-terminal (C-
terminal) (Chen et al., 1999). A mouse homolog of
RatUO-44 (GenBank Accession number U69699) an-
notated as an integral membrane-associated protein-1
(Itmap1) has also been isolated from a pregnant mouse
uterus cDNA library, their study proposed that the
protein plays an important role in uterine events during
late pregnancy (Kasik, 1998). In a more recent report,
Itmap1 has also been shown to play an essential role in
trypsinogen activation, which contributes to the in-
creased severity of pancreatitis (Imamura et al., 2002).
Majority of the CUB domain-containing proteins
(CDCPs) are developmentally regulated. CDCPs play a
part in the mammalian complement system and also aid
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in protease activation of trypsinogen and cleavage of
collagen and ﬁbronectin (Bork and Beckmann, 1993).
Both human and mouse matriptase/MT-SP1, a matrix-
degrading transmembrane serine proteinase, contains an
arginine–glycine–aspartate (RGD) integrin-binding mo-
tif in the ﬁrst CUB domain. It has been reported that the
removal of their cytoplasmic and transmembrane
regions causes the protein to remain membrane bound
on the surface of COS cells. This suggests the involve-
ment of the CUB motif in integrin-mediated cell surface
binding (Takeuchi et al., 2000). In another report, a
novel CDCP-1 has been found highly overexpressed in
human colon and lung cancers (Scherl-Mostageer et al.,
2001). Their ﬁndings suggest that the upregulation of
CDCP1 functions to modulate the cell substrate
adhesion or interaction with the extracellular matrices.
ZP domains function as conserved modules for
polymerization of extracellular proteins and are also
responsible for sperm-adhesion of the ZP (Jovine et al.,
2002). These domains are also present in multidomain
transmembrane proteins such as glycoprotein GP2,
uromodulin and TGF-b receptor type III (betaglycan)
(Bork and Sander, 1992). Binding studies have shown
that the binding of TGF-b to ZP domains surface
receptors enhances TGF-b bioactivity (Fukushima et al.,
1993). In this study, we report the cloning, characteriza-
tion and isolation of four novel splice variants of the
human ortholog of the estrogen-regulated protein UO-
44 (HuUO-44) that is associated to interactions with the
extracellular proteins and matrices.
Results
Cloning of human UO-44 (HuUO-44) cDNA
The cDNA sequence of HuU-O44 was obtained through
a combination of screening a human uterine cDNA
library and 50 rapid ampliﬁcation of cDNA end
(RACE). Screening of the cDNA library gave rise to
the isolation of four positive clones, of which one
harbored the longest insert of about 2.1 kb that was
further studied and sequenced (GenBank Accession
number AF305835). The rat and human UO-44 were 79
and 73% identical at the nucleotide and peptide levels,
respectively. Conserved domain search with the peptide
sequence of this library screened HuUO-44 clone
identiﬁed a region at amino acids 315–558 as a ZP
domain; this domain was similar to that found in TGF
betaglycan, uromodulin and members of the ZP protein
family (Einspanier et al., 1991; Bork and Sander, 1992;
Jovine et al., 2002).
50 RACE ampliﬁcation was performed using 50
directed primers located at 150 bp position of the
HuUO-44 cDNA cloned from the human uterine cDNA
library. We obtained three 50 RACE products of 0.2, 0.4
and 1.4 kb in size (Figure 1). Sequences of the three 50
RACE products aligned completely at the 30-end and
only varied in length at the 50-end. The sequence
alignment of the overlapping clones from the 50 RACE
and cDNA library screened HuUO-44 clone predicted
three transcripts of 2.2, 2.4 and 3.3 kb in size.
Genomic structure of HuUO-44
The putative gene structure of HuUO-44 was deter-
mined through BLAST search of the human genome
data from the NCBI database (www.ncbi. nlm.nih.gov)
with the sequences of the three 50 RACE contigs. All
exon–intron junctions conformed to the splice consensus
(50GT/AG30) rule (Table 1). Mapped to chromosome
10q26.13, the HuUO-44 gene spans 14 kb and contains
nine exons ranging from 151 to 1188 bp and introns
ranging from 338 to 4433 bp (Figure 2).
Splice variants of HuUO-44
Tissue expression studies using the Multiple Tissue
Northern (MTN) blot detected two transcripts of
Figure 1 50 RACE illustration and sizes of the resulting contigs. (a) 50 RACE performed with a uterine cDNA library, giving rise to
three fragments of 0.2, 0.4 and 1.4 kb in size. All three 50 RACE products were sequenced and contig to the cDNA library clone
sequence. (b) Schematic diagram of the contig alignment of the RACE products and the cDNA library screened HuUO-44 clone
resulting in contigs of 2.2, 2.4 and 3.3 kb in size
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approximately 2 and 3 kb in the pancreas (Figure 3) that
correlated to the 50 RACE contigs (Figure 1). Expres-
sion studies of HuUO-44 in normal and tumor ovarian
tissues was studied using the cancer proﬁling array
(CPA) (Figure 4) demonstrated higher HuUO-44
expression in 12 of 14 (86%) ovarian tumors compared
to corresponding normal tissues. HuUO-44 expression
was also higher in the two metastatic ovarian tumors.
Expression of the HuUO-44 spliced variants was
further investigated using RT–PCR in one paired
normal ovarian and ovarian tumor tissues, four cervical
cancer cell lines and two ovarian cancer cell lines. The
primers used resided in exons 1 and 9; four novel
HuUO-44 splice variants were isolated, cloned and
sequenced. Alternative splicing was observed between
exons 2 and 6 (Figure 2). To obtain a better separation
of the bands, RT–PCR was repeated using primers
ﬂanking only the spliced exons; the primers used in this
nested ampliﬁcation resided in exons 1 and 7 (Figure 5).
The 150 bp band represented the smallest HuUO-44
splice variant, HuUO-44A, this was 1.4 kb in size and
contains an ATG in exon 7. HuUO-44A is produced by
splicing exons 2–6 (GenBank Accession number
AY260050) (Figure 2). Conceptual translation of this
mRNA isoform from this ATG yields a protein of 241
amino acids with a predicted molecular mass of
approximately 28 kDa. Isoform HuUO-44B is 2 kb in
size and is represented by the 750 bp bands, this
transcript is obtained through the splicing of exons 2
and, an internally spliced exon 4 and 5 (GenBank
Accession number AY260049) (Figure 2). The 900 bp
bands represented HuUO-44C that is 2.2 kb in size, this
variant is produced by splicing exons 2 and 4 internally
(GenBank Accession number AY260048) (Figure 2).
The cDNA library screened HuUO-44 clone (GenBank
Accession number AF305835) contained exons 4, 5, 6, 7,
8 and 9. This cDNA library screened transcript, HuUO-
44B and HuUO-44C contained an ATG at exon 6
encoding for a protein of 326 amino acids with a
predicted molecular mass of approximately 36 kDa.
HuUO-44D the largest splice variant is 2.3 kb in size and
is represented by a 1000 bp band, this transcript is
Table 1 Exon/intron boundaries of HuUO-44
Exon no. Exon size (bp) 50 splice donor Intron size (bp) 30 splice acceptor Domains
1 414 GAGGCTGAAGgtaagaaaat 4433 tctctaacagGCAATGCAAG SP1
2 151 CCTATGTCCAgtaagtagaa 1946 ttttccacagGCTTGATCCA CUB-1
3 215 CCTAACATCTgtaagtcctc 425 gattccttagATCTTGGTTC CUB-1
4 1188 AAGAGATTTTgtaagtactg 338 ttttcaccagAGGCCCTCAT CUB-2
5 235 ATCAACACTAgtaagtcatg 480 ttcctgacagCATCTTTAAC CUB-2/ZP
6 173 AATCAGAAAGgtaaagtgaa 1080 ttccctgcagGTAGAAGATC ZP
7 392 TCAAGAGTGGgtatgtatta 765 tctgttccagATGTAGTCGA ZP
8 269 GGCAATTCAGgtaagaaaaa 1221 ccaattttagGATTTCAGCA ZP
9 293 TM
The bold characters are the Exonintron Junction consensus sequences.
Figure 2 Graphical representation of Human UO-44 genomic organization. Exons and introns are drawn to scale. The location of
each exon within HuUO-44 cDNA is depicted by a shaded box and numbered below. The dotted lines illustrate the splicing pattern of
the four novel splice variants HuUO-44A, -B, -C and -D isolated from the RT–PCR of HuUO-44 in a paired normal ovarian and
ovarian tumor tissue, ovarian and cervical cancer cell lines
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produced through splicing of exon 4 internally (Gen-
Bank Accession number AY260047) (Figure 2). This
transcript contained an ATG at exon 1 and encoded for
a protein of 607 amino acids with a predicted molecular
mass of 68 kDa. The predicted protein encoded by
HuUO-44D isoform was evaluated against the non-
redundant protein database GenBank. Functional
motifs found in HuUO-44D were identiﬁed as CUB
Figure 3 MTN. Blot was probed with a radioactive-labeled 625bp 30 HuUO-44 cDNA probe as described in the Materials and
Methods. Two transcripts of approximately 2 and 3 kb in size were observed in the pancreas (Pan). HuUO-44 mRNA was below
detectable levels in the cervix (Cr), ovary (Ov), testis (Tes), prostate (Pro), muscle (Mus), uterus (Ut), bladder (Bla), kidney (Kid),
spleen (Spl), heart (Ht), brain (Br), liver (Li), placenta (Pla) and lung (Lu)
Figure 4 CPA (normal/tumor ovary) of human UO-44. The CPA blot was probed with a radioactive-labeled 625 bp 30 human UO-44
cDNA probe. Higher expression of the HuUO-44 transcript was observed in the ovary tumor samples (a). Relative density of the UO-
44 expression in the tumor and adjacent normal ovary samples were expressed as a percentage of the total sample examined. The
outlined groups of spots represented the normal, metastatic (below the normal spot) and tumor cDNA from the same patient. The blot
was normalized against ubiquitin control (b)
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domains (at amino acids 53–145 and amino acids 154–
264) and ZP domain (at amino acids 277–519) (Figure 6).
The amino acids for polyadenylation signal shown in
bold are 80 bp from the stop codon. Signal peptide
search predicted a putative signal peptide (at amino
acids 1–21) at the N-terminal and a 19 amino acids
transmembrane region at the C-terminal. The N-
terminal containing the signal peptide, two CUB
domains and one ZP domain were predicted to be
present in the extracellular region and the remaining 18
amino acids at the C-terminal downstream of the
transmembrane region were presumably the cytoplasmic
part of HuUO-44. HuUO-44D encoded for two CUB
domains and a ZP domain while HuUO-44-A, -B, -C
and the cDNA library screened HuUO-44 clone all
encoded for only the ZP domain.
Cellular localization of HuUO-44
To further demonstrate the cellular localization of
HuUO-44 protein, the ovarian cancer cells, ATCC-
NIH-OVCAR3, were transfected with a mammalian
expression vector containing the ORF of HuUO-44D
fused to the ORF of green ﬂuorescent protein (GFP).
HuU-O44 expression was restricted to the cytosol 24 h
after transfection and localized to the cell membrane
48 h after transfection, but excluded from the nucleus
(Figure 7). This conﬁrmed the membrane-associated
nature of HuUO-44 in the cells. For the pcDNA-GFP
control-transfected cells, ﬂuorescence was observed in
both the nucleus and cytosol.
Immunohistochemical staining of HuUO-44 in ovarian
epithelial tissues and ovarian cancer cell line (NIH-
OVCAR3)
A histidine-tagged recombinant protein designed at the
ZP domain of HuUO-44 was generated in (BL21-SI)
bacteria and puriﬁed using a nickel coupled agarose
column. Polyclonal antibodies against the puriﬁed
recombinant protein were raised in rabbits. The
speciﬁcity of the antibody was determined though excess
antigen binding. Immunohistochemistry was performed
on eight-chamber slides containing NIH-OVCAR3,
ovarian cancer cells and parafﬁn-embedded sections
from human ovarian samples. Strong HuUO-44 im-
munostaining (in brown) was observed at the cell
membrane of the cells and under higher magniﬁcation,
HuUO-44 was also observed to exclusively localize at
the leading edge of the cells (Figure 8a and b). For the
normal ovarian and ovarian tumor sections, HuUO-44
immunostaining was only restricted to the epithelial cells
surrounding the stroma cells (Figure 8c and d).
To determine the expression of HuUO-44 in the
normal ovarian epithelium and ovarian tumor tissues, a
semiquantitative one-step RT–PCR was performed
using primers speciﬁc for all the HuUO-44 variants,
residing in exons 7 and 9 (Figure 8e). The levels of
Figure 5 Expression of Human UO-44 splice-variants in normal/tumor ovarian and uterine tissues. (a) Schematic diagram of RT–
PCR of HuUO-44 variants, each exon is represented by an open box and numbered below. Primers HuUO-44/F and HuUO-44-E7/R
were used in the one-step RT–PCR. (b) HuUO-44 variants in a paired normal (N)/tumor (T) ovaries, cervical cancer cell lines (1 – Hela,
3 – HT3, 4 – Caski and 5 – Siha) and ovarian cancer cell lines (2 – Pa1OV and 6 – NIH). Sequence analysis of the four RT–PCR
products reviewed four novel splice variants, HuUO-44A is represented by the 150 bp band, HuUO-44B by a 750bp band, HuUO-44C
by a 900bp band and HuUO-44D by a 1000 bp band. a-Tubulin was used as an internal control
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HuUO-44 expression were very similar in the normal
ovarian epithelium, ovarian tumors and ovarian epithe-
lial cancer cell line (NIH-OVCAR3). Lower HuUO-44
expression in the normal epithelium sample 2 was
probably due to the presence of other contaminating
cell types that were not completely removed when the
ovarian epithelial layer was peeled.
HuUO-44 antiserum inhibits ovarian cancer cell (NIH-
OVCAR3) attachment and cell proliferation
Cell attachment of NIH-OVCAR3 cells were greatly
inhibited when cultured in the presence of 10% rabbit
HuUO-44 antiserum compared to the 10% preabsorbed
antiserum (Figure 9a). Very few attached cells were
observed even at 24 h after seeding the cells in media
containing HuUO-44 antiserum. In contrast, attach-
ments of cells were observed as early as 6 h after seeding
of the cells in media containing the preabsorbed rabbit
HuUO-44 antiserum, cell proliferation was observed at
18 and 24 h postseeding. A marked increased in cell
numbers was also observed after 1, 3, 5 and 7 days of
culture in media containing preabsorbed antiserum
compared to the control antiserum plates (Figure 9b).
Discussion
We have previously isolated a uterine and ovarian
speciﬁc, tamoxifen and estrogen-induced rat UO-44
cDNA through differential display and cDNA library
screening (Huynh et al., 2001). Our previous ﬁndings
demonstrated that estrogen induces the expression of
UO-44 while pure antiestrogen ICI 182780 is inhibitory.
To further our understanding of UO-44 in the initiation
and progression of human ovarian and uterine cancers,
we isolated the HuUO-44 through library screening and
50 RACE. The rat and human UO-44 shared relatively
high sequence similarities both at the nucleotide and
peptide levels. The gene was mapped to chromosome
10 q, a region of frequently lost in many malignant
tumor types (Gray et al., 1995; Peiffer et al., 1995;
Rasheed et al., 1995; Kim et al., 1998; Somerville et al.,
1998).
We have previously shown that the RatUO-44 was
highly expressed in the ovaries and uterus; however, the
HuUO-44 expression was found highly expressed in the
pancreas (Figure 3). This differences in the UO-44
expression proﬁle between the rat and human is
attributed by the cell type speciﬁc nature of UO-44, we
Figure 6 Human UO-44 nucleotide sequence (2339 bp) and deduced amino-acid sequence (607 amino acids). The sequence of HuUO-
44D isoform is listed above, nucleotides are numbered on the left, and the amino acids are numbered on the right. The translational
start site is at the 50 end and the polyadenylation signal at the 30 untranslated region is in bold. The two CUB domains (CUB-1 and
CUB-2) is indicated by and the ZP domain by . The signal peptide (SP) is indicated by ’ at the amino terminal and a putative
transmembrane region (TM) is indicated by at the carboxyl terminal
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previously demonstrated using in situ hybridization that
UO-44 was restricted to the luminal and glandular
epithelial cells in the rat (Huynh et al., 2001). In
comparison, the rat multiple tissue expression proﬁle is a
better representation of the actual UO-44 expression as
the rat Northern blot was generated using total RNA
extracted from whole organs, compared to total RNA
extracted from tissue sections used in the human MTN
blot.
50 RACE ampliﬁcation established three contigs of
2.2, 2.4 and 3.3 kb in size coincided with the approxi-
mately 2 and 3 kb transcripts observed on the MTN
(Figure 3). The sequences of the 50 RACE products for
the 2.2 and 2.4 kb contigs were mapped to exon 4. This
suggested the presence of two possible transcription
start sites in exon 4. For the 3.3 kb contig, the
transcriptional start site was predicted to be in exon 1.
Expression studies of HuUO-44 in a paired normal
ovarian tissue and ovarian tumor, ovarian and cervical
cancer cell lines using RT–PCR demonstrated that the
gene undergoes a complex series of alternative splicing
events, which yield four different splice variants that
differ in their 50 region (Figure 5). These four splice
variants; HuUO-44A, -B, -C and -D encoded different
functional motifs. The largest splice variant, HuUO-
44D, contained two CUB domains and a ZP domain. A
bioinformatics assessment under the secreted protein
discovery inititive (SPDI) had previously identiﬁed more
than 1000 secreted and transmembrane human proteins
and HuUO-44D was one of these proteins (Clark et al.,
2003). The sequence of HuUO-44D transcript was also
annotated as human ERG1 (GenBank Accession
number NM022034); however, the publication cited in
this annotation contains only data from the rat ERG1
(GenBank Accession number AF167170) (Chen et al.,
1999), no mention of the human homolog was made in
their report. HuUO-44B, -C and -D contained only an
internally spliced exon 4A of 151 bp (Figure 2), while all
three 50 RACE contigs contained longer exon 4 that
varies in sizes (Figure 1). These larger 50 RACE contigs,
however, shared the same ORF as HuUO-44B and -C;
this suggests that the frame-shift in the ORF caused by
the presence of a longer exon 4 may function to regulate
the expression of the different functional motifs. The
functional roles of these mRNA isoforms are not known
at the present time, but one may speculate that the
transcriptional regulation and alternate splicing events
may function to regulate the gene expression as the
choice of transcriptional start sites or the loss of one or
more exons might result in a protein that lacks certain
functionally important domains. However, this hypoth-
esis requires conﬁrmation by gene expression analysis
through silencing or overexpression of each splice
variant in cell lines. Studies are underway to examine
the molecular events that potentially lead to the
activation of this gene.
The genomic structure of HuUO-44 shared high
similarity to that of the tumor suppressor DMBT1
located at 10q25.3–26.1 (Mollenhauer et al., 1997; Wu
et al., 1999; Lualdi et al., 2000; Mollenhauer et al., 2000)
a locus just upstream of HuUO-44. The protein DMBT1
also contained two CUB domains and one ZP domain
Figure 7 Transfection study of HuUO-44-eGFP in ovarian cancer cells. NIH cells transfected with 10mg of eGFP-pcDNA3.0 (a, c)
and HuUO-44-eGFP-pcDNA3.0-fusion construct (b, d). The transfected cells were harvested at 24 h (a, b) and 48 h (c, d) after
transfection. Expression of HuUO-44 was observed to be restricted to the cytosol 24 h after transfection and localized to the cell
membrane 48 h after transfection
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that were similar to those found in HuUO-44 (Figure 6).
These functional motifs are found in diverse proteins
and are evolutionarily highly conserved (Bork and
Sander, 1992; Bork and Beckmann, 1993), suggesting
that these domains may play a role in fundamental
cellular processes. The close proximity and structural
similarities between DMBT1 andHuUO-44, suggest that
HuUO-44 could be a product of gene duplication or vice
versa. CUB domains are found in developmentally
regulated proteins that participate in embryogenesis and
organogenesis (Bork and Beckmann, 1993). The verte-
brate bone morphogenetic protein (BMP-1) is one of the
CDCPs that is involved in cell adhesion or interaction
with the extracellular matrices (Bork and Beckmann,
1993). Previous studies on a CDCP1, which was
upregulated in colorectal cancer, proposed that CUB
Figure 8 Immunohistochemical staining of HuUO-44 in an
ovarian cancer cell line NIH-OVCAR3 (a, b), in parafﬁn-embedded
sections of a representative normal ovarian epithelial (c) and
ovarian epithelial cancer (d). (a) A polyclonal antibody was used in
the immunostaining of an eight-chamber slide containing an
ovarian cancer cell line showing HuUO-44 staining (in brown) is
localized to the cell membrane. (b) High magniﬁcation of the
ovarian cancer cells showing HuUO-44 staining is exclusively
localized to the leading edge of the cells. (c) Strong staining in
brown of the normal epithelial cells was observed but not detected
in the stroma cells. (d) An ovarian epithelial cancer section showing
the presence of HuUO-44 in the cancer epithelial cells. Magniﬁca-
tion: (a), (c), (d)  200 and (b)  400. The cells were counterstained
in blue with hematoxylin. (e) Semiquantitative RT–PCR of HuUO-
44 using total RNA extracted from normal ovarian epithelium,
ovarian tumors and ovarian epithelial cancer cell line (NIH-
OVCAR3). Levels of HuUO-44 expression were very similar in the
normal ovarian epithelium, ovarian tumors and ovarian cancer cell
line. a-Tubulin was used as an internal control
Figure 9 Effects of HuUO-44 antiserum on cell attachment and
proliferation of ovarian cancer cells (NIH-OVCAR3). (a) Each
35mm plates were seeded with 2 105 NIH-OVCAR3 cells in
media containing 10% rabbit HuUO-44 antiserum or preabsorbed
antiserum. Cell attachment was observed as early as 6 h postseeding
in the media containing the preabsorbed HuUO-44 antiserum with
cell proliferation observed at 18 and 24 h postseeding. Very few
attached cells were observed in the plate containing the HuUO-44
antiserum even at 24 h after seeding cells. (b) Proliferation assay of
NIH-OVCAR3 cells seeded in 12-well plates containing the above
HuUO-44 antiserum and preabsorbed antiserum media. Exponen-
tial increase in cell numbers was observed from Days 1 to 7, in wells
containing media supplemented with the preabsorbed antiserum
(--), however, cell proliferation was inhibited in the wells contain-
ing HuUO-44 antiserum media (-J-). This assay was performed in
triplicates and the mean values were used for comparison
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domains are involved in modulating the cell substrate
adhesion or the interaction with the extracellular
matrices (Scherl-Mostageer et al., 2001). In vitro, one
of the CUB-containing proteins, bovine acidic seminal
ﬂuid protein, was found to function as a mitogen,
growth factor and stimulates progesterone secretion in
cultured ovarian cells (Einspanier et al., 1991). Analo-
gous to these ﬁndings, we have shown that the antiserum
of HuUO-44 a CDCP inhibits cell attachment, thus
demonstrating the involvement of HuUO-44 in cell
adhesion (Figure 9). In ovarian cancer, HuUO-44 may
therefore function to promote cell growth and facilitate
locoregional invasion.
ZP domain proteins are proteins involved in sperm–
egg recognition found in sperm receptor ZP2 and ZP3
(Bork and Sander, 1992). This domain is also found in
TGF-b receptor type III, uromodulin and the major
zymogen granule membrane protein (GP-2) that are
related to proteins involved in binding (Einspanier et al.,
1991; Bork and Sander, 1992; Jovine et al., 2002). Each
of these ZP domain proteins occurs next to a putative
transmembrane region suggesting a conserved biological
function of the domain. Consistent to this observation,
HuUO-44 contains a ZP domain next to the transmem-
brane region at the C-terminal. Other common biolo-
gical properties of ZP domain-containing proteins are:
(i) they have all been detected in soluble form, (ii)
contain a long hydrophobic sequence segment at or near
the C-terminal, and (iii) are heavily glycosylated (Bork
and Sander, 1992). Proteins containing both the CUB
and the ZP motifs have a common feature in that they
are secreted or located on the cell surface (Bork and
Sander, 1992; Bork and Beckmann, 1993).
The presence of a signal peptide at the amino terminal
(Figure 6), one could speculate that HuUO-44 may be
located on the cell surface and the signal peptide could
signal the secretion of the protein. This membrane-
associated nature of the protein was demonstrated
through the expression of HuUO-44D tagged with a
fusion GFP protein (Figure 7) that localized the protein
to the cytosol and its subsequent migration to the cell
membrane after 48 h. We have also shown by immuno-
histochemical staining of ovarian sections that HuUO-
44 was restricted only to the normal ovarian and ovarian
tumor epithelial cells but not in the stroma cells (Figure
8c and d). This cell type speciﬁc expression of HuUO-44
was conﬁrmed using a semiquantitative RT–PCR of the
normal ovarian epithelial layers, ovarian tumors and an
ovarian epithelial cancer cell line, which also revealed
that the levels of the HuUO-44 transcript in the normal
ovarian epithelial layers were similar to that in the
ovarian tumor and cell line (Figure 8e). The ovarian
surface epithelium represents a very small fraction of the
cell mass in the ovary, however, it gives rise to more
than 80% of human ovarian carcinomas (Auersperg
et al., 1984; Tsao et al., 1995; Gregoire et al., 2001; Nitta
et al., 2001). The higher transcript expression of HuUO-
44 in the tumors observed on the CPA (Figure 4) may
therefore be due to a greater population of epithelial
cells compared to the normal samples, which contained
predominantly stroma cells. The epithelial speciﬁc
expression of HuUO-44, thus suggests that HuUO-44
might be involved in the development of ovarian
cancers.
In addition, immunohistochemical staining of HuUO-
44 have also revealed that the protein was only restricted
to the leading edge of an ovarian cancer cell line (Figure
8a and b). Furthermore, HuUO-44 antiserum have
shown to inhibit ovarian cancer cells attachment and
proliferation. The higher transcript levels of HuUO-44
in the metastatic tumor samples shown on the CPA
(Figure 4), thus suggest that the HuUO-44 may promote
tumor cell extravasation. The involvement of HuUO-44
in ovarian cancer cell attachment, metastasis and its
induction by estrogens (Huynh et al., 2001), further
highlights a potential role of HuUO-44 as a marker for
early detection of the cancer or for hormone respon-
siveness in estrogen or antiestrogen treatment.
Genes that are involved in embryonic development
often fulﬁll analogous roles in cancer (Bhatia-Gaur et al.,
1999). We have previously shown that UO-44 is an
estrogen-induced protein; in our present study we have
demonstrated the membrane-associated nature and
presence of different isoforms of its human ortholog.
The presence of a signal peptide, two CUB domains and
ZP domain present in the extracellular region, suggest
that HuUO-44 may play a role in communication,
interaction and signaling with extracellular components
and ligands. Importantly, inhibition of NIH-OVCAR3
cell attachment and proliferation by HuUO-44 antiser-
um suggest that in estrogen-stimulated ovarian cancer
cells, the presence of HuUO-44 modulates the interac-
tion with the extracellular matrices, thus constituting to
its invasiveness. During cell division, HuUO-44 was
localized to the leading edge of the cells; this led to the
speculation that protein might play a role in cell
motility. Our ﬁndings stimulate further investigation
into the physiological function of HuUO-44, its regula-
tion and its involvement in tumorigenesis, which may
aid in monitoring human ovarian cancers, and/ or as a
general marker for estrogen responsiveness.
Materials and methods
Probe labeling
All probes used in library screening, Southern and Northern
blot analyses were radioactively labeled with [a-32P]deoxy-CTP
(Perkin-Elmer, Boston, MA, USA) using the Rediprime II
DNA Labeling System (Amersham, Pharmacia Biotech,
Arlington Heights, IL, USA) as described by the manufac-
turer. Unincorporated [a-32P]deoxy-CTP was removed using a
nucleotide puriﬁcation kit (Qiagen, GmbH, Hilden, Germany).
cDNA screening of HuUO-44
To clone its human homolog, a 0.45 kb 30 fragment of the
1.9 kb RatUO-44 cDNA (GenBank Accession number
AF022147) was used as a hybridization probe to screen about
1 million plaques generated from the Human Adult Uterine
Premade cDNA Library (Invitrogen, Carlsbad, CA, USA).
Secondary screening was performed and Southern blot
analysis was used to conﬁrm clone identity. Positive clones
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were fully sequenced using T7 (50-TAATACGACTCACTA-
TAGGG-30), SP6 (50-CTATTTAGGTGA CACTATAG-30),
Nested-HuUO-44/F (50-ATGCCAATTCTTACCGGGG-30)
and Nested-HuUO-44/R (50-GAGTTAAAAGCCTCTAGG-
TAG-30) sequencing primers. The authenticity of the clones
was veriﬁed using automated sequencing (ABI 377) via
dideoxy chain termination using the BigDye version 3.0
(Applied Biosystems, CA, USA). Proligo Primers & Probes
(Singapore) supplied all primers.
MTN and CPA
The MTN and CPA (Clonetech, CA, USA) blots were
hybridized with a 30 fragment of HuUO-44 that was 625 bp
in size. This probe was radiolabeled and hybridized following
the manufacturer’s instructions. Glyceraldehydes-3-phosphate
dehydrogenase (GAPDH: American Type Culture Collection,
Manassas, VA, USA) cDNA probe was used for normal-
ization of the MTN blot, while the CPA was normalized with a
ubiquitin probe provided by the manufacturer.
RACE analysis
To establish the full-length cDNA of HuUO-44, 50 RACE was
performed using the SMARTt RACE cDNA ampliﬁcation
kit (Clonetech, CA, USA) according to the manufacturer’s
direction with the following modiﬁcation: The secondary PCR
ampliﬁcations of the primary RACE products were performed
using Advantages Genomic polymerase (Clonetech, CA,
USA), instead of the polymerase recommended, that is,
Advantages 2 Polymerase (Clonetech, CA, USA). Gene-
speciﬁc primer, 50 RACE-HuUO-44/R 30 (50-AGCTCCAG-
CAGAGGTGAGTCCTCTTCCC-30) was designed based on
the 50 end sequence of the cDNA library isolated HuUO-44
cDNA. The RACE products were subsequently cloned into
pCRs-Blunt-II-TOPO vector (Invitrogen, Carlsbad, CA,
USA) and sequenced using T7, SP6, RACE-Nested-HuUO-
44/F (50-CTCCAATCACCTGACAGTCT-30) and RACE-
Nested-HuUO-44/R (50-CCACAAAG CCATGATCCTGC-
30) primers. Sequence analysis was carried out using Laser
gene sequence analysis software (Dnastar Inc.).
Cloning of different splice variants of HuUO-44 via RT–PCR
Cloning of HuUO-44 cDNA variants was achieved using PCR
primers, forward primer FL-HuUO-44/F (50-CACCATGC-
CATTGACCCTCTTAATT-30) designed at the 50 end and the
reverse primer HuUO-44-E7/R (50-CACAATAATCTG-
GAGTTGTTTC-30) at the 30 end. To generate the cDNA
template for PCR cloning, total RNA was extracted using
Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and 1mg of
total RNA was reversed transcribed using one-step RT–PCR
Kit (Qiagen, GmbH, Hilden, Germany) following the manu-
facturer’s instructions. The one-step RT–PCR was performed
with following cycles: reverse transcription at 451C for 30min;
activating Taq Polymerase at 951C for 15min; followed by 30
cycles of 941C for 10 s, 571C for 1min, 681C for 1min 30 s, and
ﬁnal extension at 681C for 10min. The ampliﬁed products were
separated on a 1% agarose gel and Southern blot was
performed to conﬁrm the variants identity. PCR products of
the correct size were subsequently cloned into pCRs-Blunt-II-
TOPO vector (Invitrogen, Carlsbad, CA, USA) and sequenced
using T7 and SP6 primers.
Computational analysis
Sequence identity and prediction of open-reading frames were
performed using analysis software from the National Centre
for Biotechnology Information (NCBI). The homology studies
between rat and human UO-44 were performed at both the
nucleotide and the amino-acid levels. The CLUSTAL W v1.82
program (EMBL) was used to perform the multiple sequence
alignment. The predicted amino-acid sequences were analysed
using Pfam CDS-Conserved Domain Search (NCBI) to detect
conserved domains, SignalP (Nielsen and Krogh, 1998) for
analysing the presence of signal peptides, SOSUI (Hirokawa
et al., 1998) and Tmpred (Hofmann and Stoffel, 1993)
program for detection of possible transmembrane regions
and NetOGlyc 2.0 program (Blom et al., 1999) to detect
possible glycosylation sites.
Genomic structure of HuUO-44
The three 50 RACE HuUO-44 contigs were used to BLAST-
search the NCBI human genome database for the HuUO-44
genomic DNA sequence. The intron/exon boundaries were
determined through the adherence of the predicted splice
signal to the AG/GT rule (Mount, 1982). The resulting
genomic sequences were aligned with the sequences of the
four different splice variants using the Laser gene sequence
analysis software (Dnastar Inc., USA).
HuUO-44 recombinant protein expression, purification and
antibody production
After rare codon analysis, a 600 bp 30 region of HuUO-44
cDNA was selected for recombinant protein generation. This
region was ampliﬁed using HuUO-44/1168F (50-CAC-
CATGGCTCTTTTTGAATCCAATTC-30) and HuUO-44/R
(50-GTTAATAGTTCTG CAGCTTCT-30). The following
PCR cycles were used: 951C for 5min; followed by 25 cycles
of 951C for 30 s, 551C for 30 s, 721C for 1min 30 s, and a ﬁnal
extension of 721C for 5min. The PCR product was next cloned
using the Gateway Expression Systemt (Invitrogen, Carlsbad,
CA, USA) into a pDEST-17 vector that contained Histidine
tags. The pDEST17-HuUO-44 vector was then transformed
into salt inducible BL-21-SI cells. Positive clones were induced
in a 500ml culture with 300mM NaCl for 5 h and the induced
cells were lysed and puriﬁed using Nickel-NTA-agarose
(Qiagen, GmbH, Hilden, Germany) according to the QIAex-
pressionist manual provided by the manufacturer. The
recombinant protein was dialysed extensively against phos-
phate-buffered saline (PBS) and concentrated before being
used for antibody generation. Polyclonal antibodies were
raised in rabbits according to standard protocols. Antisera
following the seventh boost were used in these studies. The
speciﬁcity of the antibodies was veriﬁed by Western blot
analysis against the recombinant HuUO-44.
Generation of HuUO-44-eGFP-fusion plasmid
Ampliﬁcation of HuUO-44D transcript containing an open-
reading frame of 607 amino acids fused to a eGFP protein was
achieved using the following primers: Gate-FL-HuUO-44/F
(50-CACCATGCCATTGACCCTCTTAA TT-30), HuUO-44-
eGFP/R (50-CTCGCCCTTGCTCACCATATAGTTCTG-
CAGCTTCTGG T-30), eGFP/F (50- ATGGTGAG-
CAAGGGCGAG -30) and eGFP/R (50-TTACTTGTACAG
CTCGTCCA-30). Two separate PCR were performed with the
ORF of HuUO-44 ampliﬁed using GateHuUO-44/F and
HuUO-44-eGFP/R primers, while the ORF of eGFP was
ampliﬁed using eGFP/F and eGFP/R primers. Next an
overlapping PCR was performed with the two previous PCR
products as templates using Gate-FL-HuUO-44/F and eGFP/
R primers. All PCR were performed using the following cycles:
951C for 5min; followed by 25 cycles of 951C for 30min, 551C
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for 30min, 721C for 1min 30 s, and a ﬁnal extension of 721C
for 5min. The resulting HuUO-44-eGFP-fusion PCR product
was cloned in to a pcDNA3 (Invitrogen, Carlsbad, CA, USA)
mammalian expression vector. A eGFP-positive control was
constructed with the same strategy using only eGFP/F and
eGFP/R primers for PCR.
Transient transfection of ovarian cancer cells
Human ovarian cancer NIH-OVCAR3 cells were maintained
as a monolayer culture in DMEM (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% FCS (HyClone, Logan, UT,
USA), 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA,
USA) and grown in a humidiﬁed 5% CO2 atmosphere at 371C.
NIH-OVCAR3 cells were seeded at 5 105 over cover slips in
100mm culture dishes 24 h before transfection. Cells were
transfected with 10mg of HuUO-44-eGFP-pcDNA3 or eGFP-
pcDNA3, 30 ml of Lipofectamine and 20 ml of Plus reagent
(Invitrogen, Carlsbad, CA, USA), following the recommenda-
tions of the manufacturer. One cover slip was removed and
observed at 24 and 48 h after transfection.
Immunohistochemical analysis
NIH-OVCAR3 ovarian cancer cells were seeded into eight-
chamber slides 24 h prior to staining. Fixing was performed in
4% formaldehyde for 15min, followed by two washes with Tris
Buffer Saline (20mM Tris, 200mM NaCl, pH 7.6) (TBS) for
5min. For the ovarian tissue samples, prior written informed
consent was obtained from patients and the study received
Ethics Board approval at the National Cancer Centre of
Singapore and Singapore General Hospital, tissue samples
obtained were snap frozen in liquid nitrogen. Prior to analysis,
the samples from tumors and adjacent were ﬁxed in 10%
formalin for 24 h and embedded in parafﬁn. 5mM thick sections
were cut, dewaxed with xylene, and rehydrated as described
(Nielsen and Krogh, 1998). Antigen retrival was performed by
boiling the slides in 10mM citrate buffer pH 6.0 for 20min. The
following steps were then carried out on both the cell line slides
and tissue sections; endogenous peroxidase activity was block
by 3% hydrogen peroxide in methanol for 30min. After two
washes of Tris buffer saline (20mM Tris, 200mM NaCl, pH 7.6)
(TBS), the sections were preincubated with 5% skim milk in
TBS containing 0.1% Tween-20 (TBST) for 5min and
incubated overnight at 41C, with puriﬁed primary antisera
generate against the recombinant HuUO-44. Immunohisto-
chemistry was performed using the strepavidin–biotin perox-
idase complex method according to the manufacturer’s
instructions (Lab Vision, Fremont, CA, USA) using AEC as
the chromogen and counterstained with 5% hematoxylin.
Semiquantitative one-step RT–PCR of HuUO-44 in normal
ovarian epithelium, ovarian tumor and ovarian epithelial cancer
cell line (NIH-OVCAR3)
The normal ovarian epithelium and ovarian tumor samples
were obtained from patients and the study received Ethics
Board approval at the National Cancer Centre of Singapore
and Singapore General Hospital, tissue samples obtained were
snap frozen in liquid nitrogen. Total RNA was extracted using
Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and 1mg of
total RNA was reversed transcribed using one-step RT–PCR
Kit (Qiagen, GmbH, Hilden, Germany) following the manu-
facturer’s instructions. Expression HuUO-44 was analysed
using primers speciﬁc for all the HuUO-44 variants, residing in
exon 7 (HuUO-44/1168F, 50-CACCATGGCTCTTTTT-
GAATCCAATTC-30) and exon 9 (HuUO-44/R, 50-GTTAA-
TAG TTCTGCAGCTTCT-30). The one-step RT–PCR was
performed with following cycles: reverse transcription at 451C
for 30min; activating Taq Polymerase at 951C for 15min;
followed by 30 cycles of 941C for 10 s, 571C for 1min, 681C for
1min, and ﬁnal extension at 681C for 10min. A pair of a-
tubulin primers, TubF (50-AACGTCAAGACGG CCGTGT-
30) and TubR (50-GACAGAGGCAAACTGAGCAC-30),
which amplify a 400 bp fragment of tubulin cDNA for
normalization.
Cellular proliferation assays
Preabsorption of the HuUO-44 antiserum was performed by
ﬂowing the rabbit HuUO-44 antiserum through a recombi-
nant HuUO-44 protein-coupled CNBr-activated Sepharoset
4B (Amersham, Pharmacia Biotech, Arlington Heights, IL,
USA) column. In a 12-well culture plate, 5 104 cells were
seeded in 2ml of DMEM (Invitrogen, Carlsbad, CA, USA)
containing 1% penicillin/streptomycin (Gibco, Gland Island,
NY, USA) and supplemented with either 10% HuUO-44
antiserum or the preabsorbed HuUO-44 antiserum. After 1,
3, 5 and 7 days of incubation (371C, 5% CO2), cells were
harvested with trypsin–EDTA solution (Life Technologies,
Gaithersburg, MD, USA) and counted using a hemocyt-
ometer and trypan blue dye exclusion. Each time point was
performed in triplicates and the mean values were used for
comparison.
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Silencing expression of UO-44 (CUZD1) using small interfering RNA
sensitizes human ovarian cancer cells to cisplatin in vitro
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Ovarian cancer is currently the second leading cause of
gynecological malignancy and cisplatin or cisplatin-based
regimens have been the standard of care for the treatment
of advance epithelial ovarian cancers. However, the
efﬁcacy of cisplatin treatment is often limited by the
development of drug resistance either through the inhibi-
tion of apoptotic genes or activation of antiapoptotic
genes. We have previously reported the overexpression of
human UO-44 (HuUO-44) in ovarian cancers and the
HuUO-44 antisera markedly inhibited NIH-OVCAR3
ovarian cancer cell attachment and proliferation (Onco-
gene 23: 5707–5718, 2004). In the present study, we
observed through the cancer cell line proﬁling array that
the expression of HuUO-44 was suppressed in the ovarian
cancer cell line (SKOV-3) after treatment with several
chemotherapeutic drugs. Similarly, this suppression in
HuUO-44 expression was also correlated to the cisplatin
sensitivity in two other ovarian cancer cell lines NIH-
OVCAR3 and OV-90 in a dose-dependent manner. To
elucidate the function of HuUO-44 in cisplatin chemore-
sistance in ovarian cancer cell, small interfering RNAs
(siRNAs) were employed to mediate HuUO-44 silencing
in ovarian cancer cell line, NIH-OVCAR3. HuUO-44
RNA interference (RNAi) resulted in the inhibition of cell
growth and proliferation. Importantly, HuUO-44 RNAi
signiﬁcantly increased sensitivity of NIH-OVCAR3 to
cytotoxic stress induced by cisplatin (Po0.01). Strik-
ingly, we have also demonstrated that overexpression of
HuUO-44 signiﬁcantly conferred cisplatin resistance in
NIH-OVCAR3 cells (Po0.05). Taken together, UO-44 is
involved in conferring cisplatin resistance; the described
HuUO-44-speciﬁc siRNA oligonucleotides that can po-
tently silence HuUO-44 gene expression may prove to be
valuable pretreatment targets for antitumor therapy or
other pathological conditions that involves aberrant
HuUO-44 expression.
Oncogene (2007) 26, 870–880. doi:10.1038/sj.onc.1209836;
published online 24 July 2006
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Introduction
Despite advances in ovarian cancer treatment in the last
40 years, it remains as the second most common
gynecological malignancy (McGuire and Markman,
2003). Cisplatin is one of the most potent antitumor
agents, that are known to display clinical activity against
a wide variety of solid tumors, and cisplatin-based
treatments have been a standard of care for women
diagnosed with advanced epithelial ovarian cancer for
more than two decades (Muggia et al., 2000). Cisplatin
belongs to the chemotherapy group of alkylating agents
that binds to DNA creating adduct, crosslinks and
strand breaks that inhibit DNA replication leading to
the activation of several signal-transduction pathways
involving ATR, p53, p73 and mitogen-activated protein
kinase resulting in the activation of apoptosis (Judson
et al., 1999; Siddik, 2003). The overall clinical response
rate with cisplatin is about 67% and its failure is often
associated with signiﬁcant neurotoxicity, ototoxicity,
nephrotoxicity and gastrointestinal as well as myelo-
suppression (Muggia et al., 2000; McGuire and Mark-
man, 2003). Other new drugs including paclitaxel,
docetaxel, vinorelbine, irinotecan and gemcitabine are
currently being used in combination to cisplatin to
achieve better survival rates. However, the limited
efﬁcacy of cytotoxic chemotherapy remains a key
obstacle for the treatment of patients with advanced
ovarian cancer. This considerable toxicity observed in
patients receiving cisplatin in combination with palitaxel,
thus prompted the development of novel therapeutic
options, particularly those that employ a combinational
approach that targets genes involved in apoptosis and
tumor progression.
Advances in the ﬁeld of gene downregulation using
RNA interference (RNAi), through the introduction of
small interfering double-stranded RNAs (siRNAs) into
cells, can effectively suppress gene expression by mRNA
degradation or inhibition of translation (Ryther et al.,
2005; Tebes and Kruk, 2005). Silencing of several targets
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using siRNA has already been reported to cause growth
suppression of various cancer cell lines and is therefore
a promising approach for gene therapy (Ryther et al.,
2005; Devi, 2006). However, owing to the involvement
of numerous genes in tumor progression, simultaneous
inhibition of multiple target genes may be necessary to
effectively inhibit tumor progression. It is therefore
necessary to combine the use of siRNA with other
compounds, such as chemotherapeutic agents, to elicit
the synergistic antineoplastic effects in tumors.
In fact, a few siRNAs have already been shown to
enhance sensitivity to different chemotherapeutic drugs
in vitro (Cioca et al., 2003; July et al., 2004). For
instance, silencing various targets in ovarian cancer
including Her-2/neu can result in in vitro decreased cell
proliferation, increased apoptosis, increased G0/G1
arrest and decreased tumor growth (Yang et al., 2004).
Likewise, H-ras RNAi resulted in decreased ovarian
tumor growth and ovarian cancer cell line transforma-
tion efﬁciencies (Yang et al., 2003, 2004; Choudhury
et al., 2004). Similarly, targeting heparin-binding EGF-
like growth factor (HB-EGF) with siRNA also resulted
in decreased tumor growth in ovarian cancer cell lines
(Menendez et al., 2004). In addition, siRNA targeting
genes that confer multidrug resistance, p-gp and GST,
has also been previously shown to restore cisplatin
sensitivity in vitro (Duan et al., 2004). Correspondingly,
inhibition of ABCB1 and ABCB4 gene by siRNA has
also been shown to sensitize ovarian cancer cells to
paclitaxel (Miyamoto et al., 2004). Given the success of
RNAi in several in vivo studies as well as the promising
data from gynecologic malignancies in tissue culture and
animal studies, it is only a matter of time before RNAi
enters the realm of clinical therapeutics either as a
therapeutic agent or a chemosensitizing agent for
treatment of gynecological and/or other types of
cancers.
UO-44 (also known as CUZD1) encoded for a
transmembrane-associated protein that is ﬁrst cloned
from a pregnant mouse uterus complementary DNA
(cDNA) library (Kasik, 1998) and is expressed in the
uterus and ovaries (Huynh et al., 2001). Primary
translation product of the UO-44 gene encodes a
polypeptide of 607 amino acids, which contains a
secretory signal sequence, two CUB domains, a zona
pellucida domain and a transmembrane region (Chen
et al., 1999). UO-44 has been implicated in diverse
physiological functions, including pregnancy develop-
ment (Kasik, 1998; Chen et al., 1999), protection against
severity of pancreatitis (Imamura et al., 2002) and cell
adhesion (Huynh et al., 2001). In our previous study, we
have isolated alternatively spliced variants of the human
UO-44 gene, which may function to regulate its gene
expression (Leong et al., 2004). Another feature of
UO-44 is its overexpression in a majority of ovarian
tumors, suggesting that the gene exerts a signiﬁcant role
in tumorigenesis and progression of ovarian cancers
(Leong et al., 2004).
In general, UO-44 expression is upregulated in the
uterus during cell proliferation induced by estrogens but
downregulated during cell stress by pure anti-estrogen
(ICI 182780) (Chen et al., 1999; Huynh et al., 2001).
More speciﬁcally, the human orthologue of UO-44
(HuUO-44) is involved in ovarian cancer cell attachment
and proliferation (Leong et al., 2004). Collectively, these
previous ﬁndings identify that UO-44 functions in
ovarian cancer cell invasiveness, and silencing of UO-44
may enhance cell death following treatment with
chemotherapeutic agents. In the present study, we
discovered that cisplatin treatment resulted in the
downregulation of HuUO-44 expression and report for
the ﬁrst time that silencing of HuUO-44 using sequence-
speciﬁc siRNAs resulted in the signiﬁcant enhanced
cisplatin sensitivity in human ovarian cancer cells (NIH-
OVCAR3). Additionally, we have also demonstrated
that overexpression of HuUO-44 in NIH-OVCAR3 cells
conferred resistance to cisplatin chemotherapy.
Results
Human UO-44 expression using the cell line
proﬁling array
Effect of chemotherapeutic treatment on HuUO-44
expression in cancer cell lines was investigated using
the cancer cell line proﬁling array. There were no
signiﬁcant differences in HuUO-44 expression in the
treated lung, colon, breast, prostate, skin, brain, kidney,
liver, bone and epidermis cancer cell lines (data not
shown). Only the ovarian cancer cell line (SKOV3)
showed a reduction in HuUO-44 expression after
treatment with geldanamycin, aphidicoline, carmustine,
cisplatin, L-mimosine and demecolcine by a magnitude
of more than onefold of the control (Figure 1).
Treatment with hydroxyurea, cytochalasine D, doxor-
ubicin, desferrioxamine, camptothecin, mitomycine,
Taxol, thiotepa, hydrogen peroxide and gamma irradia-
tion observed only a half-fold reduction in HuUO-44
expression. Serum starvation, UV irradiation, heat
shock, cycloheximide, actinomycin D, etoposide and
5-ﬂuorouracil treatments did not show any signiﬁcant
effect on HuUO-44 expression in SKOV-3 cells.
Cytotoxic effect of cisplatin on ovarian cancer cell lines
To further investigate the cytotoxic effect of chemother-
apeutic drugs on ovarian cancer cell lines, four different
ovarian cancer cell lines were treated with cisplatin using
doses ranging from 0 to 26.7 mM for 48 h and the
dimethylthiazol-2-yl 2–5-diphenyltetrazolium bromide
(MTT) assay was used to determine cell viability
(Figure 2). NIH-OVCAR3 was found to be most
sensitive to cisplatin, followed by SKOV-3, OV-90 and
ES-2 cells. Rounding of NIH-OVCAR3 cells was
observed 48 h post-treatment with 3.3 mM of cisplatin,
whereas the same phenomenon was only observed in
OV-90 and SKOV-3 when treated with 6.7 mM of
cisplatin. The cytotoxic effect of cisplatin was less
pronounced in ES-2, as only very few rounded-up cells
were observed after treatment with cisplatin concentra-
tions as high as 26.7 mM.
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Effect of cisplatin on HuUO-44 expression in ovarian
cancer cell lines
Semiquantitative one-step reverse transcription–poly-
merase chain reaction (RT–PCR) demonstrated that the
dose-dependent inhibition of cell viability by cisplatin
was correlated with the suppression of HuUO-44
expression in NIH-OVCAR3, SKOV3 and OV-90
(Figure 3a). For the cisplatin-resistant ES-2 cell line,
the levels of HuUO-44 expression were the same as that
in the untreated cells. Quantitative real-time PCR was
employed to determine the magnitude of this cisplatin-
regulated suppression in HuUO-44 expression in NIH-
OVCAR3 cells, and we observed a transcript reduction
of more than 90% with 26.7 mM cisplatin treatment
(Figure 3b). Figure 3c presents the phase-contrast
micrograph of the NIH-OVCAR3 cells treated for 48 h
with varying concentrations of cisplatin (0–26.7 mM).
Sequence-speciﬁc, dose-dependent suppression of
HuUO-44 by siRNA
To further demonstrate the involvement of HuUO-44 in
cancer cell attachment and proliferation, we proceed to
silence the gene in NIH-OVCAR3 cell. Three siRNAs of
different target sequences (Table 1) were transfected into
the cells daily for 2 days. siRNA U1 was designed to
silence only the full-length HuUO-44D (GenBank
accession number AY260047); siRNA U2 targeted the
silencing of variants HuUO-44B (GenBank accession
number AY260049), HuUO-44C (GenBank accession
number AY260048) and HuUO-44D, and siRNA U3
targeted the silencing of all HuUO-44 transcripts.
Using semiquantitative one-step RT–PCR, it was
found that siRNA U3 was the most efﬁcient in silencing
the HuUO-44 gene expression. Combined transfection
of all the siRNAs (U1–3) containing one-third of each
siRNA also gave a similar level of silencing (Figure 4a).
These ﬁndings were conﬁrmed with real-time PCR
analysis, which demonstrated that the HuUO-44 siR-
NAs contributed to 17, 35, 69 and 74% of HuUO-44
transcript silencing when NIHOVCAR-3 cells were
transfected with siRNA U1, U2, U3 and a combination
of all three HuUO-44 siRNAs, respectively (Figure 4b).
Transfection with siRNA U1 did not exert any
signiﬁcant effect on HuUO-44 expression and no
Figure 1 Expression of human UO-44 (HuUO-44) in the ovarian cancer cell line (SKOV3) treated with 26 individual agents using the
cancer cell line proﬁling array. The blot was probed with a radioactive-labeled 625 bp fragment of the HuUO-44 cDNA and
normalized against the ubiquitin probe provided by the manufacturer. The relative density of the normalized spots was expressed as the
number of folds greater than or lesser than the untreated control.
Figure 2 Cytotoxic effect of cisplatin in ovarian cancer cell lines
(NIH-OVCAR3, ES-2, SKOV-3 and OV-90). The four different
ovarian cancer cell lines were exposed to 0–53.3mM of cisplatin.
After 48 h of treatment, cell viability was determined using the
MTT assay. Data were expressed as the percentage of cell survival.
The points represent the means of three independent experiments
and the error bars indicate standard deviations (s.d.).
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morphological changes were observed in the NIH-
OVCAR3 cells. However, shrinkage and rounding of
NIH-OVCAR3 cells was observed when the cells were
transfected with siRNA U2, U3 and a combination of
all three HuUO-44 siRNAs (Figure 4c). Transfection of
siRNA U3 or a combination of all HuUO-44 siRNAs
severely reduced HuUO-44 mRNA levels (Figure 4a).
These observations suggested that the variant-speciﬁc
silencing of HuUO-44 contributed to the different levels
of silencing. This cell shrinkage and rounding phenom-
enon was also observed in SKOV3 when transfected
with all three siRNAs (U1, 2 and 3) (Supplementary
Figure).
Semiquantitative one-Step RT–PCR analysis of the
transfection of different doses of HuUO-44 siRNAs
ranging from 10 to 200 nM in NIH-OVCAR3 cells
revealed a dose-dependent silencing of HuUO-44
transcripts (Figure 5a). HuUO-44 expression in NIH-
OVCAR3 cells was not affected by the tranfection with
200 nM of Medium GC control siRNA. Observation of
the cells after two daily transfections of the different
siRNA doses veriﬁed that treatment with 50 nM of
HuUO-44 siRNAs contributed to inhibition of cell
adherence, and treatment with up to 200 nM of HuUO-
44 siRNAs could result in inhibition of cell growth
(Figure 5b). Cell adherence and growth were not
affected by the treatment with 200 nM of Medium GC
siRNA controls.
Figure 3 Effect of cisplatin on HuUO-44 expression in ovarian cancer cell lines (NIH-OVCAR3, ES-2, SKOV-3 and OV-90).
(a) Ovarian cancer cell lines were exposed to 0–26.7mM of cisplatin. After 48 h, the cells were harvested and total RNA was extracted
for semiquantitative one-step RT–PCR analysis. Expression of HuUO-44 was reduced in a dose-dependent manner in NIH-OVCAR3,
SKOV-3 and OV-90 after cisplatin treatment. No reduction in HuUO-44 expression was observed in ES-2 cells after cisplatin
treatment. (b) Quantitative real-time PCR analysis conﬁrmed that the increase in cisplatin dose correlated with the suppression of
HuUO-44 expression. More than 90% suppression in HuUO-44 expression was observed with the 26.7mM cisplatin treatment in NIH-
OVCAR3 cells. (c) Phase-contrast micrography (magniﬁcation  200) showing the morphological changes of NIH-OVCAR3 cells
after treatment with 0–26.7mM of cisplatin. Rounding and shrinkage of cells (indicated by arrows) were observed at cisplatin
concentrations higher than 3.3 mM.




U1 50-UGACUGUGCAGCUUGCAUUGCCUUC-30 Exon 2
U2 50-UAUCCAGGUAACCGCCACAGUUUGG-30 Exon 4
U3 50-AUAACUCUCAUCCUGUCAGAAGAGC-30 Exon 6
Abbreviations: HuUO-44, human UO-44; siRNA, small interfering
RNA. aU1, U2 and U3 siRNA oligonucleotides have a GC/AT ratio
content of 52/48, 52/48 and 44/56, respectively. GC/AT ratio content
for the Stealth RNAi Medium GC negative control duplexes is 48/52.
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Enhanced chemosensitivity in vitro after silencing of
HuUO-44
To determine whether silencing of HuUO-44 can
enhance the cytotoxic effect of cisplatin, NIH-OVCAR3
cells were transfected with 100 nM of HuUO-44 siRNAs
and the medium GC control siRNA twice, once for
6 h followed by recovery for 18 h in growth media and
once 3 h before cisplatin (3.3 mM) treatment for 12 h.
Percentages of apoptotic cells were determined using
ﬂow cytometry after ﬂuorescent staining with Annexin
V-ﬂuorescein isothiocyanate (FITC) and propidium
iodide (PI) (Figure 6a). The percentages of early and
late apoptotic cells after 12 h cisplatin treatment were
plotted against the untreated cells (Figure 6b). Knock-
down of HuUO-44 by siRNA signiﬁcantly enhanced
cisplatin sensitivity in NIH-OVCAR3 cells (Po0.05),
increasing the percentage of apoptotic cells by more
than 50% compared to the Med GC control siRNA-
transfected cells. Figure 6c presents the phase-contrast
micrographs of the above siRNAs transfected and
cisplatin-treated NIH-OVCAR3 cells. HuUO-44 RNAi
also resulted in enhanced efﬁcacy of cisplatin, requiring
only 12 h treatment with 3.3 mM cisplatin to cause cell
rounding compared to 48 h treatment as shown in the
cisplatin cytotoxicity assay (Figure 2).
Expression of HuUO-44 conferred resistance to cisplatin
To determine whether overexpression of HuUO-44
can confer resistance to cisplatin, the cisplatin-sensitive
NIH-OVCAR3 cells were transfected with a mammalian
expression vector containing the open-reading frame
(ORF) of HuUO-44. Two stable transfectant clones
expressing low and high levels ofHuUO-44 were selected
(Figure 7a) and treated with 3.3 mM cisplatin for 18 h.
Percentages of apoptotic cells were quantitated using
ﬂow cytometry after ﬂuorescent staining with Annexin
V-FITC and PI (Figure 7b). The percentages of cell
death after 18 h cisplatin treatment were plotted against
the untreated cells (Figure 7c).
Expression of high levels of HuUO-44 signiﬁcantly
enhanced cisplatin resistance in NIH-OVCAR3 cells
with a ﬁvefold increase in the percentage of cell death
compared to the control stable clone containing the
pcDNA3 vector (Po0.05). Rounding of the pcDNA3
stable transfectants was observed after 18 h of cisplatin
treatment, this phenomenon was also observed in
the HuUO-44 stable transfectant, HuUO-44(1),
which overexpressed about fourfold more HuUO-44
transcript compared to the control (Figure 7d). Strik-
ingly, treatment with cisplatin only resulted in a few
rounded cells in the other HuUO-44 stable transfectant,
Figure 4 HuUO-44 sequence-speciﬁc siRNA silencing of HuUO-44 expression in ovarian cancer cells, NIH-OVCAR3. (a) Cells were
transfected with two daily doses of 100 nM of three different HuUO-44 siRNAs (U1, U2 and U3) or a combination of all three siRNAs
(U1–3) as described in Materials and methods. Transfection with the medium GC control siRNAs was used as a negative control.
HuUO-44 and a-tubulin mRNA levels were assayed using semiquantitative One-Step RT–PCR analysis. (b) Quantitative real-time
PCR analysis of the HuUO-44 mRNA expression shown in (a) after normalization to a-tubulin mRNA levels. The bars represent the
mean of the triplicate analysis; error bars indicate s.d. HuUO-44 siRNA U3 was the most effective in silencing HuUO-44 expression.
(c) Phase-contrast micrography (magniﬁcation  100 and  200) showing the morphological changes of NIH-OVCAR3 cells after two
daily transfections with HuUO-44 and Med GC control siRNAs. Rounding and shrinkage of cells (indicated by arrows) after siRNA
transfection are morphological changes suggestive of apoptosis. Silencing of all HuUO-44 transcripts through the transfection of a
combination of all three HuUO-44 siRNAs resulted in a more pronounced shrinkage and rounding of NIH-OVCAR3 cells.
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HuUO-44(2), which overexpressed more than 40-fold of
HuUO-44 transcript compared to the pcDNA3 control
transfectants.
Discussion
Chemotherapy has been regarded as a standard therapy
for the majority of women with advanced epithelial
ovarian cancer for several decades (McGuire and
Markman, 2003). Chemoresistance could be developed
through the alterations in apoptotic machinery, activa-
tion of antiapoptotic pathways or expression of
antiapoptotic genes (Siddik, 2003). Agents like cisplatin
that are used to destroy malignant cells may therefore
also induce expression of genes that mediate chemore-
sistance. Our present study investigates the involvement
of HuUO-44 in chemoresistance.
UO-44 is an inscrutable protein that is overexpressed
in the pancreas, uterus and ovaries (Huynh et al., 2001;
Leong et al., 2004). Despite previous in vitro and in vivo
studies, which reﬂect its multifunctionality, its common
function remains unclear. We have previously shown
that the HuUO-44 is upregulated in a majority of
ovarian cancers and have demonstrated that HuUO-44
is involved in ovarian cancer cell attachment and
proliferation (Leong et al., 2004). Our presented data
clearly demonstrated that the regulation of HuUO-44
expression was related with the chemoresistance of
ovarian cancer cells. Our ﬁrst clue relating HuUO-44 to
chemoresistance in ovarian cancer cell lines was
provided by the observation that HuUO-44 expression
was suppressed in SKOV-3 cells treated with various
chemotherapeutic agents with cytotoxic mode of action
involving DNA damage. In agreement, our further
investigation on the toxicity of cisplatin in four ovarian
cancer cell lines revealed that the sensitivity to cisplatin
was correlated to the reduction in HuUO-44 expression.
The expression of HuUO-44 was seemingly strictly
related to the cell exposure to apoptosis-inducing agents
and may therefore be related to the main HuUO-44
function under physiological conditions. Similarly,
according to a series of studies in UO-44/ mice, it
was shown that UO-44 increased the susceptibility to
severity of secretagogue and diet-induced pancreatitis
compared to the UO-44þ /þ mice. Further investigation
observed that the acinar cells had an increased suscept-
ibility to apoptotic cell death in the UO-44-deﬁcient
animals (Imamura et al., 2002).
Figure 5 Dose-dependent silencing ofHuUO-44 gene by siRNA in ovarian cancer cells, NIH-OVCAR3. (a) NIH-OVCAR3 cells were
transfected daily with the indicated concentrations of siRNA (U1, U2 and U3) oligonucleotides for 2 days. Expression of HuUO-44
and a-tubulin mRNA levels were assayed using one-step RT–PCR. (b) Phase-contrast micrography (magniﬁcation  100 and  200)
illustrated that NIH-OVCAR3 cells rounded and shrunk after transfection with 50 nM or higher concentrations of HuUO-44 siRNAs.
No morphological change was observed when the cells were transfected with 200 nM of the Medium GC negative control siRNA.
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The ability of 21-nucleotide duplexes of siRNA to
direct sequence-speciﬁc degradation of mRNA (Tuschl
et al., 1999; Harborth et al., 2001), causing gene-speciﬁc
silencing in mammalian cells, has provided us with a
rapid method for UO-44 functional analysis or to
modulate gene expression in human disease. Our present
study represents the ﬁrst report of the use of siRNA to
silence the HuUO-44 gene. We have previously isolated
four novel spliced variants of HuUO-44 and discussed
its role in regulation of its gene expression (Leong et al.,
2004). More speciﬁcally, the three HuUO-44 siRNAs,
U1, U2 and U3, were designed to target HuUO-44 exon
2, exon 4 and exon 6. Silencing of these individual exons
demonstrated the sequence-speciﬁc silencing of the
different variants, which contributed to the varying
levels of HuUO-44 gene silencing.
Furthermore, the dose-dependent silencing of HuUO-
44 through siRNAs in ovarian cancer cell line, NIH-
OVCAR3, demonstrated a decline in cell growth
through the inhibition of cell attachment (Figure 5b).
This detachment of epithelial cells from an extracellular
matrix results in a form of apoptosis known as anoikis
(Frisch and Francis, 1994). This same phenomenon was
also observed in another ovarian cancer cell line,
SKOV3, when transfected with varying concentrations
of siRNA (Supplementary Figure). However, no knock-
down of HuUO-44 expression was observed in OV-90
when transfected with HuUO-44 siRNAs and no
morphological change was observed (data not shown).
A possible reason for this could be the lower transfec-
tion efﬁciency of this cell line, which could severely
affect the delivery of the siRNAs. Strikingly, we have
Figure 6 HuUO-44 RNAi enhanced cisplatin sensitivity of ovarian cancer cells, NIH-OVCAR3. NIH-OVCAR3 cells were
transfected with 100 nM of the Medium GC control and HuUO-44 siRNAs (U1, U2 and U3), followed by treatment with 3.3mM of
cisplatin. (a) The ﬂow cytometry analysis of a representative experiment following staining with Annexin V-FITC and PI. Silencing of
HuUO-44 markedly increases NIH-OVCAR3 sensitivity to cisplatin. (b) Graphical interpretation of the percentages of early and late
apoptotic cells determined in (a). The increases in the percentage of apoptotic cells after cisplatin treatment were 6–10% for the non-
transfected and Med GC control siRNA-transfected cells, whereas the HuUO-44 siRNA-transfected cells yielded 19–20% apoptotic
cells after cisplatin treatment. (c) Phase-contrast micrography (magniﬁcation  100) of the above treatments illustrated the
characteristic morphology of the apoptotic cells in the HuUO-44 knockdown cells after cisplatin treatment. The bars represent the
means of three independent experiments and the error bars indicate s.d.
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also found that HuUO-44 RNAi chemosensitized
human NIH-OVCAR3 ovarian cancer cells in vitro
(Figure 6). Consistent with the above RNAi studies, the
overexpression of HuUO-44 conferred resistance to
cisplatin in ovarian cancer cells (Figure 7). These
ﬁndings illustrated that HuUO-44 is involved in
conferring cisplatin resistance in ovarian cancer cells
and HuUO-44 RNAi signiﬁcantly increased the efﬁcacy
of cisplatin treatment. The reduced growth in the
HuUO-44 knockdown cell line was most probably
related to the progressive loss of ability of the cells to
adhere to a substrate and cisplatin further activated
DNA damage-mediated signal-transduction pathways
that culminated in the activation of apoptosis.
In summary, our data demonstrated that the
oligonucleotide-induced suppression of HuUO-44 ex-
pression intensiﬁes apoptosis and signiﬁcantly enhances
chemosensitivity (Po0.01). Coherent to this ﬁnding, the
overexpression of HuUO-44 in ovarian cancer cell
signiﬁcantly conferred resistance to cisplatin (Po0.05).
Based on our previous observation that HuUO-44 is
overexpressed in a majority of ovarian cancers and
ovarian cancer cell lines, our present experimental
ﬁndings support the development of target strategies
employing HuUO-44 siRNAs to complement the
conventional cytotoxic therapies for advance ovarian
cancers.
Materials and methods
Cancer cell line profiling array
The probe used in the cancer cell line proﬁling array was
radioactively labeled with [a-32P]deoxy-CTP (Perkin-Elmer,
Figure 7 Overexpression of HuUO-44 conferred cisplatin resistance in cisplatin-sensitive ovarian cancer cells, NIH-OVCAR3. (a)
Quantitative real-time PCR analysis of the HuUO-44 mRNA expression of the stable transfectants after normalization to a-tubulin
mRNA levels. Stable transfectant clones HuUO-44(1) and HuUO-44(2) were found to express about than 4 and 40-fold more HuUO-
44 transcripts compared to the pcDNA3 vector stable transfectant, respectively. (b) The ﬂow cytometry analysis of a representative
experiment following staining with Annexin V-FITC and PI. The percentage of cell death after cisplatin treatment was about 4–5-fold
less in HuUO-44(2) compared to the pcDNA and HuUO-44(1). (c) Graphical interpretation of the percentages of cell death determined
in (b). (d) Phase-contrast micrography (magniﬁcation  100) illustrated the characteristic morphology of the apoptotic cells in the
pcDNA and HuUO-44 stable transfectants after cisplatin treatment. The bars represent the means of three independent experiments
and the error bars indicate s.d.
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Boston, MA, USA) using the Rediprime II DNA Labeling
System (Amersham, Pharmacia Biotech, Arlington Heights,
IL, USA) as described by the manufacturer. Unincorporated
nucleotides were removed using the Nucleotide Puriﬁcation
Kit (Qiagen, GmbH, Hilden, Germany). The cancer cell line
proﬁling array (Clontech Laboratories Inc., Palo Alto, CA,
USA) blot was hybridized with a 625 bp fragment of the
HuUO-44 cDNA (1520–2145 bp; GenBank accession number
AY260047). This array was normalized using the ubiquitin
probe provided by the manufacturer.
Cell lines and culture conditions
Ovarian cancer cell lines (ES-2, NIH-OVCAR3, OV-90 and
SKOV-3) were purchased from the American Tissue Culture
Collection (Manassas, VA, USA). ES-2 and SKOV-3 were
cultured in McCoy’s medium, whereas NIH-OVCAR3 was
cultured in Rosewell Park Memorial Institute (RPMI) 1640
medium, all containing 1% penicillin/streptomycin (Gibco,
Gland Island, NY, USA) supplemented with 10% fetal bovine
serum (FBS). OV-90 was cultured in Dulbecco’s modiﬁed
Eagle’s medium containing 1% penicillin/streptomycin
(Gibco) supplemented with 15% FBS.
Treatment of cells with cisplatin
Cisplatin stock of 1mg/ml was purchased from Mayne
Pharma Plc, Warwickshire, UK. The stock solution was
diluted with growth medium to the required concentrations
(in mM) before each in vitro experiment.
SiRNA for RNAi of UO-44
Invitrogen Life Technologies Inc. Carlsbad, CA, USA
supplied all the HuUO-44-speciﬁc siRNAs. The sequence of
the siRNAs listed in Table 1 corresponded to the HuUO-44
(CUZD1) cDNA sequence (GenBank accession number
AY260047 and NM_022034). The Stealth RNAi Negative
Control Med GC that has no homology to the vertebrate
transcriptome was used as a negative control.
Transfection of siRNA
Transfection ofHuUO-44 siRNA U1, U2, U3 and the negative
control was performed using Lipofectamine 2000 (Invitrogen).
Cells were seeded the day before siRNA transfection in six-well
plates and were 50–60% conﬂuent during transfection. The
RNA duplex was diluted in sterile water and 100 nM of the
siRNA duplex was used in each transfection mixture. NIH-
OVCAR3 cells were treated with the siRNA after 20min
preincubation with 5ml of Lipofectamine 2000 in serum-free
OPTI-MEM (Invitrogen). When cells were transfected with all
three HuUO-44 siRNAs, one-third of each siRNA duplex was
used. Six hours after transfection, the medium was replaced
with RPMI culture medium described above. Transfection of
siRNA was performed daily for 2 consecutive days, then
harvested 24 h following the ﬁnal transfection.
Cytotoxicity assay
In vitro cytotoxicity assays were performed using the
MTT(Sigma Chemical Co, St Louis, MO, USA) assay. Cells
were seeded into 48-well plates at 4 104 cells/well and were
treated with different doses of cisplatin ranging from 0 to
53.3 mM. After 48 h of treatment, 40ml of 10mg/ml MTT
reagent and 200 ml of serum-free media was added to each well
and incubated in the dark for 4 h at 371C. Formazan crystals
were dissolved in the SDS-DMF solution, which contained
0.7M SDS (Bio-Rad, Laboratories Inc., Hercules, CA, USA)
in 50% N,N-dimethylformamide (Sigma) at pH 4.3. After
dissolving the resulting formazan product, the absorbance was
determined with a Benchmark Plus Microplate Spectrophoto-
meter (Bio-Rad) at 570 nm. Normalization was performed
with the values obtained from the untreated cells to determine
the percentage of survival. Each treatment was performed in
triplicate.
Semiquantitative RT–PCR and real-time PCR analysis
Total RNA was isolated from the four different ovarian cancer
cell lines using TRIZOL (Invitrogen) according to the
manufacturer’s instructions. For the semiquantitative analysis,
1mg of total RNA was reverse transcribed followed by PCR
using the one-step RT–PCR Kit (Qiagen) following the
manufacturer’s instructions. The primer sequences used for
ampliﬁcation of HuUO-44 mRNA (1520–2158 bp; GenBank
accession number AY260047) were 50-CATGGCTCTTTTT
GAATCCAATTC-30 and 50-GTTAATAGTTCTGCAGC
TTCT-30. The cycles chosen for one-step RT–PCR reaction
were reverse transcription at 451C for 30min; activation of Taq
polymerase at 951C for 15min, followed by 30 cycles of 941C
for 10 s, 551C for 1min, 681C for 1min, and a ﬁnal extension
of 681C for 10min. The ampliﬁed products were separated on
a 1.5% agarose gel.
For quantitative real-time PCR analysis, the ﬁrst strand
cDNA was obtained through the reverse transcription of 1mg
of total RNA using SuperScript II Reverse Transcriptase
(Invitrogen) according to the manufacturer’s instructions. One
microliter of the resulting cDNA was used in the subsequent
PCR reaction in iQ SYBR Green Supermix (Bio-Rad), with
the following cycles: 951C for 3min, followed by 40 cycles of
951C for 10 s; 581C for 30 s and 721C for 30 s. MyiQ real-time
PCR Detection System (Bio-Rad) was used to monitor real-
time the PCR ampliﬁcation, and the DNA concentration of
each reaction was determined quantitatively using a standard
curve. For both semiquantitative and quantitative gene
expression analysis, a-tubulin was used as a reference gene to
normalize the differences in the amount of total RNA and to
compensate for different RT efﬁciencies. Sequence for the
a-tubulin primers were 50-AACGTCAAGACGGCCGTGT-30
and 50-GACAGAGGCAAACTGAGCAC-30. Agarose gel
electrophoresis and melt curve analysis were used to conﬁrm
the absence of nonspeciﬁc ampliﬁcation products.
Apoptosis assay
Externalization of phosphatidylserine (PS) was examined with
a two-color analysis of FITC-labeled Annexin V binding and
PI uptake ﬂow cytometry (Vermes et al., 1995). For this
analysis, 1 106 cells were stained using the commercially
available kit, Annexin V-FITC Apoptosis Detection Kit I (BD
Biosciences Pharmingen, San Diego, CA, USA) according to
the manufacturer’s instructions.
Cell debris was characterized by a low forward scatter/side
scatter and was excluded from the analysis. Single stained cells
either with FITC-Annexin V or PI were used to adjust
compensation. Fluorescence was quantiﬁed using FL1 and
FL2 channels of the FACSCalibur ﬂow cytometer (BD
Biosciences); data acquisition and analysis were carried out
using the CellQuests software (BD Biosciences). Positioning of
quadrants on Annexin V/PI dot plots was performed based on
a previous report (van Engeland et al., 1996). The lower left
quadrant represented living cells (Annexin V/PI); the upper
left quadrant represented necrotic cells (Annexin V/PIþ ); the
lower right quadrant represented early apoptotic/primary
apoptotic cells (Annexin Vþ /PI); and the upper right
quadrant represented late apoptotic/secondary necrotic cells
(Annexin Vþ /PIþ).
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Generation and transfection of HuUO-44 constructs
Ampliﬁcation of HuUO-44 FL ORF of 1824 bp was achieved
using the following primers: HuUO-44/F (50-CACCATGC
CATTGACCCTCTTAATT-30) and HuUO-44/R (50-GTTAA
TAGTTCTGCAGCTTCT-30). PCR was performed using a
plasmid containing the transcript HuUO-44D (GenBank
accession number. AY260047) as template, in a total volume
of 50 ml containing 10 pmol of each primer, 100 nmol of each
dNTP, 1 IU of native Pfu polymerase (Stratagene, La Jolla,
CA, USA), 1.5mM MgCl2 and 1 Native Pfu Buffer
(Stratagene). The following cycles were used for PCR: 951C
for 5min, followed by 25 cycles of 951C for 30min, 551C for
30min, 721C for 1min 30 s, and a ﬁnal extension of 721C for
5min. The resulting PCR product was subsequently cloned
into pCR-Blunt-II-TOPO vector (Invitrogen) and subcloned
directionally into a pcDNA3 (Invitrogen) mammalian expres-
sion vector via HindIII and NotI restriction enzyme sites found
on both vectors.
After sequence veriﬁcation of the HuUO-44FL-ORF-
pcDNA3.0 constructs, a maxi-prep of the construct was
prepared using the Endofree Plasmid Maxi Kit (Qiagen).
Before the day of transfection, 5 106 NIH-OVCAR3 cells
were seeded onto a 100mm tissue culture dish. The plate was
about 70% conﬂuent during transfection; 10mg of HuUO-
44FL-pcDNA3.0 or pcDNA3.0 plasmids was transfected into
the NIH-OVCAR3 cells after 20min preincubation with 10 ml
of Lipofectamine 2000 (Invitrogen) in serum-free OPTI-MEM
(Invitrogen). The transfection mix was replaced with growth
medium, 6 h after transfection. After a further 12 h of
incubation, the transfected cells were trypsinized and selected
in growth medium containing Geneticin–G418 (Invitrogen) for
3 weeks. Single colonies of stable transfectants were then
isolated and assayed for HuUO-44 expression using real-time
PCR analysis.
Statistical analysis
All experiments were repeated at least three times and the data
were subjected to Student’s unpaired t-test. For all statistical
tests, signiﬁcance was established at Po0.05.
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